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Many chemotherapy treatments have significant side effects because non-specific 
delivery of anticancer drugs damages healthy organs. Folate or folic acid has been 
employed as a targeting moiety of various anticancer agents to increase their cellular 
uptake within target cells since folate receptors (FRs) are vastly overexpressed in many 
human tumors. In this thesis, a biodegradable polymer poly(D,L-lactide-co-glycolide)-
poly(ethylene glycol)-folate (PLGA-PEG-FOL) was used to form micelles for 
encapsulating anticancer drug doxorubicin (DOX). The difference of cytotoxicity, 
cellular uptake and apoptosis percentage between different cancer cells and healthy cells 
implies that the folate conjugated micelles has the ability to selectively target cancer cells 
that overexpress FRs on their surface. Furthermore, the amount of folate on the micelles 
was optimized at 40%-65% in order to kill cancer cells but, at the same time, have 
minimal effect on normal healthy cells.  
 
To accelerate the drug release in endosome, a pH-sensitive block copolymer poly(β-
amino ester)-PEG-FOL was synthesized. This copolymer is hydrophilic at endosomal pH 
of 5-6. However, under physiological environment (pH 7.4), the poly(β-amino ester) 
block is hydrophobic but the PEG-FOL block is hydrophilic, resulting in the formation of 
polymer micelles with poly(β-amino ester) in the core and PEG-FOL at the shell. To 
control the drug release from the micelles, mixed micelles of PLGA-PEG-FOL and 
poly(β-amino ester)-PEG-FOL were fabricated. The incorporation of pH-sensitive 
polymer in the micelles increased the buffering ability and changed physicochemical 
properties at the endosomal pH. The release of DOX in the micelles was accelerated at 
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pH 5.0, which resulted in increased cytoplasmic concentration of DOX and improved 
cytotoxicity. This formulation would be useful as an effective intracellular delivery 
carrier of hydrophobic therapeutic agents. 
 
Another serious problem associated with cancer chemotherapy is the development of 
multidrug-resistant (MDR) tumor cells during the course of treatment. To overcome 
MDR, a new drug formulation - PLGA-PEG-FOL formulated with d-α-tocopheryl 
polyethylene glycol succinate (TPGS), known as mixed micelles, was fabricated. 
Compared with the PLGA-PEG-FOL formulation, the addition of TPGS showed higher 
cellular uptake of DOX, and subsequently a higher degree of DNA damage and apoptosis, 
and eventually a higher cytotoxicity to drug resistant cells. The enhanced cellular uptake 
of mixed micelles was related to the P-glycoprotein (P-gp) inhibition function of TPGS. 
In addition, the formulations with TPGS also selectively enhance the cytotoxicity of drug 
resistant cancer cells with overexpressed folate receptors and affect normal cells at 
minimum. The pharmacokinetics and biodistribution of this new formulation was also 
evaluated with rat tumor xenograft models. The mixed micelles formulation showed 
enhanced drug accumulation in drug resistant tumors. Based on these results, the mixed 
micelles may be an appropriate formulation for drug resistant tumors overexpressed FRs.  
 
Although TPGS is an effective P-gp inhibitor, it represents only one of the surfactants in 
the class of “Vitamin-PEG” conjugated surfactants. A new vitamin D-PEG conjugate - 
cholecalciferol polyethylene glycol succinate (CPGS) was synthesized as a new 
pharmaceutical additive. From our current study, similar to TPGS, CPGS may also act as 
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P-gp inhibitor to enhance the cytotoxicity of anticancer drugs. Compared with TPGS, 
CPGS did not show obvious cytotoxicity to cancer cells in vitro. However, CPGS may 
have anticancer effects in vivo through the active metabolites of Vitamin D. Results 
obtained from this study may broaden potential use of different vitamin-based additives 
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Cancer is the second major cause of death in the U.S. Despite the significant progress in 
the development of anticancer technology, there is still no common cure for patients with 
malignant diseases 1. In addition, the long-standing problem of chemotherapy is the lack 
of tumor-specific treatments. Traditional chemotherapy relies on the premise that rapidly 
proliferating cancer cells are more likely to be killed by a cytotoxic agent. In reality, 
however, cytotoxic agents have very little or no specificity, which leads to systemic 
cytotoxicity, causing severe side effects such as hair loss, damages to liver, kidney, heart 
and bone marrow. Therefore, many tumor targeting methods have been developed in last 
decades 2. One of the important methods is antibody based tumor targeting 3. The mAb 
moiety of antibody binds to the antigens on cancer cells and the antibody-drug conjugates 
is internalized via receptor-mediated endocytosis followed by release of the parent drug 
to its active form. In 2000, Mylotarg® was approved by FDA, providing the first mAb-
drug immunoconjugate for the treatment of cancer in clinic 4. Several other mAb-drug 
conjugates, such as BR96-doxorubicin 5 and herceptin-DM1 6 are currently in the clinical 
trials. Although using antibodies as cancer markers offers some advantages, antibodies 
are usually expensive and inevitably increase the cost of drugs. In addition, the stability 
of antibody-drug conjugates is still a problem. Therefore, it is necessary to develop 
alternative targeting vehicles which are highly selective, stable and economical.  
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Another significant obstacle for successful chemotherapy is multidrug resistance (MDR) 
in cancer cells. MDR is a phenomenon whereby tumor cells that have been exposed to 
one cytotoxic agent develop cross-resistance to a range of structurally and functionally 
unrelated compounds 7. MDR is often found in many types of human tumors that have 
relapsed after an initial favorable response to drug treatment. The sensitivity of the MDR 
tumor cells to anticancer drugs can decrease significantly, which hinders the efficacy of 
these drugs in chemotherapy 8. P-glycoprotein (P-gp) overexpression is one of the 
mechanisms of MDR, and can result in an increased efflux of cytotoxic drugs from 
cancer cells, thus lowering their intracellular concentrations. In certain cases, up to 100-
fold overexpression of P-gp in MDR cells have been observed 9. Various strategies to 
overcome MDR have been attempted. A common method is to utilize P-gp blocking 
agents, such as cyclosporine A and verapamil 10, 11. However, cyclosporine A and 
verapamil are immunosuppressant drugs and can cause side effects when they are used as 
MDR-reversing agents with anticancer drugs. Therefore, the development of safe and 
effective MDR-reversing agents without other pharmacological activities is required. 
 
1.2 Aims and scope of this project 
The aims of this thesis is to address the above two problems in chemotherapy. Since non-
specific treatments result in the side effects of chemotherapy, one of the aims is to 
develop a targeting delivery system which has high selectivity to tumors. In addition, the 
system should be stable and economical, and can be produced easily. Another aim of this 
project is to develop a safe and effective MDR-reversing agent without undesired 
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pharmacological activities. Although current drug delivery vehicles have shown promise 
in tumor targeting and MDR inhibition, few investigations have addressed the two 
problems together at the same time. The challenge is to develop a new delivery system 
which has targeting ability to cancer cells and at the same time overcome MDR in cancer 
cells. This PhD work aims to fabricate multifunctional polymeric micelles which could 
specifically target to cancer cells and overcome MDR. The scope of this thesis include 
the fabrication of multifunctional polymeric micelles, the selectivity of the micelles 
between cancer cells and tumor cells, the P-gp inhibition of the micelles, the synergistic 
effects between the tumor targeting and P-gp inhibition, and the in vivo therapeutic 
effects of the micelles. 
 
The specific objectives of this thesis include: 
1. Design a tumor targeting delivery system. A biodegradable block copolymer-
poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)-folate (PLGA-PEG-FOL) was 
prepared to form micelles for encapsulating anticancer drug doxorubicin (DOX). The 
characterization and properties of the PLGA-PEG-FOL copolymer micelles were 
fully evaluated, such as micelles size, morphology, stability, surface properties, drug 
loading content and drug release.  
 
2. Study the selectivity of the folate conjugated micelles between cancer cells and 
normal cells. Until now, the selectivity of the folate conjugated micelles has not been 
addressed. Therefore, in this thesis, the in vitro selectivity of the targeting delivery 
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system was investigated. The difference of cytotoxicity, cellular uptake and apoptosis 
percentage between different cancer cells and normal cells was studied. 
 
3. Synthesize a pH-sensitive polymer to increase the drug cytotoxicity. After folate-
mediated endocytosis, in order to accelerate the drug release in early endosome, a pH-
sensitive polymer- poly(β-amino ester)-PEG-FOL conjugate was prepared. The 
effects of the pH- sensitive polymer to drug release, cytotoxicity and cellular uptake 
were investigated.  
 
4. Fabricate multifunctional polymeric micelles which could specifically target to cancer 
cells and overcome MDR. It has been demonstrated that TPGS can enhance cellular 
uptake of drugs in the cancer cells by inhibiting P-gp mediated MDR 12-14. Folate 
conjugated micelles formulated with TPGS was fabricated to evaluate the effects of 
TPGS on the physicochemical properties, cellular uptake and selective cytotoxicity of 
the folate conjugated micelles. In particular, whether the addition of TPGS to the 
micelles can increase the cellular uptake of DOX in the drug resistant cancer cells but 
not normal cells was the main objective of this study.  
 
5. To investigate in vivo effects of the multifunctional polymeric micelles. The 
pharmacokinetics and biodistribution was evaluated with rat tumor xenograft models. 
Two different tumor models, drug sensitive model and drug resistant model, were 
compared. Different drug formulations were evaluated to compare their targeting 
ability and MDR inhibition. Tumor and heart histology was also performed to study 
the drug accumulation. 





Chapter 2  
Literature Review 
 
2.1 Tumor specific chemotherapy  
2.1.1 Side effects of traditional chemotherapy 
 
Cancer is responsible for 22.9% of annual deaths in the world and becomes the leading 
cause of deaths in recent years. However, treatments of cancer are painful, often even 
more painful than the disease itself. The most common treatment is chemotherapy, which 
means use drugs to destroy cancer cells. Many chemotherapy treatments have significant 
side effects including loss of blood cells, severe nausea, hair loss and even nerve damage.   
 
Cancer occurs when cells lose the ability to regulate growth and proliferation. Damage is 
done to surrounding tissue when cancer cells use up a large proportion of the nutrients 
normally supplied to the surrounding cells. In order to obtain even more nutrients, cancer 
cells also promote angiogenesis, or localized blood vessel creation. The mechanism of 
most cancer treatments is destroying dividing cells. Side effects occur because the 
treatments affect not only cancer cells, but also the cell linings in the gastrointestinal tract, 
hair follicle cells, and any other cells that are actively dividing. If the treatments could be 
targeted specifically to cancer cells, side effects would drastically decrease, improving 
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the quality of life for patients. Therefore, scientists focus on the research of drug delivery 
systems (DDS) to decrease the side effects.  
 
The design of an effective drug delivery system must meet two primary criteria. First, the 
drug delivery vehicle must be developed that can encapsulate anticancer drugs until it 
reaches target tumor. Second, cellular markers that are found on the tumor but not on 
healthy tissue must be identified. These markers can be used to guide the DDS to tumors. 
This targeting approach should increase the amount of drug delivered to the tumor while 
decreasing the amount of drug delivered to healthy normal tissues. 
2.1.2 Anatomical, physiological and pathological considerations  
 
Differences in the structure and physiology of normal and tumor tissues can be used for 
designing drug delivery systems facilitating tumor-specific delivery of the drug or 
prodrug and specific drug activation.  
(1) Enhanced permeability and retention (EPR) 
An important consideration is that under pathological conditions, endothelium exhibits 
modified characteristics. The vasculature of the endothelial cells of tumors is much more 
permeable than normal endothelial cells. The mechanisms underlying the high 
permeability of tumor microvessels to macromolecules may include large inter-
endothelial fenestrations, discontinuous basement membrane and a high rate of trans-
endothelial transport. These ‘holes’ in the tumor vasculature are normally between 100-
700 nm. Tumor vasculature continuously undergoes angiogenesis to provide blood 
supply that feeds the growing tumor. Extravasation of blood-borne molecule or particle is 
therefore enhanced in the tumor vessels. In most normal tissues, extravasated 
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macromolecules are drained into lymphatics and brought back to central circulation. But 
tumors generally lack functional lymphatic drainage. Therefore, extravasated fluid and 
macromolecules are more effectively retained in interstitial spaces of the tumor. This 
phenomenon is called EPR effect 15, 16 (Figure 2.1). In the extracellular fluid, after 
accumulation due to the EPR effect, the macromolecular drug carrier systems can enter 








Figure 2.1 Schematic illustration of the EPR effect principle 17 
 
(2) Extracellular pH 
The tumor extracellular pH (pHe) is a consistently distinguishing phenotype of most solid 
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patients, using invasive microelectrodes, range from pH 5.7 to 7.8 with a mean value of 
7.0. More than 80% of these measured values are below pH 7.2, while normal blood pH 
remains constant at 7.4. The acidity of tumor interstitial fluid is mainly attributed, if not 
entirely, to the higher rate of aerobic and anaerobic glycolysis in cancer cells. Such acidic 
extracellular pH promotes the establishment of pH-sensitive liposomes. However, truly 
sensitive systems to tumor extracellular pH have hardly been achieved because of the 
lack of a proper pH-sensitive functional group in the physiological pH. 
 
(3) Specific markers 
Tumor blood vessels, except leaky endothelium, express specific markers that are not 
present in the blood vessels of normal tissues. Many of the markers are proteins 
associated with tumor-induced angiogenesis (aminopeptidase N, integrins, etc.). The 
phage display strategy offers a proper selection of efficient vectors-oligopeptides that can 
be used for specific targeting of the DDS to the angiogenic tumor vasculature 18, 19. In 
addition, antibodies specific for such markers are a potent vector for tumor targeting. It is 
clear that targeting to tumor vascular endothelium is relatively non-specific and can be 
used for the treatment of a variety of tumors nourished by angiogenic vessels. Polymer 
drug conjugates with antibodies specific for targeting selected tumor receptors is limited 
only to the treatment of a single tumor. 
 
Most specific DDS use antibodies as homing devices 20 and they are directed against 
specific receptors expressed on the surface of tumor cells. After receptor-mediated 
endocytosis, the drug can be released in early or secondary endosomes by pH controlled 
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hydrolysis (pH drop from physiological 7.4 to 5-6 in endosomes or 4-5 in lysosomes) or 
specifically by enzymolysis in lysosomes.  
(4) Mononuclear phagocyte systems (MPS) 
In addition to the above three issues, the effect of macrophages in direct contact with the 
blood circulation (e.g. Kupffer cells in the liver) on the disposition of carrier systems 
must be considered. Unless precautions are taken, particulate carrier systems are readily 
phagocytosed by these macrophages and accumulated in these cells. Phagocytosis is only 
carried out by the specified cells (“professional phagocytes”) of the mononuclear 
phagocyte systems (MPS; also known as the reticuloendothelial system, RES). 
Circulating blood monocytes and both fixed and free macrophages are capable of 
phagocytosis. MPS is always on the alert to phagocytose ″foreign body-like materials″, 
removing particulate antigens such as microbes. Other foreign particulates, such as 
microspheres, liposomes and other particulate carriers, are also susceptible to MPS 
clearance. Clearance kinetics by the MPS is highly dependent on the physicochemical 
properties of the particulate, especially the particulate size, charge, and surface 
hydrophobicity. Particulates in the size range of 0.1-7 µm tend to be cleared by the MPS, 
which localize predominantly in the Kupffer cells of the liver. It has been shown that 
negatively charged vesicles tend to be removed relatively rapidly from circulation 
whereas neutral vesicles tend to remain in the circulation for longer periods. Hydrophobic 
particles are immediately recognized as ″foreign″ and are generally rapidly covered by 
plasma proteins known to function as opsonins, which facilitate phagocytosis.  
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2.1.3 Tumor Targeting 
 
In general, three destinations in the tumors are used as targets for delivery of anticancer 
drugs-tumor vasculature, extracellular space in the tumors and tumor cells. Mechanisms 
of targeting can be divided into two categories: passive targeting and active targeting. 
2.1.3.1 Passive targeting 
Passive targeting exploits the natural distribution pattern of a drug carrier in vivo and no 
homing device is attached to the carrier. For example, particulate carriers tend to be 
phagocytosed by cells of the MPS. Consequently, the major organs of accumulation are 
liver and the spleen, both in terms of total uptake and uptake per gram of tissue. An 
abundance of MPS macrophages and a rich blood supply are the primary reasons for the 
preponderance of particles in these sites. After phagocytosis, the carrier and the 
associated drug are transported to lysosomes and the drug is released upon disintegration 
of the carrier in this cellular compartment.  
 
To reduce the tendency of macrophages to rapidly phagocytose colloidal drug carrier 
complexes, ″steric stabilization″ can be employed by coating the delivery system with 
synthetic or biological materials, making it energetically unfavorable for other 
macromolecules to approach. A standard approach is to graft hydrophilic, flexible poly 
(ethylene glycol) (PEG) chains to the surface of the particulate carrier. The repulsive 
steric layer reduces the adsorption of opsonins and consequently slows down 
phagocytosis. The net effect of PEG attachment is that macrophage / liver uptake of the 
particles is delayed or reduced, thus increasing the circulation time. Research has shown 
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that a surface PEG chain molecular weight of 2000 or greater is needed to improve the 
avoidance of RES recognition 21. Another example of passive targeting is the exploitation 
of the EPR effect to deliver drug to an inflammation or a tumor site. As described above, 
the circulation time of a particular carrier in the blood can be prolonged using ″stealth″ 
technology to enhance particle hydrophilicity. If the circulation time is sufficiently 
prolonged and the particle size exceeds the size of normal endothelial fenestrations, then 
accumulation at tumor and inflammation sites (EPR effect) can be observed. 
2.1.3.2 Active targeting  
In active targeting, a homing device, which can be antibodies or ligands, is attached to the 
carrier system to effectively delivering to a specific cell, tissue or organ. Thus delivery 
systems designed for active targeting are usually composed of three parts: The backbone 










Figure 2.2 Structure of active targeting systems 22 
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2.1.3.2.1 Antibody based tumor targeting 
To achieve target delivery of any biologically active compound, the compound has to be 
attached directly or via a spacer to the homing molecules that can specifically recognize 
receptors expressed on the surface of target cells. Such molecules could be polyclonal or 
monoclonal antibodies, their fragments (Fab or F(ab)2), specific lectins, oligo 
/polysaccharides, oligo/polypeptides and other proteins and glycoproteins. Conjugates of 
a targeting antibody with a drug are usually referred to as immunoconjugates. The 
simplest way of producing immunoconjugates is to attach the drug to the antibody 
directly or via a short and simple spacer to facilitate drug release. The structure of the 






Figure 2.3 Scheme of the antibody-drug and antibody-polymer-drug conjugates 23 
The most important groups in the antibody molecule employed for conjugation with 
drugs are carboxylic (of aspartic and glutamic acid residues), amino (of lysine residue) 
and free thiol (of cysteine residue) groups 24. In addition, aldehyde groups introduced into 
an antibody molecule by sodium periodate oxidation of saccharide units in Fc part of the 
molecule have been used for coupling reaction with a drug. In most studies dealing with 
immunoconjugates, daunorubicin, other anthracyclines, methotrexate and 5-fluorouracil 
are used for the synthesis of immunoconjugates with acid-sensitive linker between the 
drug and antibody moieties. These linkers are often the same as those used in polymer-
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drug conjugate chemistry, i.e. they are based on hydrazone, cisaconityl, maleoyl and trityl 
groups in the spacers. 
 
Another way of producing immunoconjugates is to attach the drug and antibody to a 
polymer. In recent years, a considerable number of antibody-targeted polymer drug 
carrier systems have been developed and described 25, 26. Various antibodies have been 
used for conjugation with Poly (N-(2-hydroxypropyl) methacrylamide) (HPMA) 
copolymers (nonspecific ATG, monoclonal antibody anti-Thy1 and -Thy2, anti-CD71, 
anti-p53). Attachment of the targeting antibody to the carrier results in an increased 
cytotoxic activity of the conjugate and in a more pronounced in vivo anti-tumor effect 
with long-time circulation 27. Internalization and subcellular fate of free DOX as well as 
targeted and non-targeted conjugates has been tested on EL4 mouse T-cell lymphoma, 
SW620 human colorectal carcinoma, and OVCAR-3 human ovarian adenocarcinoma. 
The fate of free or polymer-bound drug is different. Free DOX is always detected in cell 
nuclei, where the polymer-bound drug is predominantly detectable in cytoplasmatic 
structures. While free DOX causes apoptosis in the population of tested cells, a 
significant amount of apoptotic cells is never found in the cells incubated with polymer 
conjugates. It has been suggested that the cells treated with PHPMA conjugates die due 
to necrosis and the toxicity of the conjugates is a combination of the toxic effect of 
released DOX and the toxic effect of polymer-bound DOX directed against cell 
membranes. It is clear that the mechanism of action of polymeric drugs is very complex 
and more studies are needed for full understanding of the interaction of polymer-DOX 
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conjugates with cancer cells as well as a full understanding of the mechanism of polymer-
drug anticancer actions. 
2.1.3.2.2 Receptor-mediated tumor targeting 
 
Several specific surface receptor targets have been studied recently, such as HER2, 
EGFRvIII, folate, and Caveolae. Each of these specific targets allows for a more 
localized delivery of anticancer drugs compared to the conventional treatment that 
harmfully acts on all cells. In this review, we focus on EGFRvIII and folate receptors.  
 
EGFRvIII 
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor found in most 
normal tissue. Epidermal growth factor (EGF) binds to EGFR, causing dimerization and 
autophosphorylation of the receptor. Phosphorylation sites then become docking sites for 
a variety of signaling proteins that cause the cell to grow and divide. When EGFR is 
activated, it is typically endocytosed and degraded. This serves as a negative feedback 
mechanism for EGFR activation.  
 
EGFRvIII is a mutated version of EGFR with a truncated extracellular domain. It is 
found in many cancers, including brain, lung, ovarian, prostate, and breast cancers. In 
fact, it is expressed in over 50% of breast cancers but not in normal tissue, making it a 
prime candidate for a cancer marker 28. If non-tumorigenic cells are transfected with the 
EGFRvIII gene, the cells become tumorigenic 29. The mechanism by which EGFRvIII 
makes the cells tumorigenic is not fully understood.  However, it is known that EGFRvIII 
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is activated in the absence of EGF and that EGFRvIII is endocytosed less than wild type 
EGFR, minimizing negative feedback.  
 
The use of EGFRvIII in treating cancer is a subject of cutting edge research. Ribozymes 
have been successfully used to destroy EGFRvIII mRNA but not EGFR mRNA in a cell-
free in vitro environment. DOX-loaded liposomes with monoclonal antibodies to EGFRs 
have successfully targeted cells in vitro 30. More specific EGFRvIII monoclonal 
antibodies have been isolated by Liu et al. to increase their potential in therapeutic use 31. 
Although EGFRvIII has potential for improving many cancer treatments, many cells 
expressing EGFRvIII have been shown to be resistant to anticancer drugs because of the 
changes in which tubulin isotypes are expressed 32.  
 
Folate Receptors (FRs) 
Folate targeting was invented soon after Kamen’s group at the University of Texas 
Southwestern Medical Center reported that folates entered cells via a receptor-mediated 
endocytic process 33. It has been also shown that the physiological process that mediates 
folate-targeted drug delivery is identical to that for the free vitamin 34, 35. As illustrated in 
Figure 2.4, exogenous folate-drug conjugates bind to externally oriented FRs located on 
the plasma cell membrane. This is a highly specific event, i.e., analogous to a key (folate) 
inserting into a lock (FR). Immediately after binding, the plasma membrane surrounding 
the folate conjugate/FR complex begins to invaginate until a distinct internal vesicle, 
called an early endosome, forms within the cell. The pH of the vesicle lumen is then 
dropped to 5 through the action of proton pumps that are colocalized in the endosome 
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membrane 36. This acidification presumably protonates numerous carboxyl moieties on 
the FR protein and promotes a conformational change that enables the folate molecule to 
be released. Eventually, the fate of the pteroate ligand, attached drug cargo and FR are 
determined during a sorting process within late endosomal elements. The reduced folate 
carrier (RFC), unlike the FR which is an anion transporter, can shuttle folate molecules 












Figure 2.4 FR-mediated endocytosis of folate-drug conjugate 37 
 
Using FR as a cancer marker has several advantages. FRs are not expressed in most 
normal tissue. In the normal tissues where they are expressed, the receptors are localized 
to the apical surface of polarized epithelial cells, making them inaccessible from the 
vasculature. However, in many types of cancer, FRs are over-expressed in a non-
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localized way, and can be detected from the vasculature 38. This makes the FR an 
excellent prospective target for the delivery of anticancer drugs. It has also been shown 
that folate achieves deeper penetration than normal antibodies as receptor ligands 37.  
 
The exploitation of FR-mediated drug delivery has been referred to as a molecular Trojan 
horse approach where drugs attached to folate are shuttled inside a targeted FR-positive 
cell in a stealth-like fashion. Folate displays extremely high affinity for its cell surface-
oriented receptor. With the proper design, folate-drug conjugates can also display this 
high affinity property which enables them to rapidly bind to the FR and become 
internalized via an endocytic process 37. Initial folate targeting studies were conducted 
with radiolabeled and fluorescent proteins covalently attached to folic acid 39. A typical 
structure for a folate-drug conjugate contains four modules, as cartooned in Figure 2.5. 
Pteroic acid (Pte) typically functions as Module 1, while the drug moiety is placed in the 
Module 4 position. Quite often, a Glu moiety is placed within the linker (Module 2) at a 
position juxtaposed to Pte. Importantly, the combination of the Pte and Glu moieties 
produces folic acid. Therefore, these molecules are typically referred to as ‘‘folate 
conjugates’’. However, the Glu residue of folic acid is found not critical for FR 
recognition 40. Since the Pte core (or some derivative of Pte) is essential for FR binding, 
we generally refer to this class of targeted molecules as ‘‘pteroate’’ conjugates. Finally, 












Figure 2.5 Structural design of a pteroate-drug conjugate 37 
 
To date, folate conjugates of radiopharmaceutical agents 41, low molecular weight 
chemotherapeutic agents 42, 43, antisense oligonucleotides and ribozymes 44, proteins and 
protein toxins 45, immuno-therapeutic agents 46, liposomes with entrapped drugs 47, drug 
loaded nanoparticles 48, and plasmids 49have all been successfully delivered to FR-
expressing cancer cells. The most recent trend of folate targeting focuses on attaching 
folic acid to polymer micelles 25, 50-53. Polymeric micelles are made of amphiphilic 
copolymers with both a hydrophobic and a hydrophilic end. The core of the polymer 
micelles is hydrophobic while the exterior is hydrophilic. The size of the polymer 
micelles is approximately less than 100 nm, which not only makes them escape from 
renal exclusion and RES elimination, but also gives them an enhanced vascular 
permeability. The attachment of folate to the polymer micelles enhances their ability of 
recognizing tumor cells. Recently, several folate conjugated polymer micelles have been 
shown to display higher cytotoxicity and cellular uptake on FR-positive cancer cells 
compared with the micelles without folate 54-58. 
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In spite of recent advances, many challenges remain for the future development of folate 
conjugates. Although many conjugates have repeatedly demonstrated activity without 
toxicity in mice, similar confirmation is needed in other animal models, and ultimately in 
patients. Furthermore, multiple drug conjugates may be needed to completely eradicate a 
tumor (due to cellular heterogeneity). Therefore, future research may concentrate on 
newer and more potent folate conjugates using drugs of different mechanisms of action as 
well as novel linkers and cleavable bonds. 
2.1.3.2.3 Peptide based tumor targeting 
Peptide-based targeting has a high potential for tumor-specific drug delivery of cytotoxic 
agents. A clear advantage of this approach is an excellent probability that highly tumor-
specific peptide sequences for various cancers could be discovered by screening 
appropriate combinatorial libraries. Since most gastrointestinal cancers are difficult to 
treat due to their multidrug resistance, this approach may shed a light on the development 
of efficacious chemotherapy. One of the inherent problems is the stability of these 
peptides in circulation, although this can be solved by appropriate design and 
modifications to prevent or slow down the amide hydrolysis. 
Bombesin (BBN) and the bombesin-like peptide, gastrin-releasing peptide (GRP), consist 
of 14 and 27 amino acid residues respectively, and have several physiological functions 
as gastrointestinal hormones and neurotransmitters 59. Moreover, these peptides also 
function as growth factors and modulate tumor proliferation 60. It was found that the 
bombesin-like peptides interact with four different receptors BBNR1–4 and the receptor 
subtypes BBNR1–3 were found in mammals. The bombesin-like peptides and its receptors 
are produced in different cancer cells such as small cell lung, breast, prostatic, and 
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pancreatic cancers. The finding that bombesin-like peptides function as growth factor and 
possess a high binding affinity to the bombesin/GRP receptors has stimulated the 
development of bombesin/GRP antagonists as potential anticancer agents. The 
bombesin/GRP antagonists have been further conjugated with doxorubicin and AN-201 
for possible tumor-targeting drug delivery 61. Cytotoxic agents can also be coupled to the 
bombesin/GRP antagonists at their amino termini via glutarate ester linker. Preliminary in 
vivo studies against the nitrosamine-induced pancreatic cancer model in golden hamsters 
showed that conjugate B4-AN-201 exhibits significant antitumor activity and is less toxic 
to the animal at the same dose as AN-20161.  
In recent years, a small peptide-cyclic Arg-Gly-Asp (RGD) has been widely utilized in 
angiogenesis targeting. Angiogenesis, a term describing the process of new blood vessel 
formation, is an essential process in the growth and metastasis of tumor. Antiangiogenic 
therapy prevents neovascularization by inhibiting proliferation, migration and 
differentiation of endothelial cells 62. Without the nutrient support of new vessels, tumor 
cells can only form perivascular cuffs restricted to a diameter of 1-2 mm 63. The 
identification of molecular markers that differentiate newly formed capillaries from their 
mature counterparts 64, 65 has paved the way for targeted delivery of cytotoxic agents to 
the tumor vasculature 66. The αVβ3 integrin is one of the most specific of these unique 
markers 67. In addition, this integrin is overexpressed on actively proliferating 
endothelium in and around tumor tissues. Thus, it is only during angiogenesis that this 
marker can be seen by targeting agents that are restricted to the vascular space. RGD 
peptides that are constrained in a preferred cyclic conformation show an increased 
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affinity for integrin interaction. By coupling cyclic RGD peptides on the surface of drug 
carrier, the affinity of the interaction with the target cells can be significantly increased.  
 
Storm et al. 68 coupled RGD to the distal end of poly(ethylene glycol)-coated long-
circulating liposomes (LCL) to obtain a stable long-circulating drug delivery system 
functioning as a platform for multivalent interaction with αVβ3 integrins. Their results 
show that cyclic RGD-peptide-modified LCL exhibited increased binding to endothelial 
cells in vitro. Moreover, intravital microscopy demonstrated a specific interaction of 
these liposomes with tumor vasculature, a characteristic not observed for LCL. RGD-
LCL encapsulating doxorubicin inhibited tumor growth in a doxorubicin-insensitive 
murine C26 colon carcinoma model, whereas doxorubicin in LCL failed to decelerate 
tumor growth. In conclusion, coupling of RGD to LCL redirected these liposomes to 
angiogenic endothelial cells in vitro and in vivo. RGD-LCL containing doxorubicin 
showed superior efficacy over non-targeted LCL in inhibiting C26 doxorubicin-
insensitive tumor outgrowth.  
 
Line et.al 69 reported the synthesis, characterization, in vivo imaging and biodistribution 
of N-(2-hydroxypropyl) methacrylamide (HPMA) conjugated with cyclic RGD4C. In 
vitro endothelial cell adhesion assays indicated that HPMA copolymer-RGD4C 
conjugates inhibited αVβ3 mediated endothelial cell adhesion while HPMA copolymer 
Arg-Gly-Glu control conjugates (HPMA-RGE4C conjugate) and hydrolyzed HPMA 
showed no activity. The scintigraphic images of prostate tumor bearing SCID mice 
obtained 24 h post injection indicated greater tumor localization of HPMA-RGD4C 
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conjugate than the control. The HPMA-RGD4C conjugates also had sustained tumor 
retention over 72 h. These results suggest that specific tumor angiogenesis targeting is 
possible with HPMA-RGD4C conjugates.  
2.1.3.2.4 Other tumor targeting methods 
 
Besides the above commonly used tumor targeting methods, several other methods are 
also effective and promising. 
Tumor-targeting with polyunsaturated fatty acids  
Essential fatty acids are polyunsaturated fatty acids (PUFAs) that can be obtained only 
from the diet. There are several known PUFAs having 18, 20, and 22 carbons, and 2–6 
unconjugated cis-double bonds separated by one methylene, such as arachidonic acid 
(AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). PUFAs have 
exhibited anticancer activity against CFPAC, PANC-1, and Mia-Pa-Ca-2 pancreatic and 
HL-60 leukemia cell lines, and their antitumor activities have been evaluated in 
preclinical and clinical studies 70. Moreover, it has been shown that PUFAs are taken up 
greedily by tumor cells, presumably for use as biochemical precursors and energy sources 
71. In addition, PUFAs are readily incorporated into the lipid bilayer of cells, which 
results in disruption of membrane structure and fluidity 72. This has been suggested to 
influence the chemosensitivity of tumor cells. These findings strongly suggest the benefit 
in the use of PUFAs for tumor-targeting drug delivery. 
Tumor-targeting with hyaluronic acid  
Hyaluronic acid (or hyaluronan) (HA) is a linear, negatively charged polysaccharide, 
containing two alternating units of d-glucuronic acid and N-acetyl-d-glucosamine 
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(GlcNAc) with molecular weight of 105–107. HA is responsible for various functions 
within the extracellular matrix such as cell growth, differentiation, and migration 73. It has 
been shown that the HA level is elevated in various cancer cells74. The higher 
concentration of HA in cancer cells is believed to form a less dense matrix, thus 
enhancing the cell’s motility as well as invasive ability into other tissues and providing an 
immunoprotective coat to cancer cells. It is well known that various tumors, for example, 
epithelial, ovarian, colon, stomach, and acute leukemia, overexpress HA-binding 
receptors CD44 and RHAMM. Consequently, these tumor cells show enhanced binding 
and internalization of HA 75.  
 
Tumor-targeting with sialic acid  
Sialic acid (SA)-containing glycosphingolipids, have attracted great interest for more 
than 20 years in the search for target molecules of relevance for tumor growth and 
formation of metastases and as potential targets for immunotherapy 76. In most cases SA, 
overexpressed on the cell surface of many cancer cells, has been used as a target and 
cancer-specific antigen. On the other end, a special type of lectins, so-called C-lectins, 
such as selectins and pentraxins, were identified on the surface of plasma membrane of 
cancer cells 77. Selectins are adhesion molecules that mediate calcium-dependent cell-cell 
interactions among leukocytes, platelets, and endothelial cells and are believed to be 
responsible for adhesion of several types of cancer cells to endothelial cells and therefore 
for spreading of tumor metastasis. Consequently, sialic acid, a well-known ligand to 
selectins, potentially can be used for targeting of anticancer agents to tumors that 
overexpress selectins. 
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2.2 Multidrug resistance of Chemotherapy 
 
Besides severe side effects result from non-specificity, another serious problem 
associated with chemotherapy is the development of multidrug-resistant (MDR) tumor 
cells during the treatment 7, 78. MDR is typically defined as the ability of a living cell to 
show resistance to a wide variety of structurally and functionally unrelated compounds. 
Patients often respond well to a first course of chemotherapy, however, their response to 
drug treatment diminishes over time and the tumor may eventually become drug resistant. 
In some cases, resistance can develop across several classes of anticancer drugs. The 
widespread occurrence of MDR in tumor cells represents a major impediment to 
successful cancer chemotherapy and is an important contributor to cancer deaths.  
 
In past years, various evidence strongly supported that the expression of a 170 kDa 
membrane glycoprotein (P-gp) on the cell membrane is associated with drug resistance in 
cancer 79-81. P-gp, the product of the MDR1 gene, is an ATP-dependent multidrug efflux 
pump. It protects cells by actively transporting toxic compounds against concentration 
gradient to reduce their intracellular concentrations 82, 83. Due to its high expression in 
almost all endothelial tissues, P-gp is probably the most important representative in the 
group of efflux pumps. Various strategies to overcome MDR have been attempted. The 
development of agents that can overcome drug resistance is seen as one of the most 
important areas of cancer research and for which there is significant unmet need.  
A common method to inhibit MDR is to utilize P-gp blocking agents, such as 
cyclosporine A and verapamil 10, 11. The mechanism of MDR inhibition of blocking 
agents is shown in Figure 2.6. However, cyclosporine A and verapamil are 
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immunosuppressant drugs, and cause side effects when they are used as MDR-reversing 
agents together with antitumor drugs. Therefore, development of safe and effective MDR 
reversing agents without other pharmacological activities is required. In recent years, 
amlodipine, a calcium channel antagonist, has been found to exhibit inhibitory effect on 
P-gp mediated transport of daunorubicin and digoxin 84. A derivative of amlodipine, 
CJX1, was also investigated to minimize P-gp mediated MDR in human myelogenous 
leukemia (K562) cells and K562/DOX cells 85. The results showed that incubation of 
K562/DOX cells with CJX1 causes a marked increase in uptake and a notable decrease in 
efflux of rhodamine 123. No such results were found in parental K562 cells. The DOX-
induced cytotoxicity, apoptosis and cell cycle perturbations can be significantly 
potentiated by CJX1. The intracellular accumulation of DOX can be enhanced in the 
presence of various concentrations of CJX1. The potency of CJX1 in the reversal of P-gp 
mediated MDR in vitro has also been shown, suggesting that the compound may become 










Figure 2.6 The mechanism of MDR and MDR inhibition 86 
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Besides small molecule blocking agents, some nonionic surfactants also exhibit P-gp 
inhibition. The A-B-A block copolymers of poly(ethylene oxide) (A) and poly(propylene 
oxide) (B), such as poloxamers or Pluronics (P85), have been shown to interact with 
MDR cancer cells. The mechanism involves the interaction of the Pluronic molecules 
with cell membranes, decrease in membrane microviscosity accompanied by significant 
inhibition of P-gp ATPase activity 87. Of equal importance is strong energy depletion 
caused by Pluronics in MDR cancer cells. The inhibition of the efflux proteins and ATP 
depletion together cause a shut-down of the drug efflux system, increase in the drug entry 
in the cells, and achieve effective sensitization of MDR cells 88, 89. Minko et.al reported 
that DOX/P85 formulation can induce apoptosis in the resistant cancer cells more 
efficiently than free DOX 90. The treatment of the cells with DOX alone simultaneously 
activated a proapoptotic signal and an antiapoptotic cellular defense. Therefore, the 
apoptosis induced by DOX was substantially limited. In contrast, the treatment of the 
cells with DOX/P85 formulation significantly enhanced the proapoptotic activity of the 
drug and prevented the activation of the antiapoptotic cellular defense. This is likely to 
result in the stronger cytotoxic response of the resistant cells to the DOX/P85 formulation 
compared to the free drug. Overall, Pluronic block copolymers represent a potent 
chemosensitizer of MDR cancer cells displaying complex effects in drug resistant cells 
that are currently under investigation.  
 
2.3 Drug Delivery Systems 
 
Since many anticancer drugs are hydrophobic, they cannot be injected directly into the 
bloodstream. The delivery vehicle must have low toxicity, high dosage, and localized 
delivery capability. The development of polymer drug delivery systems (DDS) for 
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anticancer drugs was first initiated nearly 30 years ago and many research groups since 
then have been involved in the realization of this technology, but its full practical 
implementation still remains open. The recent achievements in the design and 
development of the four polymer drug delivery systems and delivery vehicles (liposomes, 
microparticles/nanoparticles, polymer-drug conjugates, and polymeric micelles) are 
summarized in the following sections. 
2.3.1 Liposomes 
Liposomes are spherical aggregates of phospholipids, which form the basic structure of 
all cell membranes 91. When phospholipids, which have a polar head and two 
hydrocarbon tails, are placed in an aqueous solution, they spontaneously form a spherical 
bilayer where hydrophilic heads facing outside and hydrophobic tails pointing inside, 
enclosing a packet of solution. Since liposomes contain both hydrophobic regions (where 
the hydrocarbon tails are touching) and hydrophilic packets of aqueous solution, they can 
be used to encapsulate both hydrophobic and hydrophilic drugs. Hydrophobic drugs such 
as Taxol are encapsulated in the lipid bilayer of the liposome 92. The size of liposomes 
ranges from 50-300 nm in diameter. To allow for a high dosage, liposomes with 
encapsulated Taxol usually are approximately 200-250 nm in diameter 93.   
 
The mechanism of delivery of liposomes to the tumor is by the leaky vasculature 
mentioned in the previous section. This allows liposomes to enter and remain in the 
interstitial space of the tumor. Once there, the exact mechanism of transport of drug into 
the tumor cells is unknown, but most experts believe that it is via three main pathways 93. 
First, the liposomes may break down in the tumor tissue and allow for the passive 
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diffusion of the lipophilic drug out of the liposomes and into the tumor cells. Second, the 
liposomes can be internalized by receptor-mediated endocytosis. Once in the cell, they 
can be degraded in the endosome, allowing the drug to enter the cell. Finally, the 
liposomes can be internalized into the lipid bilayer cell membrane. This would further 
localize them to the tumor cell and allow for the drug to diffuse into the cell. 
 
There are many advantages of using liposomes as the delivery vehicle. The charge of the 
liposomes can be altered by using different ratios of cationic or anionic phospholipids. 
The stability and subsequent circulating time of the liposomes can be increased by 
addition of PEG chains to avoid uptake and destruction by the reticular endothelial 
system 94. In addition, the liposomes can be targeted to specific tumor cells by attaching 
antibodies or other specific ligands to their surface 95. 
 
There are also some disadvantages of using liposomes as a delivery vehicle. The dosage 
of water insoluble drugs, including Taxol and doxorubicin, is limited due to the 
encapsulation within the lipid bilayer. This dosage is higher than the concentration in the 
conventional treatment, but it is less than the dosage used in microparticles. Also, the 
addition of the drug into the bilayer may cause the liposome to be less sterically stable. 
This could cause the breakdown of the liposome prior to its entry into the tumor. In 
addition, the size of the liposome (~250 nm) could hinder extravasation into certain areas 
of the tumor. Despite these problems, liposomes have been shown to be a more efficient 
and less toxic delivery method compared to the current treatment. 
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2.3.2 Polymeric microparticles/nanoparticles 
Microparticles (inclusive of submicron particles of 100-500 nm) are delivery vehicles 
that allow for a local and controlled release of both hydrophilic and hydrophobic drugs 96. 
This is an important factor since the hydrophobic anticancer drug must be properly 
encapsulated prior to injection into the bloodstream. Microparticles/nanoparticles made 
of biodegradable copolymers, such as polylactide co-glycolide (PLGA), can be used to 
encapsulate the hydrophobic drugs 97. In recent years, many polymers or copolymers 
have been used as drug-loaded nanoparticles. These include PLGA, HPMA, 
polyethylcyanoacrylate (PECA), PLGA-PEG 98, PCL-PEG and PLA-PEG-PLA.  
 
There are many advantages of using macroparticles/nanoparticles as a delivery vehicle. 
Since they are typically made of biodegradable polymers, the release of the drugs can be 
controlled over time following the degradation of the polymers. In fact, the 
macroparticles/nanoparticles can be chemically altered to allow a delay in the release of 
drug until the nanoparticles reach the targeted delivery site. In addition, a large dose of 
hydrophobic drugs can be encapsulated into the macroparticles/nanoparticles. 
Furthermore, the macroparticles/nanoparticles can be used for localized delivery by 
attaching antibodies or other specific ligands on the outer surface of the particles.   
 
There are also some disadvantages of using macroparticles/nanoparticles as a delivery 
vehicle. The main problem is the size. When these particles are injected into the 
bloodstream, they may tend to cluster and form aggregates and cause an embolism of 
blood capillaries 25. The mechanism of delivery of macroparticles/nanoparticles to the 
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tumor site is via EPR effect. Due to their size, there would be poor extravasation of these 
vehicles from the bloodstream into the tumor tissue. Another problem that can occur with 
macroparticles/nanoparticles is the opsonization and uptake by RES. Thus, most 
microparticles/nanoparticles that are injected into the bloodstream are first coated with 
PEG which prevents the addition of opsonin by RES. The addition of opsonin to a 
particle in the body leads to immune response that involves the recruitment of 
macrophages and the uptake and destruction of the vehicles. The RES has a much higher 
recognition and uptake of particles greater than 200 nm, even if the particles have a 
modified PEG surface 99. For targeted drug delivery to tissues, PEG and ligands would be 
added to the macroparticles/nanoparticles surface. However, this would further magnify 
the aforementioned size problems of macroparticles/nanoparticles.  
2.3.3 Polymer-drug conjugates 
A simplified model of a polymer-drug conjugate (it is also called prodrug) (Figure 2.7) 
used in many studies 100-102 consists of a biocompatible water-soluble polymer carrier 
bearing drug moieties and guiding device in its side chains. The carrier could be either an 
inert or biodegradable polymer. It forms the backbone of the system and protects the drug 
from fast elimination from the body. The drug can be attached to the carrier via a 
biodegradable spacer susceptible to enzymatic or hydrolytic degradation. Proper selection 
of this spacer offers the possibility of controlling the site and the rate of drug release from 
the polymer and thus, in many cases, its activation. The site of the drug release can be 
also controlled by proper selection of the homing device (e.g. antibody) facilitating active 
targeting to specific receptors in the body, e.g. to the tumor or to surface antigens of 
tumor cells. Most of the recently studied and developed targeted or nontargeted water-
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soluble polymer DDS have been tailored as lysosomotropic drugs, i.e. oligopeptide 
spacers were prepared as substrates for lysosomal enzymes 100, 101, 103. One of the 
prodrugs that has been clinically tested is poly [N-(2-hydroxypropyl)-methacrylamide] 
(PHPMA) conjugates with DOX attached via the biodegradable oligopeptide Gly-Phe-






Figure 2.7 Scheme of a polymer prodrug 27 
 
The polymer carrier used in this method must meet certain specific criteria: its molecular 
weight and structure should protect the drug from fast elimination processes (urinary 
excretion, hepatic uptake); it should contain functional groups permitting covalent 
bonding of the drug and targeting moiety; it should be water soluble, biocompatible, and 
non-immunogenic; the spacer (and possibly also the polymer) has to be biodegradable; 
and the synthesis should be reproducible and inexpensive. Polymers suitable for 
preparation of polymer prodrugs can be categorized according to their origin (natural or 
synthetic), chemical nature (vinyl and acrylic polymers, PEG, polysaccharides, 
poly(amino acid)s, etc.), and the backbone stability (biodegradable or not). The 
biodegradable spacer has to be tailor-made either as a substrate for any lysosomal 
enzyme (lysosomotropic drugs) or susceptible to chemical hydrolysis. If the spacer is 
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hydrolysable at physiological pH (7.2), the drug can be released in blood circulation and 
partly in the tumor vasculature or interstitium. If it is hydrolysable as a result of changes 
in pH of the environment, the drug can released in mild acidic medium of the 
extracellular space of the tumor 104 or in acidic environment of endosomes or lysosomes 
following cellular uptake of the conjugate. 
 
Unfortunately, there are drawbacks limiting the practical application of the 
lysosomotropic conjugates, in particularly the complicated and expensive synthesis of the 
oligopeptide-containing spacers, monomers and polymers; the difficult selection of the 
proper spacers; and the need of the presence of sufficient concentration of lysosomal 
enzymes at the drug target. These drawbacks can be overcome using the systems in 
which free active drug is released from the carrier as a result of pH-dependent hydrolysis. 
2.3.4 Polymeric Micelles 
Polymeric micelles are made of amphiphilic copolymers with both a hydrophobic and a 
hydrophilic end. When these copolymers are placed in solution, they exist as individual 
polymer chains. However, if the polymer concentration is above the critical micelle 
concentration, these individual chains spontaneously form a spherical micelle shape 50. 
The spontaneous formation of micelles occurs as a result of two forces: an attractive force 
that leads to the association of molecules and a repulsive force that prevents unlimited 
growth of the micelles 51, 105. The core of the polymeric micelles is hydrophobic while the 
exterior is hydrophilic. This structure can be seen in Figure 2.8. The size of polymeric 
micelles ranges from 5-100 nm, depending on the length and properties of the copolymer. 
Hydrophobic drugs can be encapsulated in the hydrophobic core of the micelles.  
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Figure 2.8 Structure of polymeric micelles 106 
There are many advantages of using of polymeric micelles as a delivery vehicle. Similar 
to liposomes, the stability and subsequent circulating time of the polymeric micelles can 
be increased by adding PEG chains to avoid uptake and destruction by RES. In addition, 
the polymeric micelles can be targeted to a specific receptor in tumor cells by attaching 
antibodies or other specific ligands to their surface 106. Since the drug is encapsulated in 
the hydrophobic center of the micelle, the dosage of the drug in these vehicles is much 
higher than the conventional treatment or the use of liposomes. Finally, the small size of 
the micelles allows for extravasation into the leaky vasculature of tumor endothelial cells. 
Recent research has shown a decrease in tumor growth with delivery of the anticancer 
drugs such as Taxol via polymeric micelles compared with free drug 107, 108. Although 
polymeric micelles have many advantages, their stability in vivo needs further research. 
In addition, the relatively lower drug loading content and encapsulation efficiency 
compared with macroparticles/nanoparticles is still a problem. 
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The most recent trend of folate targeting focuses on attaching folic acid to polymer 
micelles 25, 50-53. Polymeric micelles are made of amphiphilic copolymers with both a 
hydrophobic and a hydrophilic end. The core of the polymer micelles is hydrophobic 
while the exterior is hydrophilic. The size of the polymer micelles is approximately less 
than 100 nm, which not only makes them escape from renal exclusion and reticulo-
endothelial system elimination but also gives them an enhanced vascular permeability.  
 
Biodegradable polymeric micelles made of poly(D,L-lactide-co-glycolide)-poly(ethylene 
glycol) (PLGA-PEG) is a good drug delivery carrier because of its excellent 
biodegradable property. Normally, PLGA-PEG is synthesized by ring-opening 
polymerization under high temperature 109. In this study, we adopted an alternative 
method linking PLGA and PEG together directly using the N-hydroxysuccinimide 
chemistry since PLGA with different molecular weight and different ratio between 
lactide and glycolide can be obtained from commercial source. This method is easier and 
more convenience for further modification such as antibody attachment. In order to 
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enhance the recognition ability of cancer cells, folate was attached at the PEG end to 
form PLGA-PEG-Folate (PLGA-PEG-FOL). After synthesis, the characterization and 
properties of the PLGA-PEG-FOL copolymer micelles were fully evaluated. The 
characterization is necessary since some properties (such as: surface properties, drug 
loading content, drug release etc.) are important for controlled release and targeting 
applications. Results obtained from this study can be useful for the design of micellar 
system for controlled release and tumor targeting research in the future. 
 
3.2 Materials and methods 
3.2.1 Materials 
For the synthesis of polymer micelles, poly(ethylene glycol)-bis-amine (PEG-bis-amine, 
Mw:3400), methoxy poly(ethylene glycol) (mPEG, Mn:2000), D,L-lactic acid, glycolic 
acid, stannous octanoate, N-hydroxy-succinimide (NHS), dicyclohexylcarbodiimide 
(DCC), folate, and doxorubicin (DOX) were purchased from Sigma-Aldrich. Poly(DL-
lactide-co-glycolide) (50:50, Mw:8,000) was purchased from Boehringer Ingelheim. All 
other reagents including dichloromethane (DCM), dimethylsulfoxide (DMSO), 
triethylamine (TEA), diethylether were HPLC grade and were used without further 
purification.  
 
3.2.2 Synthesis of Conjugates 
3.2.2.1 Synthesis methods comparison  
The folate conjugated copolymer PLGA-PEG-FOL could be synthesized by three 
different schemes which are described and compared as follows. 
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Scheme 1 
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(4) Synthesis of PLGA-PEG-FOL 
 From the above three schemes, it is obvious to find the last scheme is too complicated 
and the first two schemes are similar with each other. The only difference between the 
first and second scheme is the reaction sequence. The first scheme started from the 
synthesis of folate-PEG-NH2 and then attached it to actPLGA to get PLGA-PEG-FOL. 
While the second one began from the copolymer PLGA-PEG-NH2 formation, which then 
connected with the activated folate to form the final product PLGA-PEG-FOL. However, 
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PLGA-PEG was very low. The molar conjugation efficiency was only 30%. Therefore, 
the first scheme was selected as the synthesis method in this study. 
3.2.2.2 Detail synthesis procedures of Scheme 1 
The synthesis of folate conjugates followed a three-step reaction - PLGA activation, 
folate capping to form folate-PEG (FOL-PEG) and conjugation of PLGA with FOL-PEG 
to form PLGA-PEG-FOL. 
(1) PLGA Activation 
Briefly, 1 g of PLGA was activated by DCC and NHS in 5 ml DCM (molar ratio of 
PLGA: DCC: NHS = 1: 1.1: 1.1) at room temperature under nitrogen gas for 24 h 55. The 
resultant solution was filtered to remove the by-product dicyclohexylurea (DCU). After 
filtration, activated PLGA was precipitated by ice-cold diethyl ether and dried under 
vacuum. 
(2) Synthesis of FOL-PEG 
In the second step, folic acid (65 mg), DCC and NHS were dissolved in 5 ml DMSO 
(molar ratio of folic acid: DCC: NHS = 1: 1.1: 1.1) in the presence of 10 µl pyridine. The 
mixture was stirred overnight in the dark at room temperature under nitrogen gas. 
Afterwards PEG-bis-amine (500 mg) was added to the solution and the reaction was 
continued overnight at room temperature. The resulting mixture was diluted with 10 ml 
deionized water and centrifuged at 1000 g for 30 min to separate DCU. The supernatant 
was dialyzed against deionized water over 48 h to remove free folic acid and freeze-dried. 
The FOL-PEG was further purified by a DEAE (Diethylaminoethyl)-sepharose anion-
exchange column. The purity of FOL-PEG was confirmed by HPLC analysis and thin 
layer ninhydrin assay. 
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(3) Synthesis of PLGA-PEG-FOL conjugate 
The final conjugation of activated PLGA with 1.2 equivalents FOL-PEG was conducted 
in DMSO at room temperature for 8 h under nitrogen gas. The product was precipitated 
in ice-cold diethyl ether, dissolved in DMSO for dialysis against deionized water over 48 
h (MWCO: 10,000), and finally freeze-dried. The final product was analyzed by 
ninhydrin assay to confirm the absence of unreacted FOL-PEG.  
 
To compare the physicochemical properties of PLGA-PEG-FOL and the common PLGA-
PEG, PLGA-PEG block copolymer without folate conjugation was synthesized by ring-
opening polymerization as described in many references 53, 54. In brief, weighted amount 
of D,L-lactic acid, glycolic acid, mPEG and 0.5% wt% stannous octanoate (in distilled 
toluene) were added in a three-neck round bottom flask. The reaction was carried out at 
150°C in oil bath. After 15 h, the reaction was cooled down to room temperature and the 
product was dissolved in DCM and precipitated in cold methanol to remove unreacted 
monomers and mPEG. The final product was dried in vacuum oven for 2 days. 
3.2.3 Characterization of polymers 
The purity analysis of FOL-PEG was carried out by HPLC (Agilent 1100, HP). Analysis 
was performed on a TSK GEL G4000PWXL column (4.6 x 300 mm, 10 µm) using a UV 
detector at 365 nm. The mobile phase was 5mM NaCl solution. The flow rate was set at 
0.5 ml/min. The sample injection volume was 20 µl. The structures of FOL-PEG and 
PLGA-PEG-FOL were measured by DMSO-D6 at 500 MHz (AMF500, Bruker). The 
structure of PLGA-PEG-FOL copolymer was also confirmed by Fourier transform 
infrared (FT-IR) spectroscopy (Shimadzu). The samples for FT-IR analysis were 
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prepared by grinding 99% KBr with 1% copolymer and then pressing the mixture into a 
transparent tablet. The molecular weight and polydispersity were determined by gel 
permeation chromatography (GPC, Agilent 1100, HP) with a refractive index detector. 
An Agilent PLgel 5 µm mixed-C 300×7.5 mm column was used. The flow rate of the 
mobile phase (chloroform) was 1 ml/min. The injection volume was 20 µl sample 
solution (0.5% w/v). The molecular weight standard curve was established using standard 
polystyrene samples (molecular weights of 6.95×105, 5.04×104, 2.26×103 and 162 
respectively). 
3.2.4 Preparation of DOX-loaded PLGA-PEG-FOL micelles 
 
It is well-known that amphiphilic block copolymers form a micelle structure through the 
association of the hydrophobic segments in a hydrophilic solvent. The DOX-loaded 
polymer micelles were prepared based on this principle. Briefly, 10 mg DOX was 
neutralized with 2 moles excess TEA in 2 ml of DMSO. The DOX solution was then 
added into the 4 ml of DMSO solution with PLGA-PEG-FOL (or PLGA-PEG) conjugate 
(20 mg) and mixed by vortex for 10 min. The mixture was next transferred for dialysis 
(MWCO: 10,000) against deionized water for 48 h to produce the micelles 55. The water 
was replaced hourly for the first 3 h. The preparation of polymer micelles without DOX 
followed the same procedure described above in the absence of DOX.  
3.2.5 Characterization of polymer micelles 
3.2.5.1 Critical association concentration  
The critical association concentration (CAC) of block copolymers in PBS was 
determined by fluorescence spectroscopy using pyrene was used as a fluorescent probe. 
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The term CAC is usually employed for polymeric micelles to distinguish them from the 
critical micellar concentration (CMC) of surfactant micelles 110, 111. Fluorescence spectra 
were recorded by a fluorescence spectrometer (LS50B, Perkin Elmer). In brief, a thin 
film of pyrene was first formed by dropping a solution of pyrene in acetone in vials 
followed by the evaporation of acetone. The polymer solution (in PBS) was then added to 
the vials and the resulting mixture was stirred for 24 h to disperse pyrene in the polymer 
solution. The final pyrene concentration was 6×10-7 M. The excitation spectra were 
recorded from 300 to 360 nm with an emission wavelength of 395 nm. Both excitation 
and emission bandwidths were set at 2.5 nm. The intensity ratios of I333 to I335 were 
plotted as a function of logarithm of polymer concentration. The CAC value was 
determined from the change of the intensity ratio of the pyrene in the presence of 
amphiphilic polymer 112. 
3.2.5.2 Surface composition 
The surface composition of the micelles was detected by X-ray photoelectron 
spectroscopy (XPS, AXIS His-165 Ultra, Shimadzu) with curve fitting software provided 
by the manufacturer. The spectrum was recorded by fixed transmission mode with pass 
energy of 80 eV over a binding energy range from 0 to 1200 eV. 
3.2.5.3 Particle size 
Average size and size distribution of micelles were measured by the Laser Light 
Scattering technique (90-PLUS analyzer, Brookhaven Instruments). Samples were 
prepared by diluting micelles suspensions with PBS at pH 7.4. 
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3.2.5.4 Surface charge 
Zeta potential of the micelles was measured by the laser doppler anemometry (Zeta plus, 
Brookhaven Instruments). The micelles (~2mg) were suspended in PBS before 
measurement.  
3.2.5.5 Surface morphology 
The morphological examination of blank micelles and DOX-loaded micelles was 
performed using transmission electron microscopy (TEM). The micelle concentration 
used was 1 mg/ml. One drop of the micelle sample was placed on a 300-mesh copper grid. 
Excess liquid was blotted with filter paper. The samples were dried in hood for 2 h before 
examined by a transmission electron microscope (JEM-2010S, JEOL). In order to get 3D 
morphology, polymer micelles was analyzed by atomic force microscopy (AFM). The 
surface of particles was scanned with a Nanoscope IIIa Atomic Force Microscope 
(Multimode Scanning Probe Microscope, Digital Instruments) under tapping mode.  
3.2.5.6 Drug loading content and encapsulation efficiency 
 
The micellar solutions were frozen and lyophilized by a freeze dryer system (Alpha-1-4, 
Christ) to obtain dried nanoparticles. The weighted nanoparticles were dissolved and 
properly diluted in DMSO. The mass of DOX loaded in the micelles was determined by 
measuring the UV absorbance at 485 nm using UV-vis spectrophotometry (Cary 50, 
Varian). The entrapped DOX content in the micelles was calculated from the weight of 
initial drug-loaded micelles and the mass of incorporated drug using the following 
equation: 
 






The EE is defined as the ratio of actual and original amount of doxorubicin encapsulated 
in micelles. The calculation equation is as follows: 
 
 
3.2.6 In vitro drug release 
 
For drug release study, the DOX-loaded micellar solution prepared above was first 
diluted to 1 mg/ml of DOX and transferred to a dialysis tube. The dialysis tube was 
immersed in a beaker containing phosphate buffer solution (PBS, pH 7.4).The beaker was 
placed in a shaking water bath at 37°C and shaken with a speed of 100 rpm. To measure 
the release of DOX at different time intervals, 1ml of solution was withdrawn from the 
medium and replaced with fresh PBS. The DOX content in the sample was analyzed by 
reversed phase HPLC on a ZORBAX SB-C18 column (4.6 x 250 mm, 5 µm) using a 
fluorescence detector at excitation wavelength of 475 nm and emission wavelength of 
580 nm. The mobile phase consisting of acetonitrile and water was programmed with 
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3.3 Results and discussion 
 
3.3.1 Synthesis and characterization of PLGA-PEG-FOL conjugate 
3.3.1.1 HPLC analysis of FOL-PEG  
 
Reaction of activated folate with PEG-bis-amine yielded a mixture of product including 
FOL-PEG-FOL, FOL-PEG and PEG-bis-amine, although FOL-PEG is the major part. 
The purity of the product was analyzed by TSK-GEL G4000PWXL column, which is 
widely used in high performance size-exclusion chromatography (SEC). The separation 
was based on liquid exclusion-adsorption chromatography (LEAC) which is an important 
method for analysis of PEG derivatives. It was reported that the PEG derivatives can be 
separated by TSK-GEL G4000PWXL column at low ionic strength 113, 114. It was shown 
that ion-exchange interactions are mainly involved in the retention mechanism of PEG 
compounds, since retention volume decreases when salt concentration in the mobile 
phase increases (or varying the pH of the mobile phase). The major difference among the 
PEG compounds with similar molecular weights is the number of amino groups linked to 
the ends of PEG. These PEG compounds with net positive charges at appropriate pH can 
absorb to anion exchange resin. In our study, we adopted similar HPLC conditions at 
which the PEG 3350, PEG3350-NH2 and NH2-PEG3350-NH2 can be well separated 113. 
Because of the ionic difference, the uncharged FOL-PEG-FOL was washed out first and 
followed by FOL-PEG and NH2-PEG-NH2. As shown in Figure 3.1, the HPLC retention 
time of FOL-PEG-FOL and FOL-PEG is 18.6 min and 21.7 min respectively. Purified 
FOL-PEG was obtained after anion-exchange column separation and confirmed by a 
single HPLC elution peak.  









Figure 3.1 The HPLC analysis of FOL-PEG (a) before separation, (b) after separation. 
 
3.3.1.2 1H-NMR spectrum of copolymer 
3.3.1.2.1 The synthesis of FOL-PEG  
Figure 3.2 shows the typical 1H-NMR spectrum of folate. The folate structure can be 
divided to two parts- pteroate and glutamic acid. For glutamic acid, the peaks at 1.85 and 
2.1 ppm, 2.3 ppm, and 4.3 ppm belong to the β-CH2-, γ-CH- and α-CH2- of glutamic acid 
respectively. For pteroate, peaks at 6.65 ppm (3’,5’-H, 2H) and 7.66 ppm (2’,6’-H, 2H) 
belong to the protons on the benzene ring. The peak at 8.77 ppm belongs to the proton of 






Retention time (min) 
FOL-PEG
(b) (a) 



























Figure 3.2 1H-NMR spectrum of folic acid in DMSO-d6 at 500 MHz 
In the 1H-NMR spectrum of FOL-PEG (Figure 3.3), the peak at 8.67 ppm belongs to the 
proton of =CH on the quinoid ring of folate. The peaks at 6.65 ppm (3’,5’-H, 2H) and 
7.66 ppm (2’,6’-H, 2H) belong to the protons on the benzene ring. The peaks at 1.9, 2.1-
2.4 and 4.3 ppm originate from the α, β and γ -CH2- protons of glutamic acid part in the 
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3.3.1.2.2 PLGA-PEG-FOL copolymer 
The 1H-NMR spectrum of PLGA-PEG-FOL conjugate (Figure 3.4) confirmed the 
synthesis of block copolymer. The peak at 3.6 ppm is attributed to the -CH2- protons of 
PEG block. The peaks at 5.2 ppm and 1.6 ppm originate from -CH- protons and -CH3 
protons of the PLA block. The peak at 4.8 ppm belongs to the -CH2- protons of PGA 
block. The small peaks at 6.6 ppm, 7.6 ppm and 8.7 ppm are the typical protons of folate. 
The amount of folate content in PLGA-PEG-FOL was 93% (molar content) measured by 
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3.3.1.3 FT-IR spectrum of copolymers 
 
Figure 3.5 shows the IR spectra of PEG, activated PLGA and copolymer PLGA-PEG-
FOL. For PEG, a C-H stretching band appeared at 2885 cm-1 and for activated PLGA, an 
ester carbonyl band appeared at around 1760 cm-1. It is clear that the two characteristic 
peaks found in the copolymer corresponded to those in PEG and PLGA, indicating the 









Figure 3.5 Infrared spectra of PEG, activated PLGA and PLGA-PEG-FOL copolymer 
 
3.3.1.4 GPC analysis 
 
Figure 3.6 shows GPC chromatogram of PEG-bisamine, FOL-PEG, PLGA-PEG-FOL 
and PLGA-PEG. A single narrow peak of the PLGA-PEG-FOL and PLGA-PEG 
copolymer was found. It indicates that PLGA-PEG-FOL conjugate and the PLGA-PEG 
copolymer was synthesized successfully.  
 
PLGA-PEG-FOL 








Figure 3.6 The GPC of (a) PEG-bisamine, (b) PLGA-PEG and (c) PLGA-PEG-FOL 
 
Table 3.1 shows the molecular weight and weight distribution of PLGA, FOL-PEG, 
PLGA-PEG-FOL and PLGA-PEG. The increase in the Mw of PLGA-PEG-FOL 
compared with the Mw of PLGA and FOL-PEG indicates the successful conjugation of 
PLGA and FOL-PEG. The Mw of PLGA-PEG demonstrates that the ring-opening 
polymerization was also successful. 
Table 3.1 The molecular weight and polydispersity of the polymers 
 
Samples Mn Mw Polydispersity (Mw/Mn) 
PLGA 6,015 7,410 1.23 
FOL-PEG 4,575 5,262 1.15 
PLGA-PEG-FOL 9,995 12,795 1.28 
PLGA-PEG 8,155 10,874 1.33 
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3.3.2 Properties of copolymer micelles 
3.3.2.1 Critical association concentration (CAC)  
The CAC is an important factor for determining the stability of the polymer micelles in 
physiological medium such as blood. A highly diluted condition below CAC in the blood 
compartment may induce the dissociation of micelles and eventually may provoke the 
burst release of the incorporated drugs from the core. In order to detect the micelle 
formation of block copolymers in PBS medium, pyrene was chosen as a fluorescent 
probe because it is very hydrophobic and has a very low solubility in water. During 
micelle formation, pyrene preferentially solublizes itself into the hydrophobic core of the 
micelles, resulting in a substantial increase in the fluorescence intensity. In PBS, the 
maximum peak for pyrene is at 333 nm. As shown in Figure 3.7a, the peak position 
changes from 333nm to 335 nm when the concentration of block copolymer increases 
gradually. The shift of the excitation peak demonstrates pyrene transfer to the less polar 
micellar core with increasing polymer concentration. Figure 3.7b shows the change of the 
I335 /I333 fluorescence intensity ratio as a function of polymer concentration. The CAC 
value was determined from the extrapolated intersection of the non-horizontal tangents of 
the curve with the horizontal tangent through the points at low concentrations 111, 112, 115. 
At low copolymer concentration range below CAC, the intensity ratio of I335 to I333 is 
almost constant. However, as polymer concentration increases beyond CAC, the intensity 
ratio increases sharply, indicating that pyrene is accumulated to the hydrophobic core of 
the micelles. From Figure 3.7b and 3.7c, the CAC values of PLGA-PEG and PLGA-
PEG-FOL were determined to be 1.8 and 2.4 mg/l respectively. These low CAC values 
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indicate that the micelles are still stable at low concentrations, allowing their use in very 
dilute medium such as body fluids 53.  
Figure 3.7a Excitation spectra of pyrene as a function of PLGA-PEG-FOL concentration 








Figure 3.7b Plot of intensity ratios I335/I333 vs. log C of PLGA-PEG conjugate 











































Figure 3.7c Plot of intensity ratios I335/I333 vs. log C of PLGA-PEG-FOL conjugate 
 
3.3.2.2 Surface composition  
Sufficient hydrophobic folate moieties available on the surface of the micelles is 
important for specific tumor targeting because the folate groups in the core of the 
micelles may be unavailable for folate receptor targeting. The surface characterization of 
the copolymer micelles was carried out using XPS. The N1S region of the XPS data can 
be used to determine the existence of folate incorporated onto the surface of the micelles 
because the FOL part has eight nitrogen atoms in its chemical structure. From Figure 3.8, 
the N1S spectrum can be deconvoluted into two peaks. The peak at 399.2 eV belongs to 
the -NH2 group and the other peak at 398.3 eV belongs to the quinoid imine group (=N-) 
in folate. The -NH2 peak is most likely due to one -NH2 and two -NH- groups of folate. 
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groups, this may explain the relative large =N- peak observed in the data. This observed 
=N- peak indicates that some folate groups existed on the surface of the PLGA-PEG-FOL 









Figure 3.8 XPS N1S region of PLGA-PEG-FOL conjugate 
 
3.3.2.3 Morphology of polymer micelles  
In order to characterize the morphology of the nanospheric copolymer micelles, TEM and 
AFM analysis were carried out. The shape and size of the block copolymer micelles were 
examined by TEM. As shown in Figure 3.9, spherical and relatively uniform micelles 
were observed with diameters typical of those reported for other polymeric micelles 51. 
The size of most of the micelles ranges between 60-80 nm in diameter. It was reported 
that micellar diameters within the size range 50-150 nm are considered desirable for drug 
delivery since, they are large enough to escape renal excretion, yet small enough to avoid 
hepatic elimination 52. Figure 3.10 shows AFM images of PLGA-PEG and PLGA-PEG-
FOL micelles. AFM images also display that most of the micelles have a regular 
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spherical shape and have narrow size distribution. The size of the micelles shown in 
AFM is consistent with the one shown in TEM as well as the laser light scattering study 



















Figure 3.10 AFM images of (a) PLGA-PEG micelles and (b) PLGA-PEG-FOL micelles 
              (a)                                                                (b) 
 
(a) (b) 
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3.3.2.4 The micelle size, size distribution and stability 
The micelle size and size distribution were measured by laser light scattering technique. 
As shown in Table 3.2, without DOX loading, the diameters of the blank PLGA-PEG and 
PLGA-PEG-FOL micelles were 60 nm and 68 nm respectively. These sizes are 
considered similar, showing that the end groups of the copolymers (amino or folate 
groups) do not affect the size of the resultant micelles. In addition, the sizes of the 
micelles followed narrow distributions. With DOX loading, the size of the micelles 
increased, reflecting the encapsulation of the drug in the micelles. The size distribution of 
the DOX-loaded micelles was almost identical to that observed before DOX loading, 
maintaining the narrow size distribution profile as shown in Figure 3.11. 
 
Zeta potential measures the surface charge density of the micelles and it reflects the 
particle stability in suspension through the electrostatic repulsion between the particles. 
The higher absolute value of zeta potential shows larger charge on the surface of particles. 
The larger charge on the surface results in stronger repulsion among particles and 
prevents them from aggregation in the given buffer system. The zeta potential 
measurement in Table 3.2 shows that both PLGA-PEG and PLGA-PEG-FOL micelles 
are negatively charged. Compared with PLGA nanoparticles, whose zeta potential was 
approximately -30 to -50 mV 116, 117, the negative surface charge of PLGA-PEG micelles 
was much lower. Since PEG is non-ionic, this zeta potential decrease demonstrated the 
presence of PEG layer on the surface, which shifted the shear plane of the diffusive layer 
to a larger distance 118. The smaller and negative zeta potential of PLGA-PEG was also 
reported in other papers 58, 119. For the PLGA-PEG-FOL micelles, although the carboxyl 
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groups of folic acid should be on the surface of the micelles and may affect the surface 
charge, no significant change was found in our experiments. This is consistent with other 
studies on folate conjugated micelles 58, 120, 121. 
Table 3.2 Physicochemical characterizations of micelles 









Figure 3.11 Size and size distribution of DOX-loaded PLGA-PEG-FOL micelles  
 
3.3.2.5 Effects of drug feeding ratios on micelle properties  
 
Table 3.3 shows the amount of DOX introduced into micelles with varying feed weight 
ratios of DOX to copolymers, ranging from 0.1:1.0 to 1.0:1.0. The drug loading content 
was influenced by the feed ratios of the drug and copolymer. When the initial weight 
Micelles size (nm) Zeta Potential (mV) 
Copolymer 
Drug Free Drug Loaded* Drug Free Drug Loaded*
PLGA-PEG 60.2±0.03 85.3±0.04 -6.4 -8.3 
PLGA-PEG-FOL 68.3±0.04 88.1±0.04 -7.1 -7.9 
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ratio of DOX to copolymer increased from 0.1:1.0 to 0.5:1.0, the drug loading content 
increased slightly, so was the encapsulation efficiency. When the initial ratio exceeded 
0.5:1.0, the precipitation of unloaded DOX in the aqueous medium was observed during 
the preparation of micelles, resulting in the decrease of both the loading content and 
encapsulation efficiency. Due to the hydrophobic character of DOX, when the amount of 
drug increased in the aqueous medium, the interaction between drug molecules became 
stronger than that between drug and copolymer. This eventually resulted in the observed 
precipitation of the unloaded drug. Therefore, from the data, the optimal initial weight 
ratio of DOX to PLGA-PEG-FOL is 0.5:1.0, which corresponds to a drug loading content 
of 27.6% and drug encapsulation efficiency of 61.1%. Similar results were also obtained 
for the PLGA-PEG micelles. In addition, although the feeding ratio increased from 
0.1:1.0 to 1.0:1.0, the size of the micelles only increased slightly (<20%). This finding 
suggests that the copolymer micellar assemblies, where the PLGA blocks associated 
within the particle core and the PEG occupied as the outer shell, contain sufficient 
molecular space within the core itself and thus could sustain a high degree of drug 
loading without a significant increase in the micellar size. The zeta potential 
measurement in Table 3.3 shows that the copolymer micelles remained relatively steady 
with increasing feeding ratio from 0.1:1.0 to 1.0:1.0. This confirms that the colloidal 
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0.0:1.0 / / 60.2 -6.4 
0.1:1.0 8.3 49.8 80.5 -6.4 
0.2:1.0 12.9 51.3 86.5 -6.8 
0.3:1.0 19.5 55.5 83.9 -7.8 
0.5:1.0 29.3 63.3 85.3 -8.3 
0.7:1.0 15.3 28.8 86.7 -7.6 
PLGA-PEG 
1.0:1.0 10.0 22.6 92.0 -7.1 
0.0:1.0 / / 68.3 -7.1 
0.1:1.0 8.9 50.2 81.3 -7.0 
0.2:1.0 15.8 56.8 85.0 -6.7 
0.3:1.0 21.2 58.2 86.5 -7.2 
0.5:1.0 27.6 61.1 88.1 -7.9 
0.7:1.0 18.3 23.5 89.2 -6.6 
PLGA-PEG-FOL 
1.0:1.0 12.8 20.2 99.2 -6.4 
 
3.3.3 In vitro drug release 
 
Figure 3.12 shows the drug release profile of DOX-loaded PLGA-PEG and PLGA-PEG-
FOL micelles. Regardless of the end group of PLGA-PEG, the DOX release rate was 
faster in the first 10 h and reached a plateau in 24 h. The initial burst release can be 
attributed to DOX molecules located within the corona or at the interface between the 
micelle core and surface 122. Nearly 40% DOX was released in the first 24 h.  
 












Figure 3.12 The release profiles of the polymer micelles. 
 
3.4 Conclusions 
PLGA-PEG-FOL was successfully synthesized as a new drug carrier. The 
physicochemical studies show that the micelle size was small (approximately 60-80 nm) 
and the size distribution was narrow. The micelles can be formed at low concentrations, 
allowing their use in blood medium. Particle surface analysis confirms that folate groups 
are exposed on the surface of the nanospheric micelles for potential interaction with FRs. 
The optimal initial weight ratio of DOX to PLGA-PEG-FOL was 0.5:1.0, with a drug 
loading content of 28% and drug encapsulation efficiency of 61%. The DOX release rate 
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Chapter 4  
Selectivity of folate conjugated polymer micelles 




The attachment of folate to the polymer micelles enhances their ability of recognizing 
tumor cells. Recently, several folate conjugated polymer micelles have been shown to 
display higher cytotoxicity and cellular uptake on FR-positive cancer cells compared with 
the micelles without folate 54-58. However, the existing studies did not address the 
selectivity of folate micelles between cancer and healthy cells. The difference in 
selectivity of the micelles to cancer and normal healthy cells as well as the cytotoxicity of 
the micelles to healthy cells has to be evaluated before the folate conjugated micelles can 
be used for practical drug delivery applications. Furthermore, it is still unclear that how 
many folate groups conjugated to the micelles are sufficient for FR recognition to cancer 
cells and, at the same time, induce minimum non-specific binding to healthy cells. 
 
The purpose of this study was to address the abovementioned questions. In this chapter, 
the cell culture experiments of DOX loaded PLGA-PEG-FOL micelles were performed 
using KB, MATB Ш and C6 cells which have different degree of FR expression as well 
as human healthy fibroblast cells without FRs. KB and MATB Ш cell lines are known to 
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have vastly overexpressed FRs and C6 cell line has only limited FRs expression. The 
targeting ability and the selectivity of the micelles were studied by evaluating the 
cytotoxicity, cellular uptake and apoptosis perturbation. Finally, the optimal amount of 
folate content on the micelles for different cell lines was determined by balancing the 
cytotoxicity to cancer cells and healthy cells.  
 




For cell culture experiments, human carcinoma cell line of the oral cavity (KB), rat breast 
cancer cell line (MATB Ш), rat brain glioma cell line (C6), and human fibroblasts (CCL-
110) were purchased from ATCC. Folate-free RPMI 1640 medium, Dulbecco’s Modified 
Eagle’s Medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin (pen-strep), 
and Trypsin-EDTA (0.5% trypsin, 5.3mM EDTA tetra-sodium) were obtained from 
Invitrogen. 3-(4,5-dimethylthiaol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), triton 
X-100, propidium iodide (PI) were obtained from Sigma-Aldrich.  
4.2.2 Preparation and characterization of DOX-loaded micelles 
 
The synthesis of folate conjugates followed a three-step reaction - PLGA activation, 
folate capping to form FOL-PEG and conjugation of PLGA with FOL-PEG to form 
PLGA-PEG-FOL as described in Chapter 3 (Section 3.2.2). The DOX-loaded polymer 
micelles were prepared by dialysis method. Before micelle preparation, DOX was 
neutralized first. Briefly, 10 mg DOX was neutralized with 2 moles excess TEA in 2 ml 
DMSO. The DOX solution was then added into the 4 ml DMSO solution with PLGA-
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PEG-FOL conjugate (20 mg) and mixed by vortex for 10 min. The mixture was next 
transferred for dialysis (MWCO: 10,000) against deionized water for 48 h to produce the 
micelles. The water was replaced hourly for the first 3 h. Untrapped DOX and TEA were 
removed by subsequent extensive dialysis against deionized water. The characterization 
of DOX-loaded PLGA-PEG-FOL micelles was described in Chapter 3. 
4.2.3 In vitro cell culture studies 
4.2.3.1 Cell culture 
 
Three cancer cell lines (KB, MATB Ш and C6) and one human fibroblast cell line (CCL-
110) were used. KB, MATB Ш and C6 cell lines were cultured using the method 
described previously by other research groups 57, 58, 123. Briefly, KB and C6 cells were 
cultured in folate-free RPMI 1640 medium with 10% FBS and 1% pen-strep in T-75 
flasks at 37°C with 95% humidity and 5% CO2. The medium was changed two to three 
times a week. The cells were harvested with trypsin-EDTA after 80% confluence. MATB 
Ш cells were cultured in McCoy's 5a medium with 10% FBS and 1% pen-strep in T-75 
flasks. The medium was changed three times a week. CCL-110 cells were used as healthy 
cells in this study. It was cultured in DMEM medium with 10% FBS and 1% pen-strep.  
4.2.3.2 Folate receptor expression in different cell lines 
 
Cells were first cultured in 6-well plates for 5 days. Before the experiment, the culture 
medium was removed and the cells were washed twice with PBS. Subsequently, mouse 
anti-folate-receptor antibody (20µg/ml) was added at 4°C for 30 min. After washing three 
times with PBS, FITC-conjugated anti-mouse IgG (20µg/ml) was then added to the plates 
at 4°C for another 30 min. After final washing, the cells were trypsinized and suspended 
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in 1 ml PBS (1×106 cells/ml). The degree of receptor expression was evaluated by flow 
cytometry (EPICS Altra Flow Cytometry Systems, Beckman Coulter). 
4.2.3.3 Cytotoxicity assays 
 
The cytotoxicity of free DOX and DOX-loaded polymer micelles was determined by 
tetrazolium dye (MTT) assay. Cells were seeded in 96-well plate at a density of 1×104 
cells/well and incubated for 24 h before the assay. After that, the cells were incubated 
with free drug or drug loaded micelles for another 24 h. The DOX concentration in 
various formulations was 0.01, 0.1, 1.0, 10.0, 20.0 and 50.0 µM. Each DOX 
concentration was repeated three times and the culture medium without any drug 
formulations was used as the control. Blank micelles without DOX were used to test the 
cytotoxicity of the blank micelles. After 24 h incubation, the cells were washed three 
times with PBS and incubated in fresh culture medium for an additional 24 h. 
Subsequently, 20 µl of MTT solution was added to each well for 4 h in dark. The medium 
was then removed and 100 µl of DMSO was added to each well. After vigorous mixing 
to dissolve the reacted dye, the absorbance was read with a microplate reader (GENios, 
Tecan) using a test wavelength of 570 nm and a reference wavelength of 630 nm. The 
cell viability was calculated as the ratio of the number of surviving cells in the drug 
treated samples to that of the control. 
4.2.3.4 Cellular uptake of DOX 
 
Since DOX has a fairly strong fluorescence, it can be easily quantified. The cellular 
uptake experiments were performed using flow cytometry. Exponentially growing cells 
were seeded in 6-well culture plates (5×104 cells per well) and incubated for 48 h. The 
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cells were then incubated at 37°C with free DOX or DOX-loaded polymer micelles in 
medium (as described above). After exposure for 2 h, the cells were washed with cold 
PBS three times and harvested using trypsin-EDTA and fixed by 1% of 
paraformaldehyde PBS solution. Cell density was adjusted to 1×106 cells/ml and 1ml of 
this cell suspension was measured by flow cytometry using internal fluorescence of DOX. 
The cellular uptake of different cell lines was compared. Furthermore, the intracellular 
distribution of cell-associated DOX was observed using confocal laser scanning 
microscopy (LSM 410, Carl Zeiss) as the following: Cells were cultured in Lab-Tek® 
chambered coverglass (NUNC 155383) for 48 h (2×104cells/chamber) and incubated with 
medium containing free DOX or DOX-loaded polymer micelles (DOX concentration of 
10 µM). After 60 min, the medium was removed and the cells were washed with PBS 
three times, fixed with ethanol for 20 min, and washed with PBS again. The cells were 
next observed and imaged at excitation wavelength of 485 nm and emission wavelength 
of 580 nm. 
4.2.3.5 Cell cycle analysis  
 
Cells were collected and suspended in PBS (106-107 cells/ml) after incubating with 
various DOX formulations (DOX concentration of 10 µM) for 2 h. The cells were fixed 
by 70% cold ethanol for 12 h. After fixation, the cell suspension was centrifuged twice to 
remove ethanol thoroughly. Subsequently, cell pellets were suspend in 1ml PI / Triton X-
100 staining solution with RNase A and kept at room temperature for at least 30 min. 
Finally PI fluorescence in cell pellets was measured by flow cytometry. 
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4.2.3.6 The effect of folate content on targeting efficiency  
 
To investigate the effect of different folate content on the targeting ability of the folate 
conjugated micelles to cancer cells, a series of micelles with different folate content was 
obtained by mixing the copolymer PLGA-PEG-FOL with PLGA-PEG with different 
ratios. The folate content in the mixed micelles was determined by UV-vis 
spectrophotometry at 365nm using a serial dilution of folic acid in DMSO as standard. 
The cellular uptake experiments to evaluate the effect of different folate content were the 
same to that described in the previous section. The cellular uptake of DOX in cancer cells 
(KB, MATB Ш and C6 cells) and healthy cells (CCL-110) was compared. The drug 
concentration was set as 10 µM and the incubation time was 2 h. The fluorescence 
intensity was measured by the same microplate reading method. The cellular uptake 
efficiency was obtained by the fluorescence intensity ratio of cell-associated DOX to 
DOX in control.  
4.2.4 Statistical analysis  
 
All data were presented as mean ± S.D. and analysed using Student’s t test. Statistical 
significance was determined at a value p < 0.05.  
 
4.3 Results and discussion 
4.3.1 Characterization of DOX-loaded micelles 
 
As described in last chapter (Section 3.3.2.5), the diameter of the DOX-loaded PLGA-
PEG-FOL micelles was smaller than 100 nm which is typical of those reported for other 
polymeric micelles 124. The initial weight ratio of DOX to PLGA-PEG-FOL was 0.5:1.0, 
                                                                                                                                                                                Chapter 4        
 68
which corresponded to 28% DLC and 61% EE. Similar results were also obtained for the 
PLGA-PEG micelles.  
4.3.2 Expression of folate receptors in different cell lines 
 
The folate receptor (FR) expression on the surface of different cell lines (KB, MATB Ш, 
C6 and human fibroblast cells CCL-110) was evaluated by flow cytometry. Figure 4.1 
shows the amount of FR expression in different cells by FITC-conjugated anti-FR 
antibody. The amount of FRs of KB cells was approximately 4 fold higher than that of 
MATB Ш cells and 30-40 fold higher than that of C6 cells. In addition, no folate 
receptors were detected on the surface of fibroblast cells compared with the control 








Figure 4.1 Flow cytometry evaluation of the expression of folate receptors on different 
cell lines. Cells were treated with mouse anti-FR antibody and followed by FITC-
conjugated anti-mouse IgG antibody. 
 
4.3.3 Cytotoxicity Test 
The cytotoxicity of different DOX formulations (free DOX, DOX-loaded PLGA-PEG 
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drug loading in the culture medium, the PLGA-PEG-FOL micelles showed much higher 
cytotoxicity than PLGA-PEG micelles and free DOX when the drug concentration was 
between 0.1-10 µM. The IC50 values of free DOX, PLGA-PEG micelles, and PLGA-
PEG-FOL micelles were 0.96, 2.26 and 0.46 µM respectively. The cytotoxicity of free 
DOX was much higher than that of the PLGA-PEG micelles. Since free DOX is a small 
molecule, it can diffuse into the cells quickly. However, the micelles formulation can 
only be internalized in the cells by the endocytosis process. Compared with the PLGA-
PEG micelles, the overexpression of FRs on the surface of KB cells may significantly 
enhance the uptake of the PLGA-PEG-FOL micelles via FR mediated endocytosis and 
result in 5 fold higher cytotoxicity. Without DOX loading, no toxicity was observed after 
24 h incubation of 100 µM of PLGA-PEG micelles and PLGA-PEG-FOL micelles (data 
not shown). Therefore, the polymer micelles alone did not introduce any cytotoxic effect 










Figure 4.2 The cytotoxicity of different DOX formulations to KB cells. Bars marked with 
* are significantly different from bars with the same drug concentration (p<0.05). 
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To evaluate the selectivity of folate conjugated micelles, the cytotoxicity of DOX-loaded 
micelles to different cell lines (KB, MATB Ш, C6 and fibroblast cells) was also 
compared. As mentioned above, KB and MATB Ш cells vastly overexpress FRs, while 
C6 cells show limited expression of FRs and fibroblast cells has no or negligible FRs. As 
shown in Figure 4.3, the PLGA-PEG-FOL micelle was most effective against the KB 
cells followed by MATB III cells. The calculated IC50 of the PLGA-PEG-FOL micelles 
against KB, MATB Ш, C6 and fibroblast cells was 0.46, 0.62, 1.61, and 4.52 µM 
respectively. The cytotoxicity of PLGA-PEG-FOL micelles against MATB Ш cells was 
slightly less than that of KB cells. It is notable that although the C6 cells express 30 fold 
less FRs than KB cells, the IC50 of C6 cells was only 3.5 fold lower compared with KB 
cells. However, for fibroblast cells, the cytotoxicity of the PLGA-PEG-FOL micelles was 
nearly 10 fold lower than that of KB cells. These results demonstrate that the folate 
conjugated micelles can selectively target to cancer cells with overexpressed FRs even 










Figure 4.3 The cytotoxicity of DOX-loaded PLGA-PEG-FOL micelles to KB, MATB III, 
C6 and fibroblast cells. Bars marked with * are significantly different from the fibroblasts 
at the same drug concentration (p<0.05).  
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4.3.4 Cellular uptake of DOX  
Fluorescence markers are frequently used in cellular uptake studies 125, 126. In our case, 
however, because DOX is fluorescent, it can be used directly to measure cell uptake 
without additional markers. Base on our experience in the cytotoxicity study, the DOX 
concentration of 10 µM or lower in each formulation was used and the incubation time 
was within 2 h.  
 
Figure 4.4 shows the histogram of cell associated DOX fluorescence for KB, MATB Ш, 
C6 and human fibroblasts. The cells without any DOX formulations treatment were used 
as a control and showed only the auto-fluorescence of the cells. The fluorescence 
intensity is proportional to the amount of drug internalized by the cells. For KB cells, 
with equivalent DOX concentration in each formulation and same incubation time, the 
DOX-loaded PLGA-PEG-FOL micelles showed higher fluorescence intensity than free 
DOX and DOX-loaded PLGA-PEG micelles. This result further confirms that the cellular 
uptake of the micelles can be enhanced by attaching folate on their surface, and may 
explain the different cytotoxicity observed between the PLGA-PEG micelles and PLGA-
PEG-FOL micelles shown in the last section. For MATB III cells, similar to KB cells, the 
cellular uptake of PLGA-PEG-FOL micelles was much higher than that of PLGA-PEG 
micelles. The slight decrease in PLGA-PEG-FOL micelles uptake was likely due to the 
lower expression of FRs when compared with KB cells. For C6 cells, although the 
expression of FRs was very limited, the cellular uptake of PLGA-PEG-FOL micelles was 
still 2.6 fold higher than that of PLGA-PEG micelles. But for healthy human fibroblast 
cells, the fluorescence intensity of the DOX-loaded PLGA-PEG-FOL micelles overlaid 
with that of PLGA-PEG micelles and was substantially lower than that of free DOX. 
Since healthy fibroblasts have no FRs, the internalization of PLGA-PEG-FOL micelles 
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only depends on endocytosis. Compare fibroblasts with the other three cancer cell lines, it 
is obvious that the cellular uptake of PLGA-PEG-FOL micelles of cancer cells was 
substantially higher than that of fibroblasts. This confirms that the folate conjugated 



















Figure 4.4 Flow cytometry histogram profiles of KB, MATB III, C6, and fibroblast cells 
that were incubated with different drug formulations (DOX concentration of 10 µM). 
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In order to visualize the cellular uptake of DOX, the distribution of DOX by various 
formulations in KB, MATB Ш, C6, and fibroblasts cells was observed by confocal 
microscopy. Since DOX has red fluorescence, its distribution in the cells can be easily 
observed. For free DOX (Figure 4.5a), the drug was concentrated only in the nuclei of 
KB cells since red fluorescence was observed in only the nuclei but not the cytoplasm. 
This is a typical characteristic of DOX since it binds and disrupts DNA in the nuclei 127, 
128. In the case of the two micelle formulations (Figures 4.5b and 4.5c), red fluorescence 
was also observed in the cytoplasm, indicating that the DOX-loaded micelles were 
internalized by endocytosis process. The internalization of the PLGA-PEG-FOL micelles 
was much higher compared with the PLGA-PEG micelles, resulting in stronger 
fluorescence intensity. This clearly demonstrates that the presence of folate increased the 
cellular uptake of DOX substantially. Similar to KB cells, folate conjugated micelles also 
distributed in the cytoplasm of the MATB Ш, C6 and fibroblast cells (Figures 4.5d, e, f). 
The fluorescence intensity in MATB Ш cells was similar to that of KB cells while C6 
cells showed slightly weak fluorescence. But the fluorescence intensity in fibroblast cells 
was significantly lower than that of C6 cells. Since no overexpressed FRs on the surface 
of fibroblast cells, cellular uptake may not be enhanced by folate conjugated micelles.  
4.3.5 Cell cycle analysis  
To understand how various DOX formulations affect the cell cycle progression of cancer 
cells and healthy cells, the cellular DNA content at each stage was measured with PI 
using flow cytometry (Figure 4.6). When KB cells were treated with free DOX, DOX-
loaded PLGA-PEG and PLGA-PEG-FOL micelles, a reduction in the fraction of cells in 























Figure 4.5 Confocal images of KB, MATB III, C6, and fibroblast cells treated with different 
DOX formulations. (a) KB cells treated with free DOX, (b) KB cells treated with DOX-loaded 
PLGA-PEG micelles, (c) – (f) are KB cells, MATB Ш cells, C6 cells, and fibroblast cells treated 
with DOX-loaded PLGA-PEG-FOL micelles respectively. 
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the G1 and S phase and an accumulation of cells in G2/M phase were found. The PLGA-
PEG-FOL micelles exhibited a higher G2/M phase percent (20%) compared with free 
DOX (18%) and the PLGA-PEG micelles (11%). Since FR-mediated endocytosis can 
increase the cellular uptake of micelles and the drug concentration in cells, the drug 
induced G2/M arrest may be more prominent. Drug induced G2/M arrest is associated 
with double-strand DNA breakage and extensive chromosome damage by DOX 129, 130. 
Therefore, the increased G2/M phase arrest indicates cell division inhibition and cell 
growth restrain 131. Compared with KB cells, MATB Ш and fibroblast cells also showed 
G1 phase reduction and G2/M phase arrest after treatment with DOX formulations. 
Although G2/M phase arrest was not observed for C6 cells, the G1 phase reduction was 
found. It was reported that cell cycle perturbations depends on the cell line studied, the 
drug itself, the exposure time and dosage, therefore different cell lines may react 
differently to the same DOX formulation  132.   
 
Cells exhibiting less than 2n DNA content were designated to be in sub-G1 phase, which 
indicates formulation-induced apoptosis. When KB cells were treated with different DOX 
formulations, the PLGA-PEG-FOL micelles showed a much higher increase in the 
apoptosis percentage compared with PLGA-PEG micelles and free DOX. For MATB Ш 
cells, the apoptosis percent under different formulations was similar to that of KB cells. 
The C6 cells also showed comparable apoptosis percent. However, for fibroblast cells, 
the apoptosis percent of PLGA-PEG micelles and PLGA-PEG-FOL micelles was nearly 
the same, and was lower than that of free DOX. The apoptosis percent of fibroblast cells 
with the PLGA-PEG-FOL micelles treatment was also significantly lower compared with 
the KB, MATB Ш and C6 cells. This is consistent with the cytotoxicity results. 
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Figure 4.6 DOX formulations induced cell cycle perturbation and apoptosis in (I) KB cells, (II) MATB III cells, (III) C6 cells and (IV) 
fibroblast cells. (a) Control (untreated cells), (b) DOX-loaded PLGA-PEG micelles, (c) free DOX, (d) DOX-loaded PLGA-PEG-FOL 
micelles.  
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4.3.6 The effect of folate content on micelles to targeting efficiency 
The targeting ability of folate conjugated micelles relies on the specific binding of folate 
and FRs overexpressed on cancer cells. If few folate molecules are on the surface of the 
micelles, it may not be sufficient for FR recognition. However, if too many folate ligands 
are present, the micellar binding towards non-targeted cells may happen. Folic acid is 
essential for the biosynthesis of nucleotide bases 133, and physiologically cells can 
transport folate across the plasma membrane using either of two membrane-associated 
proteins, the reduced folate carrier or folate receptor. The former is found in virtually all 
cells and constitutes the primary pathway responsible for uptake of folate. The latter is 
found primarily on cancer cells, and preferentially internalizes folate via receptor-
mediated endocytosis 38, 134. Therefore, too many folate attached on the micelles may 
affect normal healthy cells, and hence the optimal amount of folate ligands needs to be 
determined in order to kill the cancer cells but have a low or negligible cytotoxic effect 
on the healthy cells.  
 
By mixing the copolymer PLGA-PEG-FOL with PLGA-PEG at different ratios, the 
folate content in the micelles was found to be 5%, 17%, 32%, 40%, 53%, 65%, 75%, 
88% and 93% based on the UV-vis spectrophotometry. Figure 4.7 shows the cell uptake 
of DOX in cancer cells and normal fibroblast cells after incubation with different folate 
conjugated micelles. For KB cells, the cellular uptake increased with more folate 
conjugation and peaked at 65% folate content. Afterwards, the cellular uptake decreased 
even at higher folate content of 75%, 88% and 93%. Too many folate ligands on the 
surface of the micelles may facilitate the binding of a single micelle to multiple receptors. 
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And the overbinding of the receptors may reduce the number of micellar uptake and 
result in the decrease of cellular DOX content 34. It was also reported that the high 
amount of intracellular folate, in the range of 2×107 to 9×107 folate molecules per cell 39, 
135, may be responsible for the saturation and shut-off of the folate receptor uptake 
pathway. The folate ligands conjugated to the micelles may contribute to the intracellular 












Figure 4.7 DOX cellular uptake as a function of folate content on the micelles. 
 
For MATB Ш and C6 cells, the trend of cellular uptake was similar to that of KB cells. 
The cellular uptake increased gradually with more folate conjugation and decreased after 
a peak. However, the MATB Ш cells peaked at 60% folate content while C6 cells peaked 
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marginally with higher folate content and was lower than that in the KB and MATB Ш 
cells. The cellular uptake difference between C6 and fibroblasts was still observable 
when the folate content is between 30%-70%. Our results also showed that approximately 
40%-65% of the folate content on the micelles was desirable for the selective targeting on 




DOX-loaded PLGA-PEG-FOL micelles were successfully synthesized as a novel drug 
targeting system. The micellar size was smaller than 100 nm. The optimal initial weight 
ratio of DOX to PLGA-PEG-FOL was 0.5:1.0, with a drug loading content of 28% and 
drug encapsulation efficiency of 61%. The difference of cytotoxicity, cellular uptake and 
apoptosis percentage between different cancer cells and healthy cells implies that the 
folate conjugated micelles has the ability to selectively target cancer cells with 
overexpressed FRs on their surface. The cytotoxicity of the folate conjugated micelles 
(PLGA-PEG-FOL) to cancer cells was also much higher than free DOX or micelles 
without folate (PLGA-PEG). Furthermore, the amount of folate on the micelles was 
optimized at 40%-65% in order to kill cancer cells but, at the same time, have minimal 
effect on normal healthy cells.  
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Chapter 5   
pH-triggered drug release for active intracellular 
drug delivery 
 
5.1 Introduction  
 
In Chapter 4, PLGA-PEG-FOL micelles were synthesized to form micelles for 
encapsulating anticancer drug-DOX. The cytotoxicity and cellular uptake of DOX-loaded 
PLGA-PEG-FOL micelles to cancer cells was found to be much higher than that of 
normal fibroblast cells, demonstrating that the folate conjugated micelles has the ability 
to selectively target to cancer cells 136. To further enhance the therapeutic effect, an 
accelerated drug release in cells is desirable to increase the intracellular drug 
concentration and to achieve higher cytotoxicity.  
 
To trigger the drug release in cells, pH sensitive polymers are usually applied as carriers. 
Poly(L-histidine) has been widely utilized as pH sensitive polymer due to its amphoteric 
nature by protonation-deprotonation. Poly(L-histidine) is hydrophobic at physiological 
pH but ionized at endosomal pH. Its hydrophilic property after ionization induces the 
destabilization of polymer micelles and enhances the release of loaded drugs in endosome 
53, 137. However, the synthetic route of poly(L-histidine) contained difficult processes such 
as the imidazole protection and deprotection as well as, purification of histidine N-
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carboxyanhydride 56, 138. In addition, the difficulty in controlling the molecular weight 
and limited solubility of high molecular weight polymer in organic solvents has restricted 
the fabrication and applications of poly(L-histidine) based drug carriers 139. Therefore, we 
sought to develop alternative pH sensitive materials to bypass the synthetic drawbacks of 
poly(L-histidine). Poly(β-amino ester) or PAE has a pKb value of approximately 6.5 
because of its tertiary amine. Below pH 6.5, it is soluble in water because of tertiary 
amine ionization, but it becomes insoluble above pH 6.5. Previously, Langer and co-
workers synthesized PAE by a Michael-type polymerization and applied this polymer as 
gene delivery carrier since the ionized tertiary amine can be conjugated with negatively 
charged DNA 140-142.  
 
PAE alone is not applicable in micelle formation because it is not amphiphilic at 
physiological pH. To apply PAE in the fabrication of pH sensitive micellar drug carriers, 
a copolymer conjugate made of PAE and PEG-FOL was used in this study. At 
physiological pH 7.4, PAE is hydrophobic and PEG-FOL is hydrophilic, therefore the 
copolymer formed micelles with PAE as the core and PEG-FOL as the shell. The folate 
moiety was used to guide the micelles to tumor cells with overexpressed FRs. After folate 
receptor-mediated endocytosis, the drug release in early or secondary endosomes could 
be accelerated by pH-induced dissociation of micelles when pH drops from physiological 
7.4 to 5-6 in endosomes. To control the drug release rate, mixed micelles of PLGA-PEG-
FOL and PAE-PEG-FOL were fabricated at three different weight ratios (PLGA-PEG-
FOL:PAE-PEG-FOL = 80:20, 50:50, 20:80, also known as 80:20, 50:50 and 20:80 mixed 
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micelles respectively) and the corresponding drug release rate, cytotoxicity and cellular 
uptake were investigated. 
 
5.2 Materials and methods 
5.2.1 Materials 
 
For the synthesis of polymer micelles, 4,4’-trimethyldipiperidine, 1,6-hexanediol 
diacrylate, poly(ethylene glycol)-bis-amine (PEG-bis-amine, Mw:3400), N-hydroxy-
succinimide (NHS), dicyclohexylcarbodiimide (DCC), folate, and doxorubicin (DOX) 
were purchased from Sigma-Aldrich. Poly(DL-lactide-co-glycolide) (50:50, Mw:8,000) 
was purchased from Boehringer Ingelheim. All other reagents including dichloromethane 
(DCM), dimethylsulfoxide (DMSO), triethylamine (TEA), diethylether and 
tetrahydrofuran (THF) were used as obtained without further purification.  
5.2.2 Synthesis of the poly(β-amino ester)-PEG-FOL conjugate 
 
The synthesis of the conjugate followed a two-step reaction – synthesis of folate-PEG 
(FOL-PEG) and synthesis poly(β-amino ester)-PEG-FOL (Figure 5.1).  
 
(1) Synthesis of FOL-PEG 
The synthesis and characterization of FOL-PEG has been conducted in our previous work 
136. In brief, PEG-bis-amine (500 mg), folic acid and DCC were dissolved in 5 ml DMSO 
(molar ratio of PEG-bis-amine: folic acid: DCC = 1: 1: 1.1) in the presence of 10 µl 
pyridine. The mixture was stirred overnight in the dark at room temperature under 
nitrogen gas. Afterwards the mixture was diluted with 10 ml deionized water and 
centrifuged at 1000 g for 30 min to separate the by-product dicyclohexylurea. The 
                                                                                                                                                                                Chapter 5        
 84
supernatant was dialyzed against deionized water over 48 h (MWCO: 1,000) to remove 
free folic acid and freeze-dried. The FOL-PEG was further purified by a DEAE-
sepharose anion-exchange column. The purity of FOL-PEG was confirmed by gel 
permeation chromatography using a TSK-GEL G4000PWXL column and thin layer 
ninhydrin assay. 
 
(2) Synthesis of poly(β-amino ester)-PEG-FOL (PAE-PEG-FOL) conjugate  
In the second step, FOL-PEG, 1,6-hexanediol diacrylate (diacrylate ester) and 4,4’-
trimethyldipiperidine (diamine) (molar ratio = 0.1:1:1) were dissolved in DCM separately, 
mixed and maintained at 50°C for the reaction 140-142. After 48 h, the reaction was cooled 
down to room temperature and dripped into diethyl ether under vigorous stirring to 
precipitate the polymer. Polymer was collected and dried under vacuum. The raw product 
was further purified by a preparation gel filtration column (HiloadTM 16/60 SuperdexTM 
200 prep grade) using phosphate buffer solution (PBS) at pH 5 as mobile phase. The final 
product was finally freeze-dried.  
5.2.3 Characterization of polymers 
 
The structural confirmation of PAE-PEG-FOL conjugate was measured by 1H-NMR in 
CDCl3 at 500 MHz (AMF500, Bruker). The molecular weight and polydispersity of 
polymers were determined by gel permeation chromatography (Agilent 1100, HP) with 
refractive index detector using an Agilent PLgel 5 µm mixed-C 300×7.5 mm column. 
The mobile phase was chloroform. The molecular weight was determined using standard 
polystyrene samples (molecular weights of 6.95×105, 5.04×104, 2.26×103 and 162 
respectively). 
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5.2.4 Preparation and characterization of DOX-loaded micelles 
 
The DOX-loaded polymer micelles were prepared by dialysis method. Before micelle 
preparation, DOX was neutralized first. Briefly, 10 mg DOX was neutralized with 2 
moles excess TEA in 2 ml DMSO. The DOX solution was then added into the 4 ml 
DMSO solution of 20 mg PLGA-PEG-FOL conjugate with different ratio of PAE-PEG-
FOL and mixed by vortex for 10 min. The mixture was next transferred for dialysis 
(MWCO: 10,000) against deionized water for 48 h to produce the mixed micelles 25, 50-53. 
The water was replaced hourly for the first 3 h. Untrapped DOX and organic solvents 
were removed by subsequent extensive dialysis against deionized water. After dialysis, 
the micelles were freeze dried. The amount of DOX loaded in the micelles was 
determined by measuring the UV absorbance at 485 nm using UV-vis 
spectrophotometry (Cary 50, Varian) after dissolved and properly diluted in DMSO. 
5.2.5 Acid-base titration 
The protonating ability of the polymer was determined by an acid-base titration. The 
polymer solution at 0.1 mg/ml was titrated to pH 11 with 0.1 N NaOH and subsequently 
titrated down with 0.1 N HCl. 
5.2.6 Physicochemical properties of polymer micelles  
 
The average size of micelles under different pH values was measured by the laser light 
scattering (90-PLUS analyzer, Brookhaven Instruments). Zeta potential of the micelles 
was measured by the laser droppler anemometry (Zeta plus, Brookhaven Instruments). 
The critical association concentration (CAC) of copolymers in PBS under different pH 
values was determined by fluorescence spectroscopy as stated in Chapter 3 (Section 
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3.2.5.1). The pH-dependent drug release under different pH values from pH 7.4 to 5.0 
was measured using the method described in Chapter 3 (Section 3.2.6). 
5.2.7 In vitro cell experiments 
 
The cytotoxicity was determined by MTT assay as stated in Chapter 4 (Section 4.2.3.3). 
The intracellular distribution of cell-associated DOX was observed using confocal laser 
scanning microscopy after different incubation time. The detailed procedures are the 
same as the description in Chapter 4 (Section 4.2.3.4). 
5.2.8 Statistical analysis  
 
All data were presented as mean ± S.D. and analysed using Student’s t test. Statistical 
significance was determined at a value p<0.05.  
 
5.3 Results and discussion 
5.3.1 Characterization of poly(β-amino ester)-PEG-FOL copolymer 
The 1H-NMR spectrum of poly(β-amino ester)-PEG-FOL (PAE-PEG-FOL) copolymer 
is shown in Figure 5.2. 1H-NMR δ (CDCl3, 500 MHz), 4.11 (br, t, 48H), 3.00 (br, m, 
48H), 2.79 (br, m, 48H), 2.65 (br, m, 48H), 2.11 (br, m, 48H), 1.70 (br, m, 94H), 1.25 
(br, m, 190H), 3.65 (s, 143H). Figure 5.2 shows the detail attribution of each peak. The 
peak at 3.6 ppm belongs to the -CH2- protons of PEG. The integration ratio of PEG 
peak and the peak at 4.11 ppm is 2.97. Since the molecular weight of PEG is 3400, 
therefore the molecular weight of the copolymer is approximately 14,170. The small 
peak at 8.67 ppm belongs to the proton of =CH on the quinoid ring of folate. The small 
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peaks at 6.65 ppm (s, 2H) and 7.66 ppm (s, 2H) belong to the protons on the benzene 












Figure 5.2 The 1H-NMR spectrum of PAE-PEG-FOL conjugate  
Table 5.1 shows the molecular weight and weight distribution of PEG-FOL and PAE-
PEG-FOL. The Mw of PAE-PEG-FOL is 13,160, which is consistent with the result 
calculated from NMR spectrum.  
Table 5.1 The molecular weight and polydispersity of the polymers 
 
Samples Mn Mw Polydispersity (Mw/Mn) 
FOL-PEG 4,575 5,262 1.15 
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5.3.2 Buffering capacity of the polymers  
The acid-base titration profile of the PAE-PEG-FOL micelle in Figure 5.3 shows a 
gradual decrease in the range of pH 8 to 5, whereas the PLGA-PEG-FOL micelle shows 
a more dramatic decrease in the same pH range. This indicates that the PAE-PEG-FOL 
micelle has a large buffering capacity attributed to the tertiary amine groups on PAE, 
whose pKb value is 6.5. The 80:20 and 50:50 mixed micelles show the similar profile 
which indicates that the mixed micelles also have the buffering capacity. The titration 
curve of 20:80 mixed micelles is not shown because it nearly overlaps with the PAE-















Figure 5.3 Acid-Base titration profiles of different micelles formulations. The polymer 
solution at 0.1 mg/ml was titrated to pH 11 with 0.1 N NaOH and subsequently titrated 
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5.3.3 The effects of pH values on the physicochemical properties of micelles 
As shown in Figure 5.4, the diameters of the PAE-PEG-FOL micelles and mixed 
micelles (80:20, 50:50, and 20:80) were measured under different pH values. When pH 
values are higher than 6.5, all the micelles size is stabilized at 62 nm. The size of PAE-
PEG-FOL micelles can not be measured below pH 6.5 because of micellar dissociation. 
For 80:20 mixed micelles, the size is nearly unaffected by pH changes. Since the weight 
percentage of PAE-PEG-FOL in the micelles is only 20%, the ionization of the polymer 
may not disrupt the micelle size significantly. For 50:50 mixed micelles, the micelles 
size were approximately 65 nm at pH > 6.5. However, when pH is lowered to 5.0, the 
size of micelles increased to 117 nm. PAE-PEG-FOL is likely ionized at this pH and 
becomes hydrophilic, resulting in water influx and swelling of the micelles. For this 
experiment, the incubation time of micelles at pH 6.5 was 1 h. If the incubation time 
was prolonged, the micelles may keep swelling and dissociate eventrually. For the 
20:80 mixed micelles, at pH 7.4, the micelles size showed similar value to the other 
micelles formulations. However, under other pH values, similar to the pure PAE-PEG-
FOL micelles, the size of 20:80 formulation can not be measured. This is most likely 
due to the micellar dissociation since the PAE-PEG-FOL is the major part of the mixed 
micelles. The zeta potential of 80:20 and 50:50 mixed micelles at pH 7.4 and 5.0 was 
also measured. For 80:20 mixed micelles, the zeta potential was -5.2 mV at pH 7.4 and 
+3.7 mV at pH 5.0. The zeta potential of 50:50 mixed micelles also showed similar 
value at pH 7.4. At pH 5.0, however, it increases to +14.3 mV. The positive charge may 
result from protonation of the tertiary amine on PAE.  
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The drug loading content of 80:20, 50:50 and 20:80 mixed micelles and pure PAE-
PEG-FOL micelles was 35.4%, 43.5%, 47.2% and 48.8% respectively. From the 
structure of PAE-PEG-FOL, it should be more hydrophobic than PLGA. Due to the 
hydrophobic property of DOX, the interaction between drug molecules and PAE is 
stronger than that between drug and PLGA. Therefore, the drug loading content is 
enhanced when increasing the percentage of PAE-PEG-FOL in the micelles. Since the 
dissociation of the PAE-PEG-FOL micelles and 20:80 mixed micelles is above pH 6, 
which is higher than the endosomal pH of 5-6, these micelles are likely be destabilized 
before endocytosis. Thus, their application for accelerated endosomal drug release is 
limited and we focused only on the 80:20 and 50:50 formulations in the subsequent 
sections.  
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5.3.4 Critical association concentration (CAC)  
CAC is an important factor for determining the stability of the polymer micelles in 
physiological medium such as blood. A highly diluted condition below CAC in the 
blood compartment may induce the dissociation of micelles and eventually may 
provoke the burst release of the incorporated drugs from the core. As shown in Figure 
5.5a, the position of maximum peak changes from 334.5 nm to 337.5 nm when the 
concentration of block copolymer increases gradually. The shift of the excitation peak 
demonstrates pyrene transfer to the less polar micellar core with increasing polymer 
concentration.  
 
Figure 5.5b shows the change of the I337.5 /I334.5 fluorescence intensity ratio as a function 
of polymer concentration at different pH for the 80:20 mixed micelles. The CAC value 
was determined from the extrapolated intersection of the non-horizontal tangents of the 
curve with the horizontal tangent through the points at low concentrations. At low 
copolymer concentration range below CAC, the intensity ratio of I337.5 /I334.5 is almost 
constant. The intensity ratio increases sharply when polymer concentration increases 
beyond CAC and pyrene is accumulated to the hydrophobic core of the micelles. The 
CAC value of 80:20 mixed micelles increases gradually when the pH value drops from 
7.4 to 5.0. At pH 7.4, the CAC value of the 80:20 mixed micelles was determined to be 
2.9 mg/l which is quite similar to the CAC value of PLGA-PEG-FOL (2.4 mg/l). When 
the pH value is 6.5 and 5.0, CAC increases to 5.6 and 9.3 mg/l respectively. This 
indicates that these micelles are not as stable as the ones at pH 7.4. Figure 5.5c shows 
the CAC value of 50:50 mixed micelles. Under pH 7.4, the CAC value of the 50:50 
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mixed micelles is 2.8 mg/l, and is similar to the 80:20 case. However, at pH 6.5, the 
CAC increases significantly to 22.1 mg/l which demonstrates the micelles are unstable 
lower pH., CAC was not found at pH 5.0, indicating that micelles can not be formed at 
such acidic environment. For the pure PAE-PEG-FOL micelles, CAC can only be 
obtained at pH 7.4. At pH 6 and below, it is not stable and thus CAC can not be 
measured. 
 
Figure 5.5a Excitation spectra of pyrene as a function of the polymer concentration. 
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Figure 5.5b Plot of intensity ratios I337.5/I334.5 vs. log C of mixed micelles 80:20 under 






















Figure 5.5c Plot of intensity ratios I337.5/I334.5 vs. log C of mixed micelles 50:50 under 
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5.3.5 In vitro drug release 
Figure 5.6 shows the in vitro drug release profile of DOX-loaded mixed micelles at pH 
7.4, 6.5 and 5.0. The drug release profile of PLGA-PEG-FOL micelles is also attached 
as a control. As shown in Figure 5.6a, compared with PLGA-PEG-FOL micelles, the 
80:20 mixed micelles shows a reduced drug release at pH 7.4 which may due to the 
relatively high hydrophobic property of PAE. At pH 6.5, the drug release rate is 
enhanced slightly after 5 h compared with the curve at pH 7.4 and reached a plateau 
after 12 h. The acceleration of drug release at pH 5.0 may be attributed to the ionization 
of PAE. From the drug release profile, the 80:20 mixed micelles formulation can be 
beneficial for chemotherapy. It has minimum drug release under physiological medium, 
which can reduce the side effects to healthy organs. In addition, the triggered drug 










Figure 5.6a  The drug release profiles of the DOX-loaded mix micelles 80:20 under 
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For the 50:50 mixed micelles, as shown in Figure 5.6b, the release profiles at neutral pH 
also shows a reduced drug release compared with the PLGA-PEG-FOL micelles. At pH 
6.5, the drug release rate is much faster than that of the 80:20 mixed micelles. At pH 5.0, 
nearly 80% drug is released after only 5 h. In addition, the initial burst is very 
prominent. In the first 3 h, nearly 40% drug is released. The mean pH value of tumors is 
reported to be 7.06 with a full range of 5.7-7.8 143, 144. Therefore, if the drug release is 
too fast in this range, the extracellular release may become dominant instead of the 
intracellular release.  
 
Figure 5.6b  The drug release profiles of the DOX-loaded mix micelles 50:50 under 
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5.3.6 Cytotoxicity Test 
The cytotoxicity of various DOX-loaded drug formulations to KB cells at pH 7.4 is 
compared in Figure 5.7. The cytotoxicity of free DOX and PLGA-PEG-FOL micelles 
was also measured as comparisons. With equivalent drug content, the PLGA-PEG-FOL 
micelles show much higher cytotoxicity (p<0.05) than the free DOX when the drug 
concentration is 0.1 µM or higher. The IC50 values of free DOX and PLGA-PEG-FOL 
micelles are 0.96 and 0.46 µM. Different drug formulations undergo different 
mechanisms of entering the cells. Since free DOX is a small molecule, it can diffuse 
into the cells quickly. Although the micelle formulation can only be internalized in the 
cells by the endocytosis process, the overexpression of FRs on the surface of KB cells 
may significantly enhance the uptake of the PLGA-PEG-FOL micelles via FR-mediated 
endocytosis and result in higher cytotoxicity.  
 
Compared with the PLGA-PEG-FOL micelles, the cytotoxicity of the mixed micelles is 
even higher. The IC50 values of the 80:20 and 50:50 mixed micelles and PAE-PEG-FOL 
micelles are 0.34, 0.32 and 0.29 µM respectively. The higher cytotoxicity is due to the 
accelerated drug release from the mixed micelles in the acidic environment of 
endosome. The cytotoxicity difference among these three PAE formulations is not 
significant under pH 7.4 incubation condition. To mimic the typically lower pH 
condition at the tumor site, we further incubated the cells with these formulations at pH 
6.5 for 24 h. As shown in Figure 5.8, the cytotoxicity of 50:50 mixed micelles and pure 
PAE-PEG-FOL micelles is lower compared with the 80:20 formulation. At pH 6.5, 
according to the CAC results, 50:50 mixed micelles and pure PAE-PEG-FOL micelles 
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are not stable, and the drug may release from micelles in extracellular environment 
before taken by the cells. The 80:20 mixed micelles are relatively stable at this 
condition, which retain more drugs in the micelles and allow higher degree of cellular 
uptake of drug via FR-mediated endocytosis. Considering the micellar stability in 
extracellular environment and cytotoxicity, the 80:20 mixed micelles is seen as a better 
formulation. 
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Figure 5.7 The cytotoxicity of different DOX formulations to KB cells at pH 7.4. The 





















Figure 5.8 Cytotoxicity of different DOX formulations to KB cells at pH 6.5. The 
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5.3.7 Cellular uptake of DOX  
In order to visualize the cellular uptake of DOX, the distribution of DOX by PLGA-
PEG-FOL micelles and 80:20 mixed micelles in KB cells at pH 7.4 was observed by 
confocal microscopy. Since DOX has red fluorescence, its distribution in the cells can 
be easily observed. The effect of incubation time on the cellular uptake of the folate 
conjugated polymer micelles was reported recently. It showed that the uptake rate 
gradually declines after the first 1 h of incubation 145. If the incubation time is too short, 
FR-mediated endocytosis of micelles may be low, thus affecting the total cellular 
uptake. To provide sufficient incubation time for FR-mediated endocytosis, and at the 
same time, to be able to compare the cellular uptake for different formulations, the 
incubation time was chosen to be 0.5 h and 3 h in this study.   
 
As shown in Figure 5.9, after 0.5 h incubation, red fluorescence can only be observed in 
the cytoplasm of the cells treated by PLGA-PEG-FOL micelles. The fluorescence 
intensity is strong due to the active endocytosis mediated by FRs. For the 80:20 mixed 
micelles, the bulk of drug is distributed in cytoplasm. However, red fluorescence can 
also be observed in the nucleus although the intensity is much weaker compared with 
that in the cytoplasm. After 3 h incubation, increased fluorescence intensity can be 
found in the cells treated with the PLGA-PEG-FOL micelles formulation, and they are 
predominantly distributed in the cytoplasm. Compared with the PLGA-PEG-FOL 
micelles, the 80:20 mixed micelles shows even stronger fluorescence intensity. In 
addition, the drug is not only localized in the cytoplasm but can vividly be seen at the 
nucleus. The spreading of drugs to the nucleus may be attributed to the endosomal 
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disruption activity of PAE at low pH in endosomal compartment right after endocytosis. 
Since DOX is to diffuse into the cell nuclei to disrupt double-strand DNA 125, 126, the 
triggered release of mixed micelles may increase the cytoplasmic drug concentration, 
resulting in a steeper diffusion gradient and higher flux of drug into the nucleus. The 






























Figure 5.9 Confocal images of KB cells treated with different drug formulations (DOX 
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Poly(β-amino ester)-PEG-FOL conjugate was successfully synthesized as a pH 
sensitive copolymer. Mixed micelles of PLGA-PEG-FOL and poly(β-amino ester)-
PEG-FOL was fabricated with different weight ratios. The mixed micelles show 
increased buffering ability. The drug release can be triggered at endosome pH due to the 
ionization of poly(β-amino ester), which resulted enhanced nucleus drug concentration 
and improved the cytotoxicity. Considering the micelles stability in extracellular 
environment, drug release rate and cytotoxicity, the 80:20 mixed micelles is a better 
formulation compared with the 50:50 mixed micelles. This new formulation can be 
useful as an effective intracellular delivery carrier. 
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Chapter 6  
Folate conjugated polymer micelles formulated 
with TPGS  
 
6.1 Introduction 
Recently, an additive named d-α-tocopheryl polyethylene glycol succinate (TPGS) has 
been used in pharmaceutical dosage forms. TPGS, a water-soluble form of the lipophilic 
vitamin E, is formed by the esterification of vitamin E succinate with polyethylene glycol 
1000 (PEG). Its chemical structure contains both a hydrophobic and hydrophilic moiety, 
making it similar to a conventional surfactant. Moreover, its hydrophobic alkyl head 
(tocopherol succinate) and hydrophilic polar tail (PEG) are bulky and have large surface 
areas. The use of TPGS in preparation of drug-loaded nanoparticles can result in narrow 
particle size distribution and high emulsification efficiency. It can also greatly improve 
the drug encapsulation efficiency, leading to the enhanced cellular uptake of 
nanoparticles and cancer cell mortality 146-148. Furthermore, it has been found that co-
administration of TPGS can enhance cytotoxicity and increase the oral bioavailability of 
anticancer drugs 149-151.  
 
The function of TPGS in the preparation of solid micro/nanoparticles (such as PLGA) 
and drug release have been frequently studied 152-154, but few studies have been carried 
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out on the effects of TPGS on the drug-loaded polymer micelles 155. In Chapter 4, we 
showed that folate conjugated polymer micelles poly(lactic-co-glycolic acid)-
poly(ethylene glycol)-folate (PLGA-PEG-FOL) selectively enhance the cellular uptake of 
anticancer drugs in cancer cells, but not normal fibroblasts. In this study, a new drug 
formulation, folate conjugated micelles formulated with TPGS (known as mixed micelles 
in this work) was fabricated to evaluate the effects of TPGS on the physicochemical 
properties, cellular uptake and selective cytotoxicity of the folate conjugated micelles. In 
particular, whether the addition of TPGS to the micelles can increase the cellular uptake 
of DOX in the drug resistant cancer cells but not normal cells was the main objective of 
this study. Although the mechanism is not fully understood, it has been demonstrated that 
TPGS can enhance cellular uptake of drugs in the cancer cells by inhibiting P-
glycoprotein (P-gp) mediated multi-drug resistance 12-14. Results obtained from this study 
demonstrate the advantages of incorporating TPGS in the polymer micelles as an 
advanced drug targeting system. 
 
6.2 Materials and methods  
6.2.1 Materials 
For the synthesis of polymer micelles, poly(ethyleneglycol)-bis-amine (PEG-bis-amine, 
Mw = 3,400), N-hydroxysuccinimide (NHS), dicyclohexyl-carbodiimide (DCC), folate, 
doxorubicin (DOX) and rhodamine-123 were purchased from Sigma-Aldrich. Poly(D,L-
lactide-co-glycolide) (Mw:8,000) was purchased from Boehringer Ingelheim. d-α-
tocopheryl polyethylene glycol 1000 succinate (TPGS) was a gift from Eastman 
Chemical. All other reagents including dichloromethane (DCM), dimethylsulfoxide 
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(DMSO), triethylamine (TEA), diethylether were HPLC grade and were used without 
further purification. 
 
For cell culture experiments, human oral cavity carcinoma cell line (KB), human colon 
carcinoma cell line (Caco-2) and human fibroblast cell line (CCL-110) were purchased 
from ATCC. Folate-free RPMI 1640 medium, Dulbecco’s Modified Eagle’s Medium 
(DMEM), fetal bovine serum (FBS), penicillin-streptomycin (pen-strep) and Trypsin-
EDTA (0.5% Trypsin, 5.3mM EDTA tetra-sodium) were obtained from Invitrogen. 3-
(4,5-dimethylthiaol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), triton X-100, 
annexin V-FITC detection kit were obtained from Sigma-Aldrich. 
6.2.2 Preparation of DOX-loaded micelles 
The DOX-loaded polymer micelles were prepared via a dialysis method. Briefly, 50 mg 
of PLGA-PEG-FOL and 20 mg of free DOX were dissolved in DMSO in the presence of 
8 mg TEA. In order to prepare mixed micelles with encapsulated drug, PLGA-PEG-FOL, 
free DOX and TPGS (5%, 10% or 20% weight percent of PLGA-PEG-FOL) were 
dissolved in DMSO in the presence of TEA. The organic phase was transferred to a 
dialysis membrane (MWCO: 2,000) and dialyzed against deionized water for 48 h to 
produce the micelles and to remove the untrapped DOX and TEA. The water was 
replaced hourly for the first 3 h.  
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6.2.3 Physicochemical properties of polymer micelles 
Average size of micelles was measured by laser light scattering (90-PLUS analyzer, 
Brookhaven Instruments). Zeta potential of the micelles was measured by laser droppler 
anemometry (Zeta plus, Brookhaven Instruments). Encapsulation efficiency (EE) was 
determined as the ratio of actual amount of DOX encapsulated in micelles and total 
amount of drug originally used in the encapsulation process. The weighted dried micelles 
were dissolved in DMSO. The mass of DOX-loaded in the micelles was determined by 
measuring the UV absorbance at 485 nm using UV-vis spectrophotometry (Cary 50, 
Varian Instruments).  
6.2.4 Drug release study 
For drug release study, the DOX-loaded micellar solution prepared above was first 
diluted to 1 mg/ml DOX in PBS and transferred to a dialysis tube (MWCO: 10,000). The 
dialysis tube was immersed in a beaker containing phosphate buffer solution (PBS, pH 
7.4). The beaker was placed in a shaking water bath at 37°C. To measure the release of 
DOX at different time intervals, 1 ml solution was withdrawn from the medium and 
replaced with fresh PBS. The DOX content in the sample was analyzed by reversed phase 
HPLC on a ZORBAX SB-C18 column (4.6 x 250 mm, 5 µm) using a fluorescence 
detector at excitation wavelength of 475 nm and emission wavelength of 580 nm. The 
mobile phase consisting of acetonitrile and water was programmed with increasing 
gradient of acetonitrile 5-45% (v/v) in 40 min at a flow rate of 1 ml/min.  
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6.2.5 In vitro cellular assays  
6.2.5.1 Cell culture 
The in vitro cell culture experiments were performed using KB cells which vastly over-
express the folate receptors. The DOX-resistant KB cells (KB/DOX) were selected after 
sequential exposure of KB cells to 0.001-10 µg/ml of free DOX concentration 139. KB 
and KB/DOX cell lines were cultured using methods described previously by other 
research groups 156. Briefly, cells were maintained in folate-free RPMI 1640 medium 
with 10% FBS and 1% pen-strep in T-75 flasks and incubated at 37°C with 95% 
humidity and 5% CO2. Medium was changed two or three times a week. The cells were 
harvested with Trypsin-EDTA after 80% confluency. Fibroblast cells and Caco-2 cells 
were cultured in DMEM medium with 10% FBS and 1% pen-strep and incubated at 37°C 
with 95% humidity and 5% CO2. 
6.2.5.2 Cellular DOX uptake  
Exponentially growing KB/DOX cells were seeded in 6-well culture plates (5×104 cells 
per well) and incubated for 48 h. The cells were then incubated at 37°C with various 
DOX formulations (DOX concentration of 10 µM) in the medium. After exposure for 2 h, 
the cells were washed with cold PBS three times and harvested using Trypsin-EDTA and 
fixed by 1% paraformaldehyde. Cell density was adjusted to 1×106 cells/ml and 1ml of 
this cell suspension was used to measure the cellular uptake of DOX by a flow cytometer 
(EPICS Altra Flow Cytometry Systems, Beckman Coulter). Since DOX has a fairly 
strong self-fluorescence, no additional fluorescence probe was needed for this experiment. 
Furthermore, the intracellular distribution of cell-associated DOX was visualized by 
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confocal laser scanning microscope (LSM 410, Carl Zeiss). Cells were cultured in Lab-
TekTM chambered coverglass (Nalge 155383, NUNC) for 48 h (2×104cells/chamber). The 
cells were incubated with medium containing free DOX or DOX-loaded polymer 
micelles (DOX concentration of 10 µM) for 2 h. After washing with PBS three times, the 
cells were then fixed with ethanol for 20 min and washed again with PBS. Finally, the 
cells were observed and imaged at an excitation wavelength of 475 nm and emission 
wavelength of 580 nm.  
6.2.5.3 Cytotoxicity assays 
Cytotoxicity of different DOX formulations (free DOX and DOX-loaded polymer 
micelles) was determined by MTT assay. Cells were seeded in a 96-well plate at a density 
of 1×104 cells/well and incubated for 24 h before the assay. DOX-loaded micelles were 
diluted with the growth medium to give final DOX concentrations of 0.01, 0.1, 1, 10, 20, 
50 µM. The cells were next exposed these micelle-containing media for 24 h followed by 
the MTT assay. Free DOX with the same concentrations was also prepared for the same 
cell exposure assay. One row of the 96-well plate was used as control without adding any 
drug formulations. The absorbance of the tetrazolium dye was read with a microplate 
reader (GENios, Tecan) at a test wavelength of 570 nm and a reference wavelength of 
630 nm. The cell viability was calculated as the ratio of the number of surviving cells in 
the drug treated samples to that of the control. 
6.2.5.4 Apoptosis assay 
Annexin V has been shown to be a useful marker for cellular apoptosis. The binding of 
cells by FITC-labeled annexin V reveals the early stages of apoptosis. After incubation 
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with DOX formulations (DOX concentration of 10 µM) for 24 h, the cells were washed 
twice with PBS and resuspended in 1×binding buffer at a concentration of 1×106 cells/ml. 
And then 5 µl of annexin V-FITC was then added and incubated at room temperature for 
10-30 min. The FITC fluorescence in cell pellets was measured by flow cytometry.  
6.2.5.5 Accumulation of rhodamine in Caco-2 cells  
Caco-2 cells were seeded in 12-well tissue culture plates at a density of 1×104 cells/well. 
After reaching 80% confluency, the cells were exposed to four different formulations: 5 
µM rhodamine in 1% (v/v) methanol in the DMEM, 5 µM rhodamine encapsulated by 
PLGA-PEG micelles, PLGA-PEG-FOL micelles and mixed micelles. Each formulation 
was repeated three times and a control was kept by adding the same rhodamine 
formulation in blank wells. After 2 h incubation at 37°C, the cells were washed three 
times with PBS and lysed with 1% (v/v) Triton X-100 followed by 100 µl DMSO. The 
fluorescence intensity of the lysed cell solution was measured by microplate reader at the 
excitation wavelength of 485 nm and emission wavelength of 530 nm. The cellular 
uptake efficiency was obtained by the fluorescence intensity ratio of samples to the 
control. The rhodamine accumulation in Caco-2 cells was also observed by confocal laser 
scanning microscopy. The sample preparation was similar to the procedures described 
earlier, except that 5 µM rhodamine was applied for encapsulation and FITC filter was 
used for image acquisition.  
6.2.6 Statistical analysis   
All data were presented as mean ± S.D. and analyzed using Student’s t test. Statistical 
significance was determined at a value p<0.05.  
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6.3 Results and discussion 
6.3.1 Physicochemical properties of DOX-loaded PLGA-PEG-FOL micelles 
Based on dynamic light scattering (DLS), the size of PLGA-PEG-FOL micelles was 
approximately 60 nm. After the drug loading, as shown in Table 6.1, the diameters of the 
DOX-loaded micelles without TPGS were approximately 80-100 nm. The polydispersity 
index indicates that the size distribution was narrow up to the DOX: PLGA-PEG-FOL 
ratio of 0.5:1.0. Above this ratio, the precipitation of unloaded DOX in the aqueous 
medium was observed during micelles preparation, resulting in the increase in size 
distribution. With the optimal ratio of DOX to micelles at 0.5:1.0, 61.1% drug 
encapsulation efficiency was achieved (as stated in Chapter 3, Section 3.3.2.5). Zeta 
potential measurements show that all micelles were negatively charged and stable, and 
were unaffected even with the increase of drug loading. 
 
At the optimal DOX to PLGA-PEG-FOL ratio of 0.5:1, the addition of TPGS only 
affected the encapsulation efficiency as well as size and zeta potential slightly. From the 
DLS results, the mixed micelles with 10% TPGS exhibited a single scattering peak with 
low polydispersity (Figure 6.1a). The absence of smaller TPGS micelles, which were 20 
nm in size (Figure 6.1b), confirmed the homogeneity of this mixed micelle formulation. 
With its amphiphilic structure, TPGS has been shown to have emulsifier function. It can 
effectively reduce the particle size and increase the drug encapsulation efficiency of solid 
PLGA nanoparticles formulations 157. In our case, however, the size of the PEG block in 
TPGS is only 1000, which is shorter compared with PEG 3400 in the PLGA-PEG-FOL 
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copolymer. Therefore, the emulsifier function of TPGS in the current formulations may 
be insignificant.  




Feed weight ratio 
(Drug:Polymer)
Encapsulation 
Efficiency (%) Diameter (nm)  ξ (mV)
0.2:1.0 56.8 84.7  -6.5 
0.3:1.0 58.2 86.5  -7.2 
0.5:1.0 61.1 88.1 -7.9 
0.7:1.0 23.5 89.2  -6.6 
0 
1.0:1.0 20.2 99.2  -6.4 
5 0.5:1.0 60.3 87.7  -7.5 
10 0.5:1.0 58.5 88.9  -7.0 
20 0.5:1.0 54.5 94.2  -6.1 
 
* TPGS (%) = TPGS weight / Polymer weight 




























Figure 6.1 Micelles size and size distribution of (a) TPGS micelles and (b) mixed 
micelles with 10% TPGS. 
 
6.3.2 In vitro drug release  
The drug release profile of DOX-loaded PLGA-PEG-FOL micelles in Figure 6.2 shows 
that all formulations (0, 5, 10 and 20% TPGS) exhibited a fast drug release in the first 10 
h and reached a plateau in 24 h with approximately 40 - 50% drug release. The initial 
burst release can be attributed to drug molecules located within the corona or at the 
interface between the micelle core and surface 122. For the 10 and 20% TPGS cases, the 
drug release rate slowed down slightly, which may be due to the interaction of DOX with 
(b) 
(a) 
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the TPGS non-polar head group. It has been reported that the hydrophobic part of TPGS 










Figure 6.2 Drug release profiles of DOX-loaded PLGA-PEG-FOL micelles and mixed 
micelles with different percent of TPGS. Each point represents the mean ± S.D. from 
three experiments. 
 
6.3.3 Cellular DOX uptake 
The cellular uptake was evaluated in KB/DOX cells and fibroblasts. The cellular uptake 
of DOX in Figure 6.3 shows KB/DOX cells treated by free DOX, DOX-loaded PLGA-
PEG micelles, PLGA-PEG-FOL micelles, and mixed micelles with 5%, 10% and 20% 
TPGS. The control is the sample without any treatment of DOX formulations. 
Fluorescence intensity in this range is considered as the auto-fluorescence. The cellular 
uptake of free DOX was remarkably lower than the micellar formulations. This may be 
related to the multi-drug resistant (MDR) effect of tumor cells. One serious problem 

























Mixed micelles (5% TPGS)
Mixed micelles (10% TPGS)
Mixed micelles (20% TPGS)
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treatment. An important mechanism of MDR in mammalian cells is the enhanced 
expression of a 170 kDa plasma membrane associated glycoprotein known as p-
glycoprotein (P-gp), which functions as an energy-dependent multi-drug membrane 
transporter to rapidly extrude hydrophobic anticancer drugs from cancer cells and thus 
prevents the drugs from exerting cytotoxic effects 11, 82, 158.  
 
The cellular uptake of DOX was significantly higher in PLGA-PEG-FOL micelles 
(profile 3) compared with PLGA-PEG micelles (profile 2) due to folate-mediated 
endocytosis. The mixed micelles with 5% TPGS (profile 4) exhibited slight increase in 
DOX uptake compared with the folate micelles without TPGS (profile 3). In the 10% 
TPGS case (profile 5), however, the fluorescence intensity was 2.4 times higher than that 
of the micelles without TPGS. The mixed micelles with 20% TPGS (profile 6) showed 
additional, but marginal increase in DOX uptake compared with the 10% TPGS mixed 
micelles. Although the mechanism is not fully understood, it was reported that TPGS can 
act as P-gp inhibitor to effectively block the transport of paclitaxel in transport assays and 
significantly increase the drug concentration in cancer cells 159, 160. Therefore, the 
increased cellular uptake here may also be resulted from the TPGS induced P-gp 
inhibition. However, for fibroblast cells (Figure 6.4), the mixed micelles with TPGS did 
not increase the drug uptake. Opposite to KB/DOX cells, which showed significantly 
enhanced cellular uptake with mixed micelles, the fibroblasts showed much lower uptake 
with mixed micelles than with free DOX. This is reasonable since normal cells do not 
have the MDR ability and overexpression of folate receptors (FRs). Without MDR effect, 
the efflux of drugs does not exist. In addition, without folate-mediated endocytosis, the 
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cellular uptake of free DOX via diffusion could be much faster than the micelles 
formulations via endocytosis.  
 
The distribution of DOX in KB/DOX cells was visualized by confocal microscopy 
(Figure 6.5). For free DOX, red fluorescence was only observed in nuclei and no 
fluorescence signal was found in cytoplasm since DOX can accumulate quickly in the 
nucleus after membrane diffusion. PLGA-PEG micelles exhibited slightly higher 
fluorescence and even higher signal was observed for PLGA-PEG-FOL micelles in both 
cytoplasm and nucleus, indicating that the important role of folate-mediated endocytosis. 
The mixed micelles with 5% and 10% (as well as 20%, not shown) TPGS showed even 
more pronounced fluorescence in cytoplasm and nucleus, showing the important role of 
TPGS in enhancing the cellular uptake of the drug. But for fibroblasts, the mixed micelles 
with 10% TPGS only showed very weak fluorescence intensity which is consistent with 
the flow cytometry results. This further illustrates the suitability of the mixed micelles for 
targeting delivery of drug since the micellar formulation yielded less drug uptake for 
normal cells. 




















Figure 6.3 Flow cytometry histogram profiles of fluorescence intensity when KB/DOX 
cells were treated by (1) free DOX, (2) DOX-loaded PLGA-PEG micelles, (3) PLGA-
PEG-FOL micelles, (4) mixed micelles with 5% TPGS, (5) mixed micelles with 10% 


















Figure 6.4 Flow cytometry histogram profiles of fluorescence intensity when fibroblast 
cells were treated by free DOX, DOX-loaded PLGA-PEG-FOL micelles and mixed 
micelles with 10% TPGS. 
Mixed 
micelles





















































Figure 6.5 Confocal images of KB/DOX cells treated with drug formulations. (a) free 
DOX, (b) DOX-loaded PLGA-PEG micelles, (c) DOX-loaded PLGA-PEG-FOL micelles, 
(d) DOX-loaded mixed micelles with 5% TPGS, (e) DOX-loaded mixed micelles with 
10% TPGS and (f) Fibroblasts treated with mixed micelles with 10% TPGS.  
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6.3.4 Cytotoxicity Test 
 
In this study, cytotoxicity of TPGS alone to cancer cells and fibroblasts was first 
compared to demonstrate the potential cytotoxic effect of TPGS. As shown in Figure 6.6, 
the cytotoxicity of TPGS alone to cancer cells was significantly higher than that of 
normal fibroblasts, indicating that TPGS has selective cytotoxicity to cancer cells. 
Animal studies of human cancer xenografts have found that TPGS effectively suppressed 
tumor growth. The anticancer activity of TPGS was reported to be due to its unique 
apoptosis-inducing properties via the generation of reactive oxygen species (ROS) 146. 
ROS can damage DNA, proteins, and fatty acids in cells, resulting in apoptotic cell death, 
depending on the strength and duration of ROS generation. The effect of TPGS on 
fibroblasts was limited since normal cells are generally more resistant to oxidative stress. 
It should be noted that compared with free DOX, the cytotoxicity of TPGS to cancer cells 
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For the cytotoxicity of PLGA-PEG-FOL micelles to KB/DOX cells which are drug 
resistant cells, folate-mediated endocytosis increased the cytotoxicity significantly 
compared with free DOX and PLGA-PEG micelles (Figure 6.7). The calculated IC50 
value of free DOX, DOX-loaded PLGA-PEG micelles and PLGA-PEG-FOL micelles 
was 31.16, 8.62, and 1.51 µM respectively. KB cells express 4 million folate receptors 
(FRs) per cell 40, and thus folate-mediated endocytosis of micelles can lead to higher 
cytotoxicity For the mixed micelles, compared with the 0% and 5% TPGS formulations, 
the 10% and 20% TPGS formulations induced significantly higher cytotoxicity (p<0.05) 
to KB/DOX cells at the concentration above 0.1 µM. This may be attributed to the TPGS 
function as a P-gp inhibitor 12-14, 159, 160. By adding TPGS in the formulation, the mixed 
micelles may reduce the P-gp induced drug efflux (see the accumulation of rhodamine 
section for the additional study on P-gp inhibition by TPGS). When free TPGS was co-
administrated with PLGA-PEG-FOL micelles (Figure 6.8), however, no enhanced 
cytotoxicity was observed. Unlike the highly selective P-gp inhibitors (e.g. cyclosporine 
A analogs) that are effective by co-administration with drugs, non-ionic surfactants (e.g. 
Pluronic and TPGS) may only influence P-gp noticeably by being present in the micelle 
formulation 161, 162.  



















Figure 6.7 The cytotoxicity of free DOX, DOX-loaded PLGA-PEG micelles, PLGA-
PEG-FOL micelles and mixed micelles to KB/DOX cells. Bars marked with * are 


















Figure 6.8 The cytotoxicity of DOX-loaded PLGA-PEG-FOL micelles added with 5%, 
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To test the cytotoxic selectivity of the PLGA-PEG-FOL micelles, the same experiment 
was conducted on normal fibroblasts (Figure 6.9). Without TPGS, the IC50 value of 
PLGA-PEG-FOL micelles to KB/DOX cells and fibroblasts was 1.51 µM and 4.48 µM 
respectively. However, the mixed micelles (with 10% TPGS) showed even more 
pronounced cell viability difference (p<0.05) between KB/DOX cells and fibroblasts with 
IC50 value of KB/DOX cells being 0.53 µM and fibroblasts being almost unchanged at 
4.42 µM. More importantly, the cytotoxicity difference of the various formulations (with 
or without TPGS) on fibroblasts was insignificant. This demonstrates that the presence of 
TPGS in the PLGA-PEG-FOL micelles exhibited marginal effect in normal cells and was 
only effective against drug resistant tumor cells. Based on the cellular uptake and 
cytotoxicity study, the weight percentage of TPGS in the system can be optimized as 
10% since mixed micelles with 20% TPGS only exhibited marginal increase in cellular 
















Figure 6.9 The cytotoxicity of mixed micelles to fibroblasts, respectively. Each bar 
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6.3.5 Apoptosis assay 
In order to determine the contribution of apoptosis to cell killing, apoptosis assay on drug 
resistant KB/DOX cells was performed. Apoptosis, or programmed cell death, is 
characterized by distinct morphological and biochemical changes in the nucleus and 
cytoplasm 163. The loss of plasma membrane integrity is one of the earliest apoptotic 
features. In living cells, phosphatidylserine (PS) is transported to the inside of the lipid 
bilayer by the Mg-ATP dependent enzyme. In apoptotic cells, PS is translocated from the 
inner to the outer of the plasma membrane, thereby exposing to the external cellular 
environment. Annexin V is a 35-36 kDa Ca2+ dependent phospholipid-binding protein 
that has a high affinity for PS and binds to cells with exposed PS 164, 165.  
 
Figure 6.10 shows the enhanced apoptotic effect of TPGS in the micelles formulation. 
The horizontal axis is the fluorescence intensity of annexin V-FITC and vertical axis 
displays the cell numbers. The portion marked with M1 indicates the apoptotic 
population. No obvious apoptotic peak was found in the control group. The apoptosis 
induced by free DOX amounted to 9%, whereas the PLGA-PEG-FOL micelles induced a 
substantially larger peak (36%) due to folate mediated endocytosis. With 10% TPGS in 
the formulation, the apoptosis population reached to 61%. Although TPGS itself can 
induce apoptosis in cancer cells through ROS generation 166, 167, this effect was found to 
be insignificant compared with the drug induced apoptosis. This result is consistent with 
the cytotoxicity result and can be attributed to the enhanced cellular uptake of DOX with 
the aid of P-gp inhibition by TPGS. 
 






























Figure 6.10 Annexin V-FITC apoptosis assay of KB/DOX cells (The portion marked 
with M1 indicates the apoptotic population).  
6.3.6 Accumulation of rhodamine in Caco-2 cells 
The enhanced cellular uptake and cytotoxicity of TPGS mixed micelles against KB/DOX 
cells can be due to MDR inhibition. However, since the KB/DOX cell line expresses both 
folate receptors and P-gp, the MDR inhibition effect of the mixed micelles may be 
interfered by the folate-mediated endocytosis. To confirm the mixed micelles can inhibit 
P-gp activity, Caco-2 cells were selected here to study MDR inhibition because it is 
Annexin V-FITC 
          (A) 









                      (D) 




                   (C) 
DOX-loaded PLGA-PEG-FOL micelles 
(Apoptosis: 36%) 
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known to express P-gp 168 but not FRs. Rhodamine, a substrate for P-gp, was used as a 
marker for P-gp activity in cells.  
 
The cellular uptake of rhodamine via four different formulations (free rhodamine, 
rhodamine loaded PLGA-PEG micelles, PLGA-PEG-FOL micelles and mixed micelles 
with 10% TPGS) at 5 µM rhodamine concentration was determined by fluorescence 
measurement (Figure 6.11) and observed by confocal microscopy (Figure 6.12). The 
cellular uptake efficiency of the mixed micelles was significantly higher than that of free 
rhodamine (p<0.05). The PLGA-PEG micelles and PLGA-PEG-FOL micelles showed 
similar cellular uptake since no FRs on Caco-2 cells. Although PLGA-PEG-FOL micelles 
showed increased cellular uptake compared with free rhodamine, this enhancement was 
1.6 times lower than that of the mixed micelles with 10% TPGS. The confocal images 
also showed a more pronounced rhodamine accumulation in mixed micellar formulations. 
The increased rhodamine accumulation confirms that mixed micelles inhibited P-gp 
activity effectively in Caco-2 cells. Based on the cytotoxicity study and the accumulation 
of rhodamine, the mixed micelle formulation may have dual functions of folate-mediated 
targeting and MDR inhibition to cancer cells, and at the same time, minimize the 
cytotoxicity of the drug to normal cells. In this regard, the new formulation exhibits a 














































Figure 6.12 The rhodamine accumulation in Caco-2 cells. (a) free rhodamine, (b) PLGA-






































In order to get more potent drug targeting carrier, TPGS was added in the drug targeting 
system DOX-loaded PLGA-PEG-FOL micelles to form mixed micelles. Compared with 
the PLGA-PEG-FOL formulation, the addition of TPGS showed higher cellular uptake of 
DOX, and subsequently a higher degree of DNA damage and apoptosis, and eventually a 
higher cytotoxicity to drug resistant cells. The enhanced cellular uptake of mixed 
micelles was related to the P-gp inhibition function of TPGS. In addition, the current 
formulations with TPGS also selectively enhance the cytotoxicity of drug resistant cancer 
cells with overexpressed folate receptors and affect normal cells at minimum. Based on 
these findings, this new TPGS formulation can potentially strengthen the therapeutic 
effect of the PLGA-PEG-FOL micelles system.  
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Chapter 7  
The pharmacokinetics and tissue distribution of 




In Chapter 6, a new drug formulation - folate conjugated micelles (PLGA-PEG-folate 
(FOL)) formulated with TPGS was fabricated 169. Compared with the PLGA-PEG-FOL 
micelles formulation, the mixed micelles formulation showed dual functions of folate-
mediated targeting and MDR inhibition to cancer cells, and at the same time, minimized 
the cytotoxicity of the drug to normal cells. In this regard, the new formulation exhibited 
a synergistic effect for treating drug resistant cancer cells with overexpression of FRs. 
Few studies have addressed the in vivo effects of folate active targeting and MDR 
inhibition at the same time. In this chapter, the pharmacokinetics and biodistribution of 
this new formulation in the breast tumor-bearing rats was studied. The breast tumor was 
induced by MATB Ш cells which over expressed FRs. Two different tumor models were 
compared-drug sensitive model induced by MATB Ш cells and drug resistant model 
induced by MATB Ш/DOX cells. The tumor targeting ability and P-gp inhibition effect 
of the four different formulations were evaluated in this study - free DOX, DOX-loaded 
PLGA-PEG micelles (DOX/micelles), DOX-loaded PLGA-PEG-FOL micelles 
(DOX/folate micelles) and DOX-loaded PLGA-PEG micelles formulated with 10% 
TPGS (DOX/mixed micelles) (Based on our previous study, the weight percentage of 
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TPGS in the system was optimized as 10%). The tumor and heart morphology was also 
studied to compare the drug accumulation.  
 
7.2 Materials and methods 
7.2.1 Materials 
For cell culture experiments, rat breast cancer cell line (MATB Ш) was purchased from 
ATCC. McCoy's 5a medium, fetal bovine serum (FBS) and penicillin-streptomycin (pen-
strep) were obtained from Invitrogen. 3-(4,5-dimethylthiaol-2-yl)-2,5-diphenyltetra- 
zolium bromide (MTT) were obtained from Sigma-Aldrich.  
 
Female Wistar rats (6-8 weeks old, 250-300 g) were obtained from Centre for Animal 
Resources of National University of Singapore and acclimated for 7 days after arrival. 
The animals were housed in a pathogen-free laboratory environment in air-conditioned 
facility and provided with standard food and filtered water. Care and handling of animals 
and animal experiment protocols were approved by the Institutional Animal Care and Use 
Committees (IACUC), Office of Life Science, National University of Singapore. All 
experiments on the animals strictly followed the protocols. 
7.2.2 In vitro cell culture studies 
 
MATB Ш cell line which vastly over-expresses the FRs was selected for cell culture 
studies and implantation to rat body. The DOX-resistant MATB Ш cells (MATB Ш 
/DOX) were selected after sequential exposure of MATB Ш cells to 0.001-10 µg/ml of 
free DOX concentration 139. MATB Ш and MATB Ш/DOX cell lines were cultured 
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using methods described previously by other research groups 170. Briefly, cells were 
cultured in McCoy's 5a medium with 10% FBS and 1% pen-strep in T-75 flasks at 37°C 
with 95% humidity and 5% CO2. The medium was changed two to three times a week. 
The cytotoxicity and cellular uptake is the same as described in last chapter. 
7.2.3 Subcutaneous tumor growth 
To establish breast cancer xenografts, MATB Ш or MATB Ш/DOX cells suspension (0.1 
ml) containing 1×107 cells was subcutaneously implanted on the back of rats. Tumor 
volume was calculated using a formula, tumor volume = 0.5 × length × (width)2. The 
dimension was measured by an electronic digital caliper. After the implantation, tumors 
were allowed to grow for 10 days or until tumor volume of 500 mm3, followed by 
intravenously (i.v.) bolus injection of drug formulations (dose of DOX = 2 mg/kg) 
through the lateral tail vein of the rats. Three rats were used per formulation.  
7.2.4 Pharmacokinetics of the four drug formulations 
 
Different drug formulations were injected i.v. through the tail vein of rats bearing s.c. 
MATB Ш or MATB Ш/DOX xenograft. At given time intervals (0, 0.5, 1, 1.5, 2, 3, 5, 8, 
10 and 24h), 0.5 ml of blood for each drug formulation (3 rats for each formulation) was 
collected into eppendorf tubes with 10 µl 50 U/ml heparin. Blood samples were 
centrifuged at 1900 rpm for 10 min to separate plasma. Subsequently, 1 ml of organic 
solvents (chloroform: methanol = 4:1) was added to the plasma. The mixture was 
vigorously mixed for 5 min and centrifuged at 14000 rpm for 10 min. The organic phase 
was extracted and evaporated. The drug residue was redissolved in 0.2 ml methanol for 
HPLC analysis.  
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The DOX concentration in plasma or tissues was analyzed by reversed phase HPLC on a 
ZORBAX SB-C18 column (4.6 x 250 mm, 5 µm) using a fluorescence detector at 
excitation wavelength of 475 nm and emission wavelength of 580 nm. Methanol: PBS 
(70:30, v/v) was used as the mobile phase and the pH of PBS was adjusted to 2.47 by 
acetic acid. The flow rate was 1 ml/min and 50 µl of sample was injected by an 
autosampler. The temperature of the column was 35°C. The DOX content in plasma or 
tissues was determined using a calibration curve established by adding a series of mass 
concentration of free DOX to 1.0 ml normal plasma or 1 g different normal tissues 
harvested from control rat 171. The calibration curves showed a linear correlation for the 
plasma samples at the concentration between 0.01-10 µg/ml and a linear correlation for 
the tissue samples at the concentration between 0.1-20 µg/g respectively.  
 
The pharmacokinetic parameters were calculated using non-compartmental analysis of 
WinNonlin software program (Version 5.1, Pharsight). Cmax values were obtained from 
visual inspection of the data and clearance (CL) calculated by dividing dose by AUC0-∞. 
The data were analyzed for statistical significance by unpaired Student’s t-test. All results 
were expressed as the mean ± standard deviation (S.D.). 
7.2.5 Biodistribution study 
 
In this study, the above four different formulations were injected i.v. through tail vein in 
rats bearing tumors. At given time intervals, i.e. 6, 12, 24 h for free drug (the DOX level 
was not detected by a fluorescence detector after 24 h post administration) and 12, 24, 48 
h for micelles formulation), rats were sacrificed and various organs such as heart, lung, 
liver, kidney, spleen and tumor were removed and lyophilized. After weighed, the organs 
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were homogenized with PBS at pH 7.4 and followed by an acidic hydrolysis in 2 M HCl 
solution at 80°C for 10 min 172. Subsequently, 1 ml of organic solvents (chloroform: 
methanol = 4:1) was added to the tissue solution. After vigorous vortex mixing, the 
organic layer was collected by centrifugation at 14000 rpm for 30 min and evaporated. 
The drug residue was redissolved in methanol for HPLC analysis as described above. 
 
To observe the drug distribution in normal and tumor tissues, a histopathological 
evaluation of excised tumor tissue samples was performed. The tumor tissues were 
embedded in paraffin wax and trimmed to 5 µm of thickness using a rotary microtome 
(Leica RM 2135, Leica) based on standard histological protocols 173-175.  Hematoxylin 
and eosin (H&E) staining was used to stain the tumor tissues. Finally the tissues were 
observed using a fluorescence microscope (Olympus BX51, Olympus) with a 40× 
objective lens.  
 
7.3 Results and discussion 
7.3.1 Tumor growth 
Figure 7.1 shows the tumors size and position 7 days after tumor cells implantation. After 
tumor cells inoculation, the tumors developed very fast.  
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7.3.2 Pharmacokinetics of the DOX-loaded micelles 
The plasma concentration profile (Figure 7.2) of different drug formulations showed 
biphasic clearance kinetics. All formulations experienced an initial rapid clearance from 
the blood for the first 3 h followed by slow clearance 3 h post injection. A significant 
difference in plasma DOX concentration was found between the free DOX and micelles 
formulations. The free DOX was rapidly eliminated from the blood compartment. The 
concentration of DOX delivered through micelles was significantly higher (p<0.05) than 
free DOX after 3 h post injection. Micelles formulation could escape from renal clearance 
due to their larger size than the renal threshold 176, therefore their plasma DOX 
concentrations decreased much slower that of free DOX. Compared with DOX/micelles, 
the DOX/folate micelles showed lower drug concentration in blood after 3 h post 
injection which was consistent with previous studies on FR-targeted liposomes 95, 177. 
This can be attributed to the increased uptake rate of DOX in the tumor due to the FR-
mediated endocytosis (see the biodistribution result). For the DOX/mixed micelles, the 
plasma concentration was slightly lower than that of DOX/folate micelles. From in vitro 
drug release profiles (Chapter 6, Section 6.3.2), DOX/mixed micelles released the drug 
faster. Therefore, the clearance for DOX/mixed micelles could be faster compared with 
other micelles formulations.  
The plasma pharmacokinetics parameters of different formulations were calculated using 
non-compartment model analysis and summarized in Table 7.1. The in vivo plasma 
elimination half-life of formulations correlated well with the in vitro release profile. The 
plasma circulation half-life (t1/2) significantly increased for all the micelles formulations 
with increased mean residence time (MRT) and decreased clearance. Given the size of 
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these micelles and the long circulation time, they were likely to be preferentially 
accumulated in solid tumors due to the enhanced permeability and retention (EPR) effect. 
The DOX loaded micelles with a size below 100 nm may likely pass through the 
endothelial junction of the capillaries in the tumor tissue, but not in normal ones, since 
the cell junctions are not as tight as those of normal tissues. In addition, tumors lack 
functional lymphatic drainage, extravasted fluid and marcromolecules (such 
DOX/micelles) are more effectively retained in interstitial spaces. The AUCs of the 
micelles formulations were much higher than the free DOX formulation. Among the 
different micelles formulations, the AUC of DOX/micelles was higher than that of 
DOX/folate micelles and DOX/mixed micelles, which may result from the increased 

















Figure 7.2 The plasma drug concentration-time profiles of drug formulations after i.v. 
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Table 7.1 The plasma pharmacokinetics parameters of different drug formulations 





Cmax (µg/mL) 9.26±0.36 4.05±0.21 4.18±0.25 3.87±0.15 
AUC0-24 (µg/mL*h) 3.97±0.21 11.15±0.35 7.97±0.18 6.70±0.21 
AUC24-∞(µg/mL*h) 0.20±0.03 2.39±0.11 1.94±0.08 1.38±0.05 
AUC0-∞(µg/mL*h) 4.17±0.33 13.55±0.75 9.91±0.84 8.07±0.52 
t1/2 (h) 1.76±0.02 15.54±0.35 15.06±0.28 15.05±0.39 
Cl (mL/kg/h) 2.40±0.04 0.64±0.02 1.11±0.02 1.37±0.03 
MRT0-24 (h) 3.83±0.15 18.7±0.43 14.5±0.35 13.05±0.65 
V (mL/kg) 9.19±0.52 12.03±0.35 16.04±0.82 17.89±1.05 
7.3.3 Biodistribution  
Figure 7.3 shows the in vivo biodistribution of different drug formulations in tumor 
bearing rats induced by MATB Ш cells. For free DOX, the DOX level was not detected 
by a fluorescence detector after 24 h post injection. For DOX/micelles formulation, a 
higher concentration of DOX was observed in the tumor compared with the rest of the 
organs. Furthermore, DOX was found in tumor even after 48 h. As considerable amount 
of micelles targeted towards tumor, a low DOX concentration was detected for heart, 
lung and kidneys. Compared with DOX/micelles, DOX/folate micelles and DOX/mixed 
micelles showed higher drug concentration in tumor. The drug accumulation of 
DOX/folate micelles was nearly 3 fold higher than that of micelles without folate moiety. 
Compared with DOX/folate micelles, DOX/mixed micelles showed similar drug 
accumulation in tumor. Similar to the results for DOX/micelles, DOX concentration for 
DOX/folate micelles and DOX/mixed micelles in heart, lung and kidney were rather low 
as compared to those in tumor.  
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Figure 7.3 The biodistribution of drug formulations in rat tissues after i.v. administration 
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Figure 7.4 shows the biodistribution of different drug formulations in tumor bearing rats 
induced by MATB Ш/DOX cells. For free DOX formulation, the drug concentration in 
tumor was much lower compared with the same formulation in tumor induced by MATB 
Ш cells, which may attributed to the drug efflux by P-gp. DOX/micelles and DOX/folate 
micelles also showed drug concentration decrease in the drug resistant model. However, 
the accumulation of DOX/mixed micelles was similar in both drug sensitive and drug 
resistant models. The DOX concentration observed in the other organs showed rather 
similar results as obtained for rats with drug sensitive tumors.  
 
The removal of free DOX occurred at a rather fast rate, leading to the elimination of most 
of the drug within 24 h post injection. This was likely due to the renal excretion. With 
low molecular weight, free DOX was unable to exceed the threshold value of the 
glomerular filtration in the kidneys and was effectively filtered by the kidneys. 
Furthermore, due to the non-specificity, the DOX level in various organs was comparable 
to that in tumor. This result showed that free DOX did not preferentially accumulate in 
tumor and possess no targeting ability towards tumor. Compared with free DOX, the high 
drug concentration in tumor by micelles formulations could be attributed to the EPR 
effect occurring in the tumor for nanosized micellar delivery systems. This passive 
targeting effect of the micelles enabled a significant amount of DOX to be located in the 
tumor as observed. Furthermore, DOX was found in tumor even after 48 h, and this was 
likely due to the long circulation of DOX/micelles in bloodstream and the high retention 
effect of tumor. A low concentration in the kidneys was likely due to the fact that 
micelles formulations have molecular weights greater than the renal excretion threshold, 
therefore escaping the glomerular filtration of kidney. The liver and spleen had much 
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higher DOX concentration compared with the other organs, and was probably due to 
recognition by the RES. Micelles usually show much lower accumulation in liver and 
spleen compared with solid nanoparticle formulations (such as PLGA, PLA) because 
PEG aids in RES escape. Other factors such as surface chemistry and charge may also 
affect the RES as well 178.  
 
The drug accumulation of DOX/folate micelles was nearly 3 fold higher than that of 
micelles without folate moiety. Since the tumor was induced by drug resistant MATB 
Ш/DOX cells which overexpress FRs, the presence of high drug concentration in tumor 
is likely due to the active targeting effect of folate. In addition, the EPR effect may also 
enhance the local accumulation of micelles in tumor sites for active targeting. This high 
drug accumulation in tumor resulted in a significantly less available amount of micelles 
to accumulate in other organs.  
 
Compared with DOX/folate micelles, the drug accumulation of DOX/mixed micelles in 
drug resistant tumor model was 1.4 fold higher. Besides folate active targeting, TPGS 
could enhance cellular uptake of anticancer drugs in cancer cells by inhibiting P-gp 
mediated MDR, therefore result in higher DOX concentration in tumor.  
 
The biodistribution results showed the cardiac toxicity in descending order – free DOX > 
DOX/micelles > DOX/folate > DOX/mixed micelles. Concentration of DOX in heart for 
DOX/mixed micelles was the lowest among all the formulations, though DOX/folate 
micelles showed very similar results. Concentration in the tumor followed a similar but 
opposite trend with the lowest concentration for free DOX and highest for DOX/mixed 
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micelles. These trends that occurred for the heart and tumor were likely due to EPR, FR-
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Figure 7.4 The biodistribution of drug formulations in rat tissues after i.v. administration 
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7.3.4 Tumor and heart morphology analysis 
H&E histology and fluorescence microscopy from the same tissue area was performed to 
observe the drug distribution in tumor and heart. Figure 7.5 shows the morphology of 
tumor tissues induced by drug sensitive cells. After H & E staining, the nuclei were 
stained to blue by hematoxylin and cytoplasm was stained to pink by eosin. The DOX 
was observed as red color which is clearly distinguishable from the background. After 24 
h post injection, the free DOX in drug sensitive tumors can only be found at the surface 
of the tumor and the fluorescence intensity was weak compared with other drug 
formulations. However, for the DOX/micelles formulation, the drug was distributed in 
the tumor and the fluorescence intensity was strong because of EPR effect. The 
DOX/folate micelles and DOX/mixed micelles showed similar results and the 
fluorescence intensity was much stronger than that of DOX/micelles, which demonstrates 
the effect of folate mediated targeting. Figure 7.6 shows the morphology of tumor tissues 
induced by drug resistant cells. The fluorescence intensity of free DOX in drug resistant 
tumor was very weak due to the MDR effect. The DOX/micelles and DOX/folate 
micelles showed enhanced fluorescence intensity compared with free DOX, but the 
intensity was still lower compared with the results for drug sensitive tumors. The 
DOX/mixed micelles demonstrated higher fluorescence intensity than DOX/folate 
micelles and the fluorescence intensity was comparable with the results for drug sensitive 
tumors. This further confirms the function of TPGS as P-gp inhibitor. 
 
Figure 7.7 shows the heart morphology of tumor bearing rats induced by MATB Ш/DOX 
cells. The heart morphology showed that only free DOX formulation had red 
fluorescence, all the micelles formulations showed no visible fluorescence. This is 
consistence with the biodistribution data. 













































Figure 7.5 The tumor morphology 24 h after i.v. administration against MATB Ш cells. 
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Figure 7.7 The heart morphology 24 h after i.v. administration against MATB Ш/DOX cells. 
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DOX 













The pharmacokinetics and biodistribution study showed that free drug was eliminated 
rapidly by renal excretion and the drug concentration in tumor was very low. However, 
all the micelles formulations had longer circulation time and enable the passive targeting 
of micelles to tumor by EPR effect. Compared with DOX/micelles, the DOX/folate 
micelles showed higher drug concentration in tumor because of the folate targeting effect. 
The DOX/mixed micelles formulation showed enhanced drug accumulation in drug 
resistant tumors which result from the P-gp inhibiting function of TPGS. Based on our 
results, the DOX/mixed micelles might be the appropriate formulation for drug resistant 
tumors overexpressed FRs because it shows combined effects of EPR, folate active 



























Potential use of cholecalciferol polyethylene glycol 
succinate as a novel pharmaceutical additive 
 
8.1 Introduction 
In Chapter 6, TPGS has been found to be effective to inhibit P-gp. However, TPGS 
represents the only surfactant in the class of “Vitamin-PEG” conjugated surfactants. Until 
now, other surfactants in this class virtually do not exist. If the effectiveness of this type 
of surfactants does not limit to tocopheryl-based ones, synthesizing surfactants of PEG 
and other vitamins can have important implications because each of the surfactant or a 
combination of them can generate copious new formulations in fabricating new drug 
carriers. In order to determine the effectiveness of Vitamin-PEG conjugated surfactants 
as additives in formulating drug delivery carriers, we hypothesized that any hydrophobic 
vitamins combined with PEG may achieve similar effectiveness that TPGS has brought in 
drug delivery formulation. Among all vitamins, Vitamin A and D share similar degree of 
hydrophobicity to Vitamin E. Coincidently all three of them contain a hydroxyl group for 
possible conjugation. Compared with Vitamin A, Vitamin D is of much interest in this 
study because of its cancer prevention functions 179, 180. A growing number of studies 
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have suggested that Vitamin D can be effective in certain types of cancer 
chemoprevention and treatment  181-183.  
 
In this chapter, Vitamin D3 (cholecalciferol) was used to synthesize a new Vitamin-PEG 
conjugate – cholecalciferol polyethylene glycol succinate (CPGS). Similar to TPGS, 
CPGS was synthesized from the esterification of Vitamin D succinate with polyethylene 
glycol methyl ether (mPEG). Currently, TPGS is used as the surfactant for fabricating 
nanoparticles and P-gp inhibitor for improving the bioavailability of poorly absorbed 
drugs. In recent studies, TPGS was also found to inhibit cancer cells growth 147. 
Therefore, to exploit the potential applications for CPGS, the emulsification, P-gp 
inhibition and cytotoxicity study of CPGS were evaluated and compared with that of 
TPGS. Results obtained from this study may broaden the spectrum of the vitamin-based 
additive for drug delivery system. 
 
8.2 Materials and methods 
8.2.1 Materials 
D-α-tocopheryl polyethylene 1000 glycol (TPGS) was a free gift from Eastman 
Chemicals. Cholecalciferol (Vitamin D3), poly(ethylene glycol) methyl ether (average Mn 
2,000) (mPEG 2000), succinic anhydride, 4-dimethylaminopyridine (DMAP), poly(DL-
lactide-co-glycolide, 50:50) (Mw: 40,000-75,000), N-hydroxy-succinimide (NHS), 
dicyclohexyl-carbodiimide (DCC), doxorubicin (DOX), rhodamine-123 and 3-(4,5-
dimethylthiaol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were purchased from 
Sigma-Aldrich. All other reagents including dichloromethane (DCM), pyridine, 
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diethylether were analytical grade and used as received. Caco-2 cell line was purchased 
from ATCC. Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), 
penicillin-streptomycin (pen-strep) and Trypsin-EDTA were obtained from Invitrogen.  
8.2.2 Synthesis of cholecalciferol polyethylene glycol succinate (CPGS) 
CPGS was synthesized by a two-step reaction scheme shown in Figure 8.1. 
(1) Synthesis of Vitamin D succinate (VDS) 
Known amounts of cholecalciferol and succinic anhydride (molar ratio of cholecalciferol: 
succinic anhydride = 1:4) was dissolved in pyridine. The solution was stirred and heated 
at 100oC under nitrogen gas for 20 h in the dark. The reaction progress was monitored 
using thin-layer chromatography (TLC) with methanol and chloroform (1:10 v/v) as 
developing solvents. After the reaction, pyridine was removed and diethyl ether was 
added to the mixture and placed at 4oC for 15 h to precipitate the unreacted succinic 
anhydride. Subsequently, the mixture was filtered and the filtrate was then washed with 
0.1 M hydrochloric acid and water. Residual water was removed from the product using a 
rotary evaporator to yield viscous dark yellow oil. The oil was then further dried at 60oC 
in vacuum for 2 days to get a dark brown powder. Finally the product was purified on 
silica gel 60 and eluted with a 9:1 chloroform/methanol mixture.  
(2) Synthesis of CPGS 
Predetermined amount of VDS and mPEG 2000 (molar ratio of VDS: mPEG = 1:1.1) 
was dissolved in anhydrous DCM and stirred at room temperature. DMAP (0.1 
equivalent) and DCC (1.1 equivalent) was sequentially added in the solution. The 
reaction was stirred at room temperature overnight. The reaction mixture was filtered and 
the filtrate was concentrated using a rotary evaporator. The final product was dried in 
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vacuum for 2 days. mPEG 1000 was not commercially available and thus only mPEG 
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8.2.3 Characterization of CPGS 
The structural conformation of CPGS was determined by 1H-NMR in CDCl3 at 500 MHz 
(ACF500, Bruker). FT-IR spectroscopy (FTIR-8400, Shimadzu) was used to investigate 
functional groups present in the intermediate product VDS and the final product CPGS. 
Purity analysis was carried out using HPLC (HPLC-10 Atvp, Shimadzu). Analysis was 
performed on a ZORBAX SB-C18 (4.6 x 250 mm, 5 µm) column using a UV detector at 
290 nm. The mobile phase was methanol and acetonitrile (50:50). The flow rate was set 
at 1 ml/min. The sample injection volume was 20 µl.  
8.2.4 Preparation of DOX-loaded PLGA nanoparticles 
The DOX-loaded polymer nanoparticles were prepared by a dialysis method. Briefly, 50 
mg of PLGA and 2 mg of free DOX without or with TPGS/CPGS (5%-15% wt% of 
polymer) were dissolved in 4 ml DMSO in the presence of 4 mg of TEA. The organic 
phase was subsequently transferred into a dialysis membrane. The dialysis membrane 
was then placed into aqueous phase with gentle stirring to produce nanoparticles. DMSO 
and TEA were removed by extensive dialysis against deionized water for 24 h. Finally, 
the nanoparticles in the membrane were collected by centrifugation at 15,000 rpm for 30 
min and freeze dried for 2 days.   
8.2.5 Characterization of polymer nanoparticles  
The CMC of CPGS in phosphate buffer solution (PBS) was determined by fluorescence 
spectroscopy as described in the previous chapters. The shape and surface morphology of 
the nanoparticles was observed by scanning electron microscopy (SEM, JSM-5600LV, 
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JEOL). The average size of particles, zeta potential, encapsulation efficiency and in vitro 
drug release was measured by the methods stated in previous chapters.  
8.2.6 Accumulation of rhodamine in Caco-2 cells  
Caco-2 cells were seeded in 12-well tissue culture plates at a density of 1×104 cells/well. 
After the cells reached 80% confluence, the cells were exposed to three different 
formulations: 5 µM rhodamine in 1% methanol in the DMEM, 5 µM rhodamine 
encapsulated by TPGS and CPGS micelles. Each rhodamine formulation was repeated 
three times and a control was kept by adding the same rhodamine formulation in the 
blank wells. After 2 h incubation, the cells were washed three times with PBS and lysed 
with 1% Triton X-100 followed by 100 µl DMSO. The fluorescence intensity of the lysed 
cell solution was measured by a microplate reader (GENios, Tecan) at the excitation 
wavelength of 485 nm and emission wavelength of 530 nm. The cellular uptake 
efficiency was obtained by the fluorescence intensity ratio of samples to the control.  
 
The rhodamine accumulation in Caco-2 cells was observed by confocal laser scanning 
microscopy (LSM 410, Carl Zeiss, Inc.). Cells were cultured in Lab-Tek® chambered 
，coverglass (Nalge 155383 NUNC) for 48 h (2×104 cells/chamber). The cells were then 
incubated with DMEM containing rhodamine or rhodamine encapsulated in TPGS or 
CPGS micelles (rhodamine concentration: 5 µM). After 2 h, the cells were washed with 
PBS three times, fixed with ethanol for 20 min, and followed with another PBS wash. 
The cells were observed by confocal microscopy with the FITC filter.  
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8.2.7 Cytotoxicity assay 
Caco-2 cell line was cultured in DMEM medium with 10% (v/v) FBS and 1% (v/v) pen-
strep in T-75 flasks at 37°C with 95% humidity and 5% CO2. The medium was changed 
two to three times a week. The cells were harvested with trypsin-EDTA after 80% 
confluence. The cytotoxicity of free DOX and DOX-loaded polymer nanoparticles with 
or without TPGS or CPGS additives at different DOX concentration was determined by 
MTT assay. Cells were seeded in 96-well plate at a density of 1×104 cells/well and 
incubated for 24 h before the assay. Free drug or drug loaded nanoparticles were then 
added for another 24 h. Each sample was repeated thrice and one row of 96-well plates 
was used as a control without adding any drug formulations. After 24 h incubation, cell 
viability was measured using MTT assay. The formation of formazan crystals by active 
mitochondrial respiration was determined using a microplate reader (GENios, Tecan). 
The cell viability was calculated as the ratio of the number of surviving cells in the drug 
treated samples to that of the control. The cytotoxicity of CPGS and TPGS alone to Caco-
2 cells was also measured. 
8.2.8 Statistical analysis 
All data were presented as mean ± S.D. and analyzed using Student’s t test. Statistical 
significance was determined at a value p<0.05.  
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8.3 Results and discussion 
8.3.1 Characterization of CPGS  
The structure of CPGS was determined by 1H-NMR using Vitamin D protons (Figure 
8.2a) as a reference. The NMR spectra of Vitamin D and its metabolites were previously 
reported by Gumhalter et al. 184. From their results, Vitamin D and its analogue have a 
characteristic broad and undecipherable “steroid hump”. This hump which occurs 
between 1 to 2.5 ppm contains over 60% of the proton resonance and is not suitable for 
identification. Fortunately, there are a few characteristic peaks that can be identified. As 
shown in Figure 8.2a, the methyl groups at H-21, 26 and 27 each appeared at 
approximately 1 ppm since no electronegative group or other de-shielding groups was in 
the vicinity. Another noticeable peak was the singlet of H-3 adjacent to the hydroxyl 
group located at 3.95 ppm. Furthermore, the doublets at H-6 and H-7 and the singlets at 
H-19Z and H-19E were all located downfield above 4.5 ppm because the conjugation of 
alkenes in the vicinity strongly de-shields the attached protons. Figure 8.2b shows the 1H-
NMR spectrum of Vitamin D succinate (VDS). The ‘steroid hump’ was still visible after 
succinate conjugation. As before, the peaks from 0.5 ppm to 2 ppm were generally 
undecipherable, except for the methyl groups at H-26 and 27. Comparing both the spectra 
of Vitamin D and VDS, it can be seen that the H-3 peak at 3.95 ppm in Vitamin D shifted 
downfield after the reaction. This indicates that the hydroxyl group adjacent to C-3 
reacted with succinic anhydride. In addition, the characteristic peak of succinic anhydride 
at 3 ppm was not found in Figure 2b, indicating that no unreacted succinic anhydride was 
in the product. The NMR spectrum of CPGS (Figure 8.2c) was the combination of the 
spectrum of VDS and PEG 2000. The peaks of methyl protons at H-21, 26 and 27 in 
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Vitamin D located at 1 ppm was still prominent. The peak at 3.75 ppm was attributed to 
the methylene protons of PEG. The noticeable point in the spectrum is that the ratio of 
the methylene protons in PEG to the methyl protons at H-21, 26 and 27 in Vitamin D 
(peak areas at 3.6 ppm and 1 ppm respectively) was calculated to be 21. This value is 
close to the theoretical value (18.6) and implies that the CPGS was successfully 










































































































Figure 8.2 The 1H-NMR spectrum of (a) Vitamin D, (b) VDS, (c) CPGS 
 
Figure 8.3 shows the FT-IR spectrum of Vitamin D, VDS, mPEG and CPGS. Compared 
with Vitamin D (Figure 8.3a), VDS (Figure 8.3b) shows that the C-H stretching vibration 
band at 2960 cm-1 was overlapped by the broad wing of O-H stretching vibration of the 
carboxyl group occurred in the region. This indicates that the succinic anhydride ring was 
opened during the reaction with Vitamin D such that one end was linked to Vitamin D, 
leaving a free carboxyl end. Another important difference in the spectrum is the presence 
of an additional distinctive band at about 1735 cm-1 in the VDS spectrum. This band is 
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well as from the carboxyl end of VDS. In contrast, the carbonyl band is not observed in 
the spectrum of Vitamin D. The reactant succinic anhydride is known to have a very 
strong characteristic stretching band of carbonyl group in the region of 1870-1820 cm-1. 
This band was not observed in the VDS spectrum, indicating the effectiveness of the 
purification step of removing excess succinic anhydride from VDS. Considering the 
chemical structure of mPEG and CPGS, all the bands in the PEG spectrum (Figure 8.3c) 
existed in the spectrum of CPGS (Figure 8.3d) since all the functional groups in mPEG 
were present in the product. As a polyether, mPEG has very strong absorption associated 
with the numerous C-O-C groups in the region of 1150-1060 cm-1. The absence of the 
board wing of carboxylic acid in the CPGS spectrum indicates that the carboxyl group of 




















Figure 8.3 The FT-IR spectrum of (a) 
Vitamin D, (b) VDS, (c) mPEG, (d) CPGS
Figure 8.4 The HPLC analysis of CPGS 
and TPGS 
Wave Number (cm-1) Retention time (min) 
CPGS 
TPGS 
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The HPLC analysis of CPGS is shown in Figure 8.4. For comparison, TPGS was also 
measured using the same method. CPGS displayed a single peak with a retention time of 
9.15 min where TPGS displayed a time of 10.91 min. Due to the structure similarity, the 
retention time of CPGS and TPGS was close. The difference of retention time may due to 
the polarity difference of Vitamin D and E or the size of PEG chain. Based on the above 
NMR, FT-IR and HPLC analysis, it is evident that CPGS was synthesized successfully. 
8.3.2 Critical micelles concentration (CMC) of CPGS 
 
As a surfactant for drug formulations, the CPGS micelles must be stable in physiological 
medium such as blood. The CMC is an important factor for determining the stability of 
micelles. In order to detect the micelle formation of CPGS in PBS medium, pyrene was 
chosen as a fluorescent probe because it is very hydrophobic and has a very low 
solubility in water. During micelle formation, pyrene preferentially solublizes itself into 
the hydrophobic core of the micelles, resulting in a substantial increase in the 
fluorescence intensity. As shown in Figure 8.5a, the peak position changed from 334.5 
nm to 337.5 nm when the concentration of CPGS increased gradually. The shift of the 
excitation peak demonstrates that pyrene transferred to the less polar micellar core with 
increasing polymer concentration. Figure 8.5b shows the change of the I337.5/I334.5 
fluorescence intensity ratio as a function of polymer concentration. At low concentration 
range below CMC, the intensity ratio of I337.5/I334.5 was almost constant. However, as 
concentration increased beyond CMC, the intensity ratio increased sharply, indicating 
that pyrene was accumulated to the hydrophobic core of the micelles. The CMC value 
was determined from the extrapolated intersection of the non-horizontal tangents of the 
curve with the horizontal tangent through the points at low concentrations 34, 112, 185. From 
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Figure 8.5b, the CMC value of CPGS was determined to be 0.08 mg/ml. The CMC value 
of TPGS was reported to be 1.3×10-4 M or 0.2 mg/ml 185. Compared with TPGS, the 
lower CMC value of CPGS indicates that the CPGS micelles can be more stable, even 























Figure 8.5b Plot of intensity ratios I337.5/I334.5 vs. log C of CPGS 
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8.3.3 The effect of CPGS on physicochemical properties of nanoparticles  
In this study, CPGS and TPGS were used as surfactants to form DOX-loaded PLGA 
nanoparticles. The effect of these additives on the physicochemical properties of the 
nanoparticles, such as size, encapsulation efficiency and zeta potential, was studied and 
compared. From Table 1, the particle size of PLGA nanoparticles with 5 wt% CPGS was 
233 nm, which was similar to that of nanoparticles with 5 wt% TPGS (247 nm) and much 
smaller than that without any additives (298 nm). The SEM pictures (Figure 8.6) also 
show that the nanoparticles with CPGS appeared to be smaller in size and have smooth 
spherical shape. It was reported that TPGS can effectively reduce the particle size and 
increase the encapsulation efficiency 186, 187. With its amphiphilic structure similar to 
TPGS, CPGS exhibited the emulsifier function. During the fabrication of nanoparticles, 
CPGS may absorb on the surface of nanoparticles to lower the free energy at the interface 
of organic phase and water. This reduces the flocculation of nanoparticles and 
subsequently decreases the size of the particles. With the concentration of CPGS 
increased, the nanoparticles size further reduced since the interfacial energy was lowered. 
Similar behavior was also found when TPGS was used as an additive 146. Compared with 
TPGS, although the length of PEG chain in CPGS was doubled, its emulsifier function 
was not significantly enhanced. This may due to the similar hydrophilic lipophilic 
balance (HLB) of CPGS and TPGS despite of the longer PEG block in CPGS. HLB is the 
ratio of oil soluble and water soluble portions of a molecule. It is usually used to predict 
the emulsification properties of the nonionic surfactants. The HLB of TPGS was reported 
to be 13 188, whereas the HLB of CPGS was calculated to be 15 according to the HLB 
empirical calculation formula 189. 









Figure 8.6 SEM images of (a) PLGA nanoparticles, (b) PLGA nanoparticles with 5% 
CPGS additive 
 
Table 8.1 The effect of CPGS on the physicochemical properties of PLGA nanoparticles  
 





PLGA 56.8 298±22 -31.5 
PLGA+TPGS (5%) 78.5 247±19 -27.3 
PLGA+CPGS (5%) 81.7 233±15 -25.5 
PLGA+CPGS (10%) 88.5 205±15 -20.3 
PLGA+CPGS (15%) 93.0 192±10 -21.5 
 
The encapsulation efficiency (EE) of PLGA nanoparticles with CPGS additive, as shown 
in Table 8.1, was higher than that without CPGS. During the formation of solid 
nanoparticles, the organic phase diffuses from the emulsion droplet into the aqueous 
phase and the aqueous phase diffuses inward into the droplet simultaneously. Therefore, 
the polymer and the drugs may diffuse across this interface from the organic phase 
(a) (b) 
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toward the external aqueous phase. Such cross diffusion can reduce the encapsulation 
efficiency. The amphiphilic property of CPGS may partition the two phases and 
minimize the diffusion of the hydrophobic drug from polymer to external phase, and 
consequently lead to the increase in the encapsulation efficiency. 
 
Zeta potential measures the surface charge density of the nanoparticles and reflects the 
particle stability in suspension through the electrostatic repulsion between the particles. 
The larger absolute value of zeta potential means higher charge on the surface of particles 
which result in stronger repulsion among particles and better particles stability. Table 8.1 
shows that PLGA nanoparticles were negatively charged with zeta potential value -31.5 
mV and was consistent with the result of other researchers 116. Compared with PLGA 
nanoparticles, the negative surface charge density of the nanoparticles with TPGS or 
CPGS additives was relatively low. This phenomenon may be attributed to TPGS/CPGS 
concentrating at the surface of the nanoparticles, which acts as a barrier to reduce water 
infusion for PLGA carboxyl ionization and results in a lower surface charge measured by 
zeta potential.  
8.3.4 Drug release 
The in vitro drug release profiles of DOX-loaded nanoparticles with or without additives 
were shown in Figure 8.7. From the release profiles, the TPGS and CPGS additives has a 
significant effect on the release characteristics of nanoparticles. Without the additives, the 
drug release showed a large initial burst at day 1 and reached a plateau at day 5 with 
nearly 90% of drug release. The initial burst release can be attributed to DOX molecules 
locating near the surface or on the surface of the nanoparticles. For nanoparticles with 
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TPGS additive, the release profile exhibited lower initial burst and more sustained release 
patterns. Adding TPGS during the nanoparticle formation may introduce a hydrophilic 
layer on the surface of the nanoparticles to form a double-wall configuration and 
subsequently delay the drug release of DOX. The release profile of nanoparticles with 
CPGS additive was similar to that of nanoparticles with TPGS since both have similar 
structure. The degradation time for PLGA with molecular weight 40,000-75,000 takes 
more than 4 weeks, therefore most of the drug release during the first ten days was likely 
controlled by diffusion predominantly and not polymer erosion 190. From the results of 
drug release, the TPGS and CPGS additives are useful in reducing the drug release rate.  
Figure 8.7 Drug release profiles of DOX-loaded PLGA nanoparticles without additive or 
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8.3.5 Accumulation of rhodamine in Caco-2 cells 
 
One serious problem associated with cancer chemotherapy is the development of MDR in 
tumor cells during treatment. Besides systematically synthesized inhibitors (such as 
cyclosporine analogs), surfactants such as Tween 80, Spans and Pluronic block 
copolymers were found to improve cellular uptake of P-gp substrates in vitro and in vivo 
191. In Chapter 6, TPGS showed P-gp inhibition to effectively block the transport of 
rhodamine increase the drug concentration in cancer cells. Considering the structure 
similarity of TPGS and CPGS, CPGS may also have similar P-gp inhibition. Therefore, 
in this study, the cellular uptake of free rhodamine, rhodamine-loaded TPGS micelles and 
rhodamine-loaded CPGS micelles was measured to evaluate the P-gp inhibition of CPGS. 
The PLGA nanoparticles were not used here to avoid PLGA complicating the rhodamine 
release. Similar to Chapter 6, rhodamine was used as a marker for P-gp activity in cells 
because of its green fluorescence. Caco-2 cell line was selected in this study because it is 
known to express P-gp 168.  
 
The cellular uptake of three different formulations (free rhodamine, rhodamine loaded 
TPGS and CPGS micelles) with 5 µM rhodamine concentration was determined by 
fluorescence measurement (Figure 8.8) and observed by confocal microscopy (Figure 
8.9). The cellular uptake efficiency of the TPGS micelles and CPGS micelles was similar 
and significantly higher than that of free rhodamine (p<0.05). The confocal images also 
show a more pronounced rhodamine accumulation in two micellar formulations. The 
increased rhodamine accumulation confirms that TPGS inhibited P-gp activity in Caco-2 
cells. In addition, the increased rhodamine accumulation found in the CPGS case 
suggests that CPGS may have the similar P-gp inhibition function as TPGS to prevent  
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drug efflux. The mechanism of TPGS/CPGS influence efflux is not fully understood. The 
interaction with the cellular lipid membrane was reported as a likely mechanism for 
TPGS to block the transport of rhodamine because of its amphiphilic structure 160, 192. 
Lehr and co-workers 193 showed that the length of PEG in TPGS is essential to influence 
rhodamine efflux in vitro. Their data suggested that the optimal PEG chain length is 
between 1100 and 1500 Da. Based on our results, however, no significant difference in 
rhodamine accumulation was found between TPGS 1000 and CPGS 2000, and this 
















Figure 8.8 Cellular uptake efficiency of Caco-2 cells incubated with rhodamine 
formulations for 2 h. (a) Free rhodamine, (b) Rhodamine-loaded TPGS micelles, (c) 



























                                                                                                                                                                                Chapter 8        
 166
 
Figure 8.9 The rhodamine accumulation in Caco-2 cells. (a) free rhodamine, (b) 
rhodamine-loaded TPGS micelles, (c) rhodamine-loaded CPGS micelles. 
 
8.3.6 Cytotoxicity test 
 
Since TPGS and CPGS inhibited P-gp mediated drug efflux, the cytotoxicity of different 
DOX formulations with or without these additives should be different. Figure 8.10 shows 
the cytotoxicity of free DOX, DOX loaded PLGA nanoparticles without additives or with 
5 wt% TPGS and CPGS additives measured by MTT assay. With equivalent drug 
contents in the culture medium, a similar degree of cytotoxicity to Caco-2 cells among all 
formulations was observed at 0.1 µM or lower DOX concentration. At 1  µM or higher 
concentration, however, the DOX-loaded PLGA nanoparticles with TPGS or CPGS 
additives showed much higher cytotoxicity (p<0.05) than the DOX-loaded PLGA 
nanoparticles without additives and free DOX. As described above, P-gp acts as a pump 
and decreases the intracellular concentration of free DOX. When DOX was encapsulated 
in PLGA nanoparticles, controlled release properties of the nanoparticles may counteract 
the multidrug resistance to some extent. For nanoparticles with TPGS or CPGS additives, 
(a) (b) (c) 
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the P-gp inhibition effect of TPGS and CPGS may further enhance the drug concentration 
in cells and thus an increased cytotoxicity was observed.  
 
After incubating Caco-2 cells with various concentrations of CPGS and TPGS for 24 h, 
the cytotoxicity of TPGS and CPGS alone (without DOX) was also measured and 
compared. As shown in Figure 8.11, the cytotoxicity of TPGS to Caco-2 cells was higher 
than that of CPGS, especially when the concentration was 15 µM or higher (p<0.05). 
This cytotoxicity difference may be attributed to the property difference between TPGS 
and CPGS. TPGS has been demonstrated to have selective cytotoxicity to cancer cells but 
not normal cells 167. The selective anticancer effect of TPGS is mediated by its apoptosis-
inducing properties, which appear to be mediated through the generation of reactive 
oxygen species. Since the selective cytotoxicity of TPGS comes from Vitamin E 
succinate head and not the PEG chain, the substitution of Vitamin E with Vitamin D3 
may be the reason for the low cytotoxicity of CPGS. Having said this, Vitamin D3 itself is 
a precursor of biologically active metabolites. It is well known that Vitamin D3 is 
hydroxylated in the liver to form 25-hydroxycholecalciferol, which can be further 
hydroxylated to form 1,25-hydroxycholecalciferol in the kidney 179. There is growing 
evidence that 1,25-hydroxycholecalciferol has anticancer effects to many types of cancer 
cells 194, 195. Therefore, as a conjugation of Vitamin D3 and PEG, CPGS may still have 
anticancer effects in vivo. Additional animal studies are needed to investigate the 
anticancer effects of CPGS.  
 
 



















Figure 8.10 The cytotoxicity of DOX formulations in Caco-2 cells. Bars marked with * 
are significantly different from free DOX and DOX loaded PLGA nanoparticles at the 


















Figure 8.11 The in vitro cytotoxicity of TPGS and CPGS to Caco-2 cells. CPGS marked 
with * are significantly different from TPGS at the same concentration (p<0.05). 




A new vitamin D-PEG conjugate - cholecalciferol polyethylene glycol succinate (CPGS) 
was synthesized as a new pharmaceutical additive. The structure of CPGS suggests that it 
will have similar properties to TPGS. From our current study, CPGS could be used as a 
surfactant to prepare drug-loaded nanoparticles. CPGS improved the drug encapsulation 
efficiency and reduced the initial burst of drug release. Similar to TPGS, CPGS may also 
act as P-gp inhibitor to enhance the cytotoxicity of anticancer drugs in Caco-2 cells. 
Compared with TPGS, CPGS did not show obvious cytotoxicity to cancer cells in vitro. 
However, CPGS may have anticancer effects in vivo through the active metabolites of 
Vitamin D. Results obtained from this study may broaden potential use of different 


























Chapter 9  
Conclusions & Recommendations 
 
9.1 Conclusions 
In this Ph.D. work, we sought to resolve the two major problems of chemotherapy-non-
specific treatment and multidrug resistance. Folate was conjugated to the polymer 
micelles to endow the targeting ability to the carrier. The novelty of this study focused on 
the selectivity of folate conjugated micelles between cancer cells and normal cells. In 
addition, this study also determined the optimum folate conents conjugated to the 
micelles which are sufficient for FR recognition to cancer cells and induce minimum 
non-specific binding to healthy cells. To address the drug efflux from cells, folate 
conjugated polymer micelles were formulated with TPGS. This novel formulation have 
dual functions of folate-mediated targeting and MDR inhibition to cancer cells, and at the 
same time, minimize the cytotoxicity of the drug to normal cells. The in vivo study 
showed that this formulation might be the appropriate formulation for drug resistant 
tumors overexpressed FRs because it shows combined effects of EPR, folate active 
targeting and P-gp inhibition. Therefore, for the first time, non-specific drug delivery and 
multidrug resistance can be resolved together. Based on these new findings, a new 
vitamin D-PEG conjugate - CPGS was synthesized as a new pharmaceutical additive to 
broaden the P-gp reversing agents. 
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The major findings of this thesis include the following: 
 
1. PLGA-PEG-FOL was synthesized as a new drug carrier. The physicochemical studies 
show that the micelle size was small (approximately 60-80nm) and the size distribution 
was narrow. The micelles can be formed at low concentrations, allowing their use in 
blood medium. Particle surface analysis confirms that folate groups are exposed on the 
surface of the nanospheric micelles for potential interaction with FRs. The optimal initial 
weight ratio of DOX to PLGA-PEG-FOL was 0.5:1.0, with a drug loading content of 28% 
and drug encapsulation efficiency of 61%. The DOX release rate was faster in the first 10 
hours and reached a plateau in 24 h.  
 
2. The difference of cytotoxicity, cellular uptake and apoptosis percentage between 
different cancer cells and healthy cells implies that the folate conjugated micelles has the 
ability to selectively target cancer cells with overexpressed FRs on their surface. The 
cytotoxicity of the folate conjugated micelles (PLGA-PEG-FOL) to cancer cells was also 
much higher than free DOX or micelles without folate (PLGA-PEG). Furthermore, the 
amount of folate on the micelles was optimized at 40%-65% in order to kill cancer cells 
but, at the same time, have minimal effect on normal healthy cells.  
 
3. Poly(β-amino ester)-PEG-FOL conjugate was successfully synthesized as a pH 
sensitive copolymer. Mixed micelles of PLGA-PEG-FOL and poly(β-amino ester)-PEG-
FOL was fabricated with different weight ratios. The mixed micelles showed increased 
buffering ability. The drug release was triggered at endosome pH due to the ionization of 
poly(β-amino ester), which resulted in enhanced nucleus uptake of drug and improved the 
                                                                                                                                                             Chapter 9                             
 172
cytotoxicity. Considering the micelles stability in extracellular environment, drug release 
rate and cytotoxicity, the 80:20 mixed micelles of poly(β-amino ester)-PEG-FOL and 
PLGA-PEG-FOL is the most suitable formulation. This new formulation would be useful 
as an effective intracellular delivery carrier.  
 
4. In order to get more potent drug targeting carrier, TPGS was added in the drug 
targeting system DOX-loaded PLGA-PEG-FOL micelles to form mixed micelles. 
Compared with the PLGA-PEG-FOL formulation, the addition of TPGS showed higher 
cellular uptake of DOX, and subsequently a higher degree of DNA damage and apoptosis, 
and eventually a higher cytotoxicity to drug resistant cells. The enhanced cellular uptake 
of mixed micelles was related to the P-gp inhibition function of TPGS. In addition, the 
current formulations with TPGS also selectively enhance the cytotoxicity of drug 
resistant cancer cells with overexpressed folate receptors and affect normal cells at 
minimum. Based on these findings, this new TPGS formulation can potentially 
strengthen the therapeutic effect of the PLGA-PEG-FOL micellar system.  
 
5. The pharmacokinetics and biodistribution study showed that free drug was eliminated 
rapidly by renal excretion and the drug concentration in tumor was very low. However, 
all the micelles formulations had longer circulation time and enable the passive targeting 
of micelles to tumor by EPR effect. Compared with DOX/micelles, the DOX/folate 
micelles showed higher drug concentration in tumor because of the folate targeting effect. 
The DOX/mixed micelles formulation showed enhanced drug accumulation in drug 
resistant tumors which may be attributed to the P-gp inhibition function of TPGS. Based 
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on our results, the DOX/mixed micelles might be the appropriate formulation for drug 
resistant tumors overexpressed with FRs.  
 
6. A new vitamin D-PEG conjugate - cholecalciferol polyethylene glycol succinate 
(CPGS) was synthesized as a new pharmaceutical additive. The structure of CPGS 
suggests that it will have similar properties to TPGS. From our study, CPGS could be 
used as a surfactant to prepare drug-loaded nanoparticles. CPGS improved the drug 
encapsulation efficiency and reduced the initial burst of drug release. Similar to TPGS, 
CPGS may also act as P-gp inhibitor to enhance the cytotoxicity of anticancer drugs in 
Caco-2 cells. Compared with TPGS, CPGS did not show obvious cytotoxicity to cancer 
cells in vitro. However, CPGS may have anticancer effects in vivo through the active 
metabolites of Vitamin D. Results obtained from this study may broaden potential use of 
different vitamin-based additives for pharmaceutical formulations. 
 
9.2 Recommendations for future work 
9.2.1 Effects of PEG length of folate conjugates on targeting ability and antitumor 
effects  
It was reported that for nonfolate linked vehicles, increasing the PEG molecular weight 
from 1900 to 5000 had no effect for prolonged circulation 196. However, for folate 
conjugated micelles to bind FRs, they have to extravasate from tumor vasculatures, pass 
through the intracellular space and reach the FRs on the cell surface. Therefore, to 
increase the possibility of FR targeting, the PEG length should be long enough to extend 
systemic circulation in vivo. The liposomes conjugated to folate via PEG spacers have 
been used to deliver chemotherapeutic agents. From the result of folate-PEG linked 
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liposomes, it is known that the length of the PEG linker chain is important for the 
liposomes to be internalized via FR mediated endocytosis 47. In this thesis, only PEG 
3400 was utilized to prepare PLGA-PEG-FOL micelles. From in vivo study, the 
pharmacokinetics results showed the prolonged circulation of folate conjugated micelles 
with PEG 3400. However, the optimum PEG molecular weight for FR binding is not 
known. Therefore, higher PEG molecular weight (such as 5000 and 10,000) should be 
utilized in the future work. The relation between PEG length and antitumor effects should 
be studied.  
 
Shiokawa et al. reported the antitumor effect of folate-linked microemulsions in terms of 
the PEG length of the folate-PEG linker chain 197. The drug microemulsions were coated 
with PEG2000-distearoylphosphatidylethanolamine (DSPE) and either folate-PEG2000- 
DSPE or folate-PEG5000-DSPE (Figure 9.1). Their work showed that extending the PEG 
chain length of the folate-PEG lipid from 2000 to 5000 dramatically improved the 
targeting ability and antitumor effects of the formulation. This may be resulted from the 
easier accessibility of folate on PEG5000 for FRs binding. In Chapter 4, the effect of folate 
contents to targeting efficiency was performed using mixed micelles of PLGA-PEG-FOL 
and PLGA-PEG with the same PEG length. If longer PEG length of PLGA-PEG-FOL 
was adopted, the optimum folate contents for tumor targeting may be different. In the 
future work, this possibility should be explored to make the formulation more effective at 
tumor targeting.  









Figure 9.1 Folate-linked microemulsions consisted of folate-linked lipids and PEG2000-
DSPE 197. 
 
9.2.2 The antitumor efficacy of different drug formulations 
In Chapter 7, pharmacokinetics and biodistribution study of different drug formulations 
in vivo were performed. To evaluate the targeting ability and therapeutic effects of drug 
formulations, the antitumor efficacy was also investigated. To evaluate the antitumor 
effects of drug formulations, cancer cells were inoculated subcutaneously in rats (day 0) 
and allowed for growth for 7 days. The rats were then grouped randomly. Treatments 
were started on day 8 at a dose of 2 mg DOX/kg of four drug formulations - free DOX, 
DOX/micelles, DOX/folate micelles and DOX/mixed micelles. The drugs were 
administrated by i.v. injection via the lateral tail vein on every 3rd day (on day 8, 11, 14, 
17, 21). Tumor size was also measured on every 3rd day ten times (on day 8, 11, 14, 17, 
21, 24, 27, 30, 33, 36). Tumor volume was calculated by the equation described in 
Chapter 7. The preliminary results showed that the DOX/mixed micelles formulation was 
effective in tumor growth inhibition (Figure 9.2) of drug resistant tumor model. However, 
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most of the rats died after 17 or 21 days. The death may be resulted from tumor transfer 
to other organs because metastatic tumors were observed during rat dissection. Therefore, 
in the future work, the drug treatment should be started earlier to control tumor growth, 
such as on day 4 instead of day 8. In addition, the number of cancer cells inoculated in 











Figure 9.2 Tumor volume vs. Time 
 
9.2.3 The mechanism of TPGS or CPGS on the MDR inhibition  
In Chapter 6, folate conjugated micelles formulated with TPGS was studied for MDR 
inhibition. However, the mechanism of the TPGS on MDR inhibition is not fully 
understood. The mechanism is of considerable interest for the potential application of 
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It became lately evident that the impact of Pluronic block copolymers in cancer cells is 
more diverse. A recent analysis of the global gene expression profiles in the selected cells 
suggested that Pluronic can significantly alter the genomic responses to the drug 198. It is 
noteworthy that in the absence of a drug, Pluronic has little effects on gene expression 
profiles. Thus, it is possible that it affects the intracellular signal transduction pathways. 
It has been demonstrated that synthetic polymers, such as poly(2- 
hydroxypropylmethacrylate) (pHPMA) and PEG, conjugated to anticancer drugs can 
considerably affect the apoptosis signaling pathways 199. A recent study showed that 
polymer excipients (Pluronic) with the drugs that are not covalently bound to a polymer 
have similar effects 90.  
 
The group of genes responsible for apoptosis plays an important role in chemoresistance 
in cancer cells attributed to a “disabled apoptotic program”. In particular, apoptosis can 
be restricted in MDR cells by the elevated level of an antiapoptotic gene, BCL2, related 
to the expression of BCL2 protein 200. Moreover, reduced expression of a proapoptotic 
gene, P53, also results in chemoresistance in more than 50% of all human malignances 
and clinically has been correlated with the worse prognosis for patients with several types 
of cancers 201. Finally, the intimate relationship between the P-gp overexpression and 
inhibition of multiple forms of caspase-dependent apoptosis was shown in MDR cells 78. 
Therefore, the effects of TPGS or CPGS on drug induced expression of antiapoptotic and 
proapoptotic genes should be demonstrated in future study. In particular, the effect on the 
expression of antiapoptotic genes is of great importance. Downregulation of these genes 
is associated with better therapeutic outcome. The early and late stages of apoptosis can 
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be detected by Annexin V and TUNEL methods respectively. The expression of genes 
related to apoptosis, such as BCL2, BCLXL, BAX, P53, APAF1, Caspase 3, and Caspase 
9 can be determined by RT-PCR.  
9.2.4 Using the current delivery system as magnetic resonance imaging (MRI) 
contrast agents 
Magnetic Resonance Imaging (MRI) is one of the most important non-invasive imaging 
modalities in clinical diagnostics, since it excels in depicting tissues with high spatial 
resolution and has superior soft tissue contrast. Nevertheless, there are many pathological 
conditions that do not lead to significant morphological changes and do not display 
specific enough changes in the relaxation times. Under those circumstances, the 
pathology may be detected using an MRI contrast agent that locally changes the 
relaxation times of the diseased tissue 202. Therefore, MRI applications are becoming 
more and more dependent on contrast agents. Various metals such as Gd, Fe, and Mn are 
used for MRI contrast agents. However, this low molecular weight contrast agent has 
significant problems such as short half-life in blood and lack of specificity to target 
organs and tissues for diagnosis. Therefore, much of the contrast agent is administered to 
a patient before an image is taken and this substantial agent injection is a heavy burden 
for patients. In recent years, many macromolecular carriers have been examined for 
increases in relaxivity and specificity, such as poly(ethylene glycol) 203, dendrimers 204, 
polysaccharide 205 and PEG-grafted poly(L-lysine) 206, 207. Since selective delivery to the 
target tissues or organs is very beneficial for the MRI diagnosis, our current delivery 
system can be applied as MRI contrast agent to achieve tumor specific imaging. 
Additionally, the total dose for the MRI imaging can be reduced owing to this targeting 
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effect. On the basis of this perspective, we fabricated a novel polymeric micelles contrast 
agent - Fe3O4 nanoparticles encapsulated in PLGA-PEG-FOL micelles. As stated in 
Appendix I, the fabrication procedures were carefully optimized to get higher Fe3O4 
loading and smaller micelles size. Under current fabrication method, the Fe3O4 loading 
content was 58% and the micelles size was 195 nm. In the future work, the in vitro 
cytotoxicity, cellular uptake and T1-shortening ability relative to the MRI contrast agent 
should be explored. 
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1. The fabrication of iron oxide (Fe3O4) nanoparticles 
Materials: FeCl3.6H2O, oleic acid, octadecene, methanol and NaOH 
The synthesis of Fe3O4 requires two steps. Step 1 is to synthesize the intermediate 
product, Fe(III) Oleate; and Step 2 is to form Fe3O4 from the intermediate product. In 
Step 1, 0.54g of FeCl3.6H2O was dissolved in 10ml of methanol (solution 1). Separately, 
0.24g of NaOH was dissolved in 20ml of methanol (solution 2). Under vigorous stirring, 
1.7 ml oleic acid was added into solution 1. Oleic acid is a long chain surfactant which 
acts as a stabilizer in ferrofluid suspension to prevent agglomeration. After homogeneous 
mixing, solution 2 was added into solution 1 under stirring. The intermediate product 
Fe(III) oleate was formed after the brown precipitate was dried under vacuum. 
Subsequently, Step 2 was carried out to produce Fe3O4. The intermediate product was 
placed on a hot plate with magnetic stirrer and 15ml of octadecene was added in. The 
mixture was stirred while being heated at 80◦C until the precipitate was dissolved 
completely. At this point, 1.7ml of oleic acid was added into the mixture and the solution 
was heated at 300◦C for 30 mins and cool down to room temperature. The final product is 
Fe3O4 in oleic acid. 
 
2. The preparation of Fe3O4 loaded PLGA-PEG-FOL micelles 
Known amount of Fe3O4 and PLGA-PEG-FOL was dissolved in 5 ml of DCM and stirred 
until the mixture was well-mixed. Subsequently, the oil mixture was dripped into DI 
water by drop wise. The mixture was stirred overnight to evaporate the organic solvents.  
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Figure A1 FT-IR spectrum of the Fe3O4 loaded PLGA-PEG-FOL micelles 
 
4. The morphology of Fe3O4 loaded PLGA-PEG-FOL micelles 
 
  Figure A2 TEM images of iron oxide nanoparticles encapsulated in micelles 
Since TEM can not focus on both nanoparticles and the micelles, only iron oxide 
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believed that the iron oxide clusters are encapsulated in the micelles. Due to the 
limitation of equipment, micelles were not visible under TEM. From the images, the 
average size of iron oxide encapsulated PLGA-PEG is 100-200 nm. 
 
 
Figure A3 FESEM images of (a) Fe3O4 encapsulated in polymeric micelles, (b) a 
zoomed-in micelle. 
 
The FESEM images also show that micelles size is around 100 to 200 nm. The zoomed-
in image demonstrates that iron oxide nanoparticles were encapsulated within the 
polymer micelles.  
(a) (b)
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